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1
This thesis encompasses an exploration of the state-of-the-art imaging techniques magnetic 
resonance (MR) imaging and MR spectroscopic imaging in the diagnostic process of men 
with prostate cancer.
Chapter 2 provides a review of the imaging modalities available for detecting and localizing 
prostate cancer and determines their comparative strengths and weaknesses. From these, a 
potential scheme is proposed for prostate cancer detection and localization.
In Chapter 3, the imaging modalities for staging prostate cancer are reviewed and a scheme 
is proposed for their use in patient management.
In Chapter 4, the first published prostate cancer patient cohort to undergo MR imaging with 
an endorectal coil at 3 tesla is presented, using prostatectomy as standard of reference in 
order to establish the feasibility of accurately staging prostate cancer with this technique.
In Chapter 5 a prospective study of a patient cohort that underwent both body-array coil 
and endorectal coil MR imaging at 3 tesla for the purpose of prostate cancer localization and 
local staging is presented.
Chapter 6 encompasses a study of the changes in prostate diameters and volumes after the 
introduction of an endorectal coil using MR imaging at 3 tesla in a patient cohort.
In Chapter 7, the MR spectroscopic imaging technique using only a body-array coil at 3 
tesla to detect recurrent disease within the prostate gland as well as metastatic disease in a 
lymph node in a patient is outlined.
Chapter 8 presents the feasibility of performing MR spectroscopic imaging at 3 tesla using 
only a body-array coil in localizing prostate cancer in a patient cohort that underwent radical 
prostatectomy.
In Chapter 9, a direct comparison of the prostate cancer localization performance between 
body-array and endorectal coil MR spectroscopic imaging at 3 tesla is performed in a patient 
cohort that subsequently underwent radical prostatectomy.
Chapter 10 reflects a selection from the imaging chapter of the 2007 Dutch comprehensive 
cancer centres (CBO) guideline regarding the use of imaging in prostate cancer diagnosis. 

Stijn W.T.P.J. Heijmink
Jurgen J. Fütterer
Stephen S. Strum
Wim J.G. Oyen
Ferdinand Frauscher
J. Alfred Witjes
Jelle O. Barentsz
Acta Oncologica 2011; 50(S1):25-38.
CHAPTER 2
State-of-the-art uroradiologic imaging 
in the diagnosis of prostate cancer
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In the diagnostic process of prostate cancer, several radiologic imaging modalities 
significantly contribute to the detection and localization of the disease. These range from 
transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) to positron emission 
tomography (PET). Within this review, after evaluation of the literature, we will discuss the 
advantages and disadvantages of these imaging modalities in clarifying the patient’s clinical 
status as to whether he has prostate cancer or not and if so, where it is located, so that 
therapy appropriate to the patient’s disease may be administered. TRUS, specifically with 
the usage of intravenous contrast agents, provides an excellent way of directing biopsy 
towards suspicious areas within the prostate in the general (screening) population. MRI 
using functional imaging techniques allows for highly accurate detection and localization, 
particularly in patients with prior negative ultrasound guided biopsies. A promising new 
development is the performance of biopsy within the magnetic resonance scanner. 
Subsequently, a proposal for optimal use of radiologic imaging is presented and compared 
with the European and American urological guidelines on prostate cancer.
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With a total of 217 730 new cases estimated for 2010, prostate cancer (PC) now accounts 
for 28% of all new male cancers diagnosed in the USA [1]. In their lifetime, one in six men 
will be clinically diagnosed with having PC, although many more men are found to have 
histological evidence of PC at autopsy [2–4]. Presently, approximately 1 in 10 men will die 
of PC [5,6]. The everaging population and wider spread use of the prostate-specific antigen 
(PSA) test [7,8], as well as the tendency to apply lower cut-off levels for this test [9], will 
further increase the diagnosis of this disease [10].
An elevated PSA level, abnormal changes in PSA level (i.e. PSA dynamics) such as PSA velocity 
or doubling time, or an abnormal digital rectal examination are biologic indicators signaling an 
increased risk of PC. With the improvement and wider range of curative therapies, detection 
and subsequent exact localization of PC have become increasingly important because of 
their influence on treatment strategy [11,12]. Two such affected treatments are laparoscopic 
(robotic) radical prostatectomy and intensity-modulated radiation therapy (IMRT [13]). 
The urologist’s inability to palpate the operating field during laparoscopic surgery makes it 
even more crucial to know where the cancer is located. Similarly, the urologist must know 
whether the cancer is near a neurovascular bundle since this affects the decision of whether 
or not to perform nerve-sparing prostatectomy [14]. IMRT also necessitates accurate PC 
localization. While giving a standard dose to the prostate, a higher (i.e. boost) dose can be 
given to any dominant intraprostatic lesion(s) as these lesions regularly appear to be the 
sites of recurrent disease [15]. Furthermore, precision radiation dosimetry will decrease 
radiation complications, particularly rectal wall toxicity [16], thereby likely diminishing the 
development of post-radiation rectal cancer [17].
In order to determine the optimal treatment for the individual patient, it is necessary 
to evaluate all patient and cancer characteristics. Most often used for this purpose are 
laboratory values (PSA level and dynamics), the results of digital rectal examination (clinical 
staging), and histopathological prostatic biopsy findings (Gleason score). However, imaging 
may play an important role in detecting and localizing areas most reflective of the actual 
aggressiveness of the cancer. This directly influences the assessment of the patient and may 
lead to important changes in treatment strategy which can mean the difference between 
treatment success and failure.
Currently, a spectrum of imaging modalities is available to clinicians for tackling detection- 
and localization-related problems. To provide optimal and cost efficient patient care, these 
techniques should be used in the appropriate clinical context to aid clinicians in detecting 
and localizing PC.
This review 1) presents an overview of the currently available imaging methods to aid in 
PC detection and localization. 2) Additionally, a scheme is proposed for optimal evidence-
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based use of imaging in detecting and localizing prostate cancer and a critical comparison is 
made between this scheme and the most recent guidelines as put forward by the American 
Urological Association (AUA) and European Association of Urology (EAU).
LITERATURE SEARCH
Relevant articles were retrieved using combinations of both Medical Subject Headings 
(MeSH) and free search terms in the MedLine® (WebSPIRS Version 5.12, Build 20060224, 
Ovid Technologies) and Pubmed (U.S. National Library of Medicine) online search engines.
MeSH terms included: “Prostate”, “Anatomy”, “Prostatic Neoplasms”, “Neoplasm 
Staging”, “Ultrasonography”, “Tomography, X-Ray Computed”, “Magnetic Resonance 
Imaging”, “Magnetic Resonance Spectroscopy”, “Diffusion Magnetic Resonance Imaging”, 
“Radionuclide Imaging”, and “Positron- Emission Tomography”.
Free search terms included: “prost*”, “cancer”, “detect*”, “localization”, “localisation”, 
“biops*”, “stag*”, “capsul*”, “extracapsular penetration”, “extracapsular extension”, “seminal 
vesicle invasion”, “transrectal ultraso*”, “TRUS”, “computed tomography”, “CT”, “magnetic 
resonance imaging”, “MRI”, “ferumoxtran-10”,“magnetic resonance spectroscopy”, 
“spectroscopy”, “MRS”, “bone scan*”, “bone scintigraphy”, “positron-emission tomography”, 
“PET”, and “ProstaScint”.
Reference lists of selected articles were further analyzed for relevant articles.
PROSTATE CANCER DETECTION AND LOCALIZATION IN REFERENCE TO 
PROSTATE ANATOMY AND ESSENTIAL PROSTATE CANCER CHARACTERISTICS
In order to effectively apply the various imaging modalities, it is important to first understand 
both the normal prostate anatomy and the distribution and intrinsic characteristics of PC.
Normal anatomy as related to PC localization
On the basis of its embryological origins, the prostate is anatomically divided into three 
zones that are eccentrically located around the urethra: the innermost transition zone (TZ), 
the central zone, and the outermost peripheral zone (PZ) [18,19]. In older patients, the 
former two cannot be distinguished radiologically due to compression of the central zone 
by benign prostatic hyperplasia (BPH) in the TZ and together they are referred to as the 
central gland; this as opposed to the outer gland, which comprises the PZ. Furthermore, the 
prostate is craniocaudally divided into apex (the caudal one-third), mid-gland, and base (the 
cranial one-third).
Anatomical distribution of PC
Up to 70–80% of PC is located in the PZ [20] and overall analysis of these cancers has 
shown homogeneous distribution across the entire PZ [21], with over half of the prostates 
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containing two or more distinct cancer foci [22]. Nevertheless, while up to 20–52% of all PC 
originate in the TZ, only a small (3.6–25%) percentage of these cancers [21,23] occur solely 
in the TZ as many will have concurrent PZ cancer foci [20,24,25].
Pathological grading of PC aggressiveness
Presently, the most widely used histological scaling system for PC aggressiveness is the 
Gleason score [26,27], which consists of two numbers: a primary and secondary Gleason 
grade reflecting the two grades most frequent in the specimen. Each Gleason grade is 
assigned a value between 1 and 5, the higher numbers indicating a more aggressive cancer. 
The prognostic value of the Gleason grading system is well-documented [28,29].
PATIENTS CLINICALLY AT RISK FOR PROSTATE CANCER: RADIOLOGICAL 
IMAGING TO DETECT AND LOCALIZE PRIMARY PC
Transrectal ultrasound (TRUS): Reliable, although not perfect, daily-use modality
Grayscale TRUS. Today, in regular clinical practice, prostate biopsies are performed under 
TRUS guidance. Even though the traditional ultrasound appearance of PC is a PZ hypoechoic 
lesion (Figure 1A, B), other conditions such as prostatitis and prostatic intraepithelial 
neoplasia may also present as hypoechoic lesions [30,31]. It is important to note that over 
40% of PC lesions are isoechoic (Figure 1C, D) while only 5% are hyperechoic [32]. Therefore, 
targeting only hypoechoic areas is not an optimal approach for successful PC detection 
[33] and various biopsy protocols that sample tissue at standard locations (i.e. systematic 
biopsy) within the prostate have become the most common biopsy technique [34]. The 
number of cores taken per session varies across institutions. Recently, however, emphasis 
has been put on adequate tissue sampling from more laterally located PZ regions [35,36] 
and on the relative unimportance of biopsying the central gland [37]. Despite the use of 
extended systematic biopsy protocols, there is still an approximately 20% chance that the 
Gleason score at prostatectomy will differ from that at biopsy to a clinically relevant degree 
[38]. Recently, it was observed that biopsies performed with an endfire probe obtained 
a significantly higher biopsy rate compared with side-fire probes [39]. PC detection rates 
have varied from 19–40% [40,41] and repeat biopsy sessions are often necessary [42]. 
Localization sensitivity varied widely between 39–75% (Table).
Doppler TRUS. Because increased blood flow due to neovascularity is one of the 
characteristics of PC, this is a means of targeting lesions. In a study of 96 patients with 
lower urinary tract symptoms and PSA levels over 4 ng/ml [43], the degree of Doppler signal 
correlated with the microvessel density and Gleason score of a lesion. One study achieved 
Doppler imaging-based detection rates of 40% [44]. Power Doppler TRUS could improve 
the localization specificity [45]. However, a drawback of Doppler imaging is the high inter-
observer variability [46,47], reflected in the widely spread sensitivity and specificity figures 
in the literature (27–98% and 46–84%, respectively) (Table).
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Contrast-enhanced TRUS. An innovation is the application of gas-filled microbubble contrast 
agents, such as Levovist® (Schering, Berlin, Germany) and SonoVue® (Bracco, Milan, Italy) 
[48]. These microbubbles remain intravascular, thereby enhancing the visibility of the 
vascular tree in and around the prostate. This improves the ability to detect PC and to thus 
target areas more representative of the aggressiveness of PC. In experienced hands, it is 
reported that compared with systematic biopsy, targeting only lesions with pathological 
enhancement after contrast administration requires less than half the number of biopsy 
cores to obtain the same diagnostic yield [49–51]. A recent randomized clinical trial 
comparing systematic biopsy and contrast-enhancement targeted biopsy confirmed these 
findings [52]. In addition, contrast-enhanced TRUS biopsies on average detected significantly 
more aggressive cancers compared with systematic biopsy. Therefore, we can speculate that 
by using this technique the difference in Gleason score between biopsy and prostatectomy 
specimens would most likely diminish. If the latter is confirmed by future studies, pre-
Figure 1. (A) Axial gray-scale transrectal ultrasound image (AplioTM, Toshiba) of the prostate 
of a 65-year-old man (PSA level 19.02 ng/ml, biopsy Gleason score 6, normal digital rectal 
examination). A hypoechoic lesion was observed in the right peripheral zone (arrows). 
(B) Histopathology of the prostatectomy specimen confirmed the presence of a Gleason 
3 + 4 adenocarcinoma (T). (C) In another patient (69 years, PSA level 3.59 ng/ml, biopsy 
Gleason score 7, normal digital rectal examination), the axial gray-scale image did no show 
any echogenic abnormality while at histopathology (D) a number of cancer foci (T) were 
reported.
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therapeutic risk assessment of patients will increase in accuracy. Disadvantages of using 
contrast agents are the longer duration and higher degree of invasiveness of the examination; 
however, the risk of hypersensitivity to the substance is rare and most adverse events are 
minor and self-resolving [53]. Sensitivities and specificities of PC detection using contrast-
enhanced TRUS varied between 48–94% and 46–88%, respectively (Table I). A preliminary 
study suggests that a 14-day prebiopsy course of dutasteride, a dual 5α-reductase inhibitor, 
causes a relative high reduction in blood flow in healthy prostate tissue compared with 
cancer tissue and could increase the diagnostic yield of contrast-enhanced TRUS targeted 
biopsy [54].
Sonoelastography. Transrectal sonoelastography is a new non-invasive technique that 
analyzes the compression characteristics of prostate tissue. A study by König et al. of 404 
men undergoing biopsies based on real-time sonoelastography revealed a detection rate 
of 37.4% [55]. In a comparative study, Pallwein et al. found a significantly higher per core 
detection rate for sonoelastography-targeted biopsy compared with systematic biopsy. 
Sonoelastography-targeted biopsy was 2.9 times more likely to detect cancer [56]. A drawback 
of the latter study was the heterogeneity of the population since more than half of the 
patients had already undergone one or more negative biopsy sessions. A study comparing 
real-time sonoelastography with radical prostatectomy reported a localization sensitivity of 
88% [57]. While sonoelastography-based targeted biopsy improves the diagnostic yield it is 
not yet clear whether it can replace systematic biopsy [58]. Future randomized studies are 
required to determine the true value of sonoelastography in prostate cancer detection and 
localization.
Computed Tomography (CT) scanning: Inadequate soft tissue contrast and radiation burden
The literature search resulted in identifying only one recent study on the ability of CT 
scanning to document histologic PC sites within the prostate gland. This study revealed that 
contrast-enhanced helical CT scanning was able to detect only 58% of the 102 histologic 
PC sites documented by TRUS-guided biopsies in 25 patients [59]. In general, CT scanning 
has inadequate soft tissue contrast resolution to discern the subtle tissue changes due to 
PC (Figure 2A) and, therefore, should not be used for PC detection and localization. An 
additional disadvantage of CT is that it involves ionizing radiation. 
Endorectal Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopic 
Imaging (MRSI): High soft-tissue resolution, radiation-free, but costly and time consuming
T2-weighted imaging. Contrary to CT scanning, MRI has a high soft-tissue contrast 
resolution. The use of an endorectal coil (ERC) combined with other external coils at 1.5 
tesla (T) increases soft-tissue contrast significantly and is now the accepted standard for MRI 
of the prostate [60]. A drawback is the extra time required for insertion and checking of the 
position of the disposable ERC, as well as substantial expense.
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On MRI, PC typically appears as an area of low signal intensity within the brighter, healthy 
PZ using a T2-dominated sequence [61–63] (Figure 3A–E). In the central gland, PC is not as 
clearly discernable because the central gland generally has lower signal intensity than the 
PZ and is more inhomogeneous due to BPH-induced architectural changes that may mimic 
PC. A recent study showed that a homogeneous low T2 signal intensity and lenticular shape 
were significantly associated with presence of central gland PC [64]. It was reported that 
higher Gleason score cancers had lower signal intensities (relative to muscle) compared 
with low Gleason score cancers [63]. T2-weighted imaging can be performed in multiple 
planes or as a three dimension (3D) volume acquisition [65]. Comparing T2-weighted MRI 
with prostatectomy specimens, MR attained high (52– 83%) sensitivities in PC localization, 
while specificities were somewhat lower (46–88%) (Table I). 
Figure 2. A comparison of the soft-tissue resolution between CT scanning, transrectal 
ultrasound, and MRI in a 67-year-old man with a PSA level of 38.72 ng/ml, a biopsy Gleason 
score of 6, and normal digital rectal examination. (A) On the axial CT-scan image the prostate 
(P) could be discerned. After contrast administration (arrow) no clear enhancement within 
the prostate was seen. (B) On gray-scale transrectal ultrasound imaging (Viking®, BK Medical) 
an area of hypoechogenicity (arrows) was visible ventrally. (C) The ventral cancer focus 
(arrows) was also visible on axial MRI at 3 T with external surface coils. (D) Histopathology 
confirmed the presence of a ventral cancer focus (Gleason score 7) corresponding to the 
area of echogenicity on transrectal ultrasound and low signal intensity on MRI.
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Figure 3. 59-year-old patient with PSA 12, Gleason 8 tumor (circle) right PZ, stage T3a 
(arrows) at prostatectomy. (A) T2-w axial image, (B) DCE image showing wash-out at the 
tumor site, (C) ADC-map tumor shows marked restriction, which argues for high Gleason 
grade, (D) DWI image (b 800) tumor has high signal, (E) sagital T2-weighted image, (F) 
concentration time curve shows fast wash-in and fast wash-out. G. MR spectrum shows 
high choline (arrow). This patient scores for all modalities five points (20/20). Scale: 1 no 
tumor, 5 definitely tumor.
A study that directly compared endorectal MRI with digital rectal and TRUS-guided biopsy 
localization revealed significant incremental value from MRI [66]. In patients subjected to 
multiple prior negative TRUS-guided biopsies, anatomical MRI by means of T2-dominated 
acquisition plays an important role. In this patient population, an 83% sensitivity and 50% 
positive predictive value for MRI have been established [67].
Postbiopsy hemorrhage causes areas of low signal intensity on T2-weighted imaging, 
thereby making prostate cancer detection more difficult. However, it was shown recently 
that the amount of hemorrhage was significantly lower in areas of cancer compared with 
healthy tissue [68].
MRSI. Additionally, MRSI (Figure 3G) can be added to the protocol to provide metabolic 
information based on the citrate, choline, and creatine levels, and their ratios within the 
prostate. This is highly informative since the ratio between choline and citrate alters during 
the transformation from healthy to malignant prostatic cells [69,70] and an increasing 
choline + creatine/citrate ratio was correlated with higher Gleason scores [71]. Presently, 3D 
MRSI of the entire prostate can be performed [72], thereby aiding in the diagnosis of central 
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gland PC. The addition of 3D MRSI to MRI has increased localization accuracy, particularly by 
raising specificity up to 91% [73]. However, a limitation of MRSI is its low spatial resolution. 
Compared to systematic biopsy, PC localization by means of MRI and MRSI was found to be 
more sensitive (67% and 76% versus 50%) but less specific (69% and 57% versus 82%) than 
systematic biopsy [74]. With whole-mount section histopathology as standard of reference, 
3D MRSI had a significantly larger area under the receiver-operating curve (AUC) of 0.80 in 
localizing cancer, compared with 0.68 with T2-weighted MRI [75]. Adding the combination 
of T2-weighted imaging and MRSI to clinical data was shown to have the highest accuracy 
(AUC 0.85) in predicting the probability of a patient having insignificant prostate cancer [76], 
significantly higher than that of clinical nomograms. A recent multi-institutional American 
College of Radiology Imaging Network study raised doubts on the additive value of MRSI 
over T2-weighted imaging alone [77]. However, potential factors for this result were the 
selected prostatectomy population, the small average cancer focus size, and the inclusion of 
centers without any previous MRSI experience.
Diffusion weighted imaging (DWI). DWI is a novel non-invasive technique that measures the 
fractional anisotropy of water molecules within the prostate which is expressed in apparent 
diffusion coefficient (ADC) mapping. Thereby, cancer tissue is deemed to result in a more 
restricted movement of water molecules and thus producing lower ADC values (Figure 3C, 
D) [78,79]. A recent study in 38 patients, performed at 1.5T with an ERC observed that the 
mean ADC values of regions of interest placed within prostate cancer tissue was significantly 
lower than those placed within healthy prostate tissue [80]. In preliminary studies, 
combining this technique with MRSI [80] or T2-weighted imaging [81] significantly improved 
the localization accuracy. A recent study in 37 patients revealed a significant increase in 
sensitivity from 51% for T2-weighted imaging to 71% for combined T2-weighted and DWI 
reading [82]. In a recent multiparametric analysis, DWI was the best-performing parameter 
[83]. Preliminary studies at 3T show promising results [84–86]. The b value used appears to 
affect the PC localization accuracy, as in a preliminary study imaging with a b value of 2000 
s/mm2 was shown to have a significantly higher accuracy compared with 1000 s/mm2 [87], 
possibly due to a fall in the signal-to-noise ratio. At biopsy, DWI may aid in differentiating 
between low-risk and high-risk patients [88].
Dynamic contrast-enhanced MRI [83,89]. To further enhance localization accuracy of 
MRI, one may use contrast agents. Dynamic contrast-enhanced endorectal MRI, in which 
the contrast agent concentration is followed in time [90], is able to discriminate between 
healthy prostatic tissue and PC [91]. Early contrast enhancement and high (relative) peak 
enhancement are the most accurate predictors of PC of the PZ, while fast washout of 
contrast agent and high permeability of the blood vessels (Figure 3B, F) are most sensitive 
for central gland PC [92,93]. A recent study showed that the AUC for localizing PC increased 
significantly from 0.68 with regular anatomical MRI to 0.91 by applying contrast agent [75]. 
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However, limitations of using contrast agents are the higher costs and possible adverse 
reactions, of which the most serious, anaphylaxis, is rare [94,95].
Multiparametric imaging. Combining any number of these techniques (‘multiparametric 
imaging’) has shown to increase the ability of MRI to detect and localize prostate cancer 
(Figure 3A–G) [96–98].
High-field imaging. An important future direction is the use of higher magnetic field strengths 
(e.g. 3T) [99–101] (Figure 4). Compared with body array coil MRI, the higher resolution 
obtained with ERC MRI at 3T significantly improved PC localization accuracy [102].
Figure 4. A comparison of the image quality between axial endorectal coil (ERC) MRI at 1.5 T 
(A) and 3 T (B) in the same patient (age: 58 years, PSA level: 2.7 ng/ml, Gleason biopsy score: 
6, normal digital rectal examination). The visibility of the internal architecture of the central 
gland (*) increased and the capsule (arrowheads) is better delineated at a field strength of 3 
T and the tumor (T) as outlined by the histopathology (C) is also better appreciated (arrows).
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Biopsy. Another development is to directly biopsy the prostate by means of MRI [103]. 
Preliminary results of direct MR-guided transrectal biopsy of suspicious lesions on pre-
biopsy MRI in patients with prior negative or inconclusive TRUS-guided biopsy results 
demonstrated the feasibility of MR prostate biopsy without complications. Nevertheless, 
disadvantages of the biopsy device are its limited reach, particularly towards the base of 
the prostate, and procedure duration [104]. In a study of 68 patients with at least two prior 
negative TRUS biopsy sessions, MR guided biopsy established cancer in 59% [105].
Positron Emission Tomography (PET) Scanning: Metabolic information yet not sufficiently 
discriminatory from benign disease
FDG. The utility of PET scanning with fluorine-18-labelled deoxyglucose (FDG) in detecting 
PC is compromised by the relatively low uptake of FDG by prostate cancer cells [106] and 
significant overlap with marker uptake by BPH. Moreover, reports of FDG uptake correlating 
with PC aggressiveness have been conflicting, although FDG uptake was substantially higher 
in metastasized compared to organ-confined primary cancers [107]. A further drawback 
is that the normal urinary FDG excretion results in high bladder activity which obscures 
pathological FDG uptake in the prostate. Generally, FDG PET is not recommended for 
evaluation of the prostate as sensitivities are as low as of 4–64% with a specificity in the 
order of 50% [108–110].
11C-choline. Another tracer, carbon-11-labelled choline (11C-choline), accumulates in 
prostatic cells and has the advantage that, unlike FDG, it is not excreted via the urinary tract, 
and thereby does not influence the visualization of the prostate [111]. Furthermore, the 
prostate is the only organ in the pelvis to accumulate 11C-choline. The 11C-choline uptake 
was higher in PC compared with BPH, but the difference was not significant [112]. In a 
direct comparison between 11C-choline PET and MRSI, a significant linear correlation was 
observed between the maximum standardized uptake value (SUV) of 11C-choline and the 
MRSI metabolite ratios. Also, 11C-choline PET was more accurate than MRSI in accurately 
predicting the laterality (i.e. left- or right-sidedness) of the cancer: 81% (13/16) versus 50% 
(8/16), respectively [113]. Recently, it was shown that 11C-choline preferentially detected 
more aggressive prostate cancer foci [114]. Drawbacks are the high costs of 11C-choline and 
the short half-life of 11C-choline (20 minutes). This latter precludes application of 11C-choline 
in centers without cyclotrons. Nevertheless, the results of the first two studies combining 
11C-choline PET/CT scanning were encouraging, with a sensitivity of 66% and specificity 
between 81–84% on a sextant basis [115,116]. However, the high rate of false negative 
findings was a concern. A direct preoperative comparison between 11C-choline PET, FDG PET, 
and MRI in 43 patients showed that 11C-choline outperformed FDG PET in localizing prostate 
cancer but that MRI was superior to both [117].
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Other radiopharmaceuticals. A preliminary PET/CT study using fluoro-18-choline (18F-choline) 
demonstrated its feasibility, but reported its inability to distinguish cancer from BPH [118]. 
In a small population of both primary and recurrent disease, dual-phase 18F-choline showed 
that areas of malignancy had stably high or increasing uptake while benign areas had 
decreasing uptake [119]. Thereby, this technique may aid in differentiating malignant from 
benign prostatic tissue. In a double-tracer study, 11C-acetate PET was more sensitive than 
FDG, showing consistently increased uptake in PC lesions [120]. A further advantage was 
that 11C-acetate did not accumulate in the urine. Again, a considerable uptake overlap was 
described between normal prostatic tissue, BPH and PC [121].
ProstaScint® scanning: No place in regular clinical practice
ProstaScint® (Cytogen, Princeton, NJ) is an Indium-111 labeled monoclonal mouse antibody 
specific for prostate-specific membrane antigen. A significant association between the PSA 
level and detection of ProstaScint® activity in the prostate was reported [122]. A recent 
study revealed sensitivities between 37–87% and specificities between 0–50%, concluding 
that the scan could not be used to reliably localize prostate cancer foci within the prostate 
[123]. In a single study of only seven patients in which the results of ProstaScint® fusion with 
CT scanning were correlated with systematic biopsy a sensitivity and specificity of 79% and 
80%, respectively, were found [124]. In 47 of 51 (92%) preoperative patients at high risk of 
metastatic disease an increased ProstaScint® activity in the prostate was observed [125].
A drawback is that the antibodies clear slowly from the vasculature and muscle. Blood and 
bone modality has no place in primary prostate cancer detection and localization.
CONCLUSIONS AND DISCUSSION
In summary, new developments in ultrasound imaging (Doppler imaging and particularly the 
application of contrast agents) have proved capable of increasing the PC detection rate with 
fewer biopsy cores necessary as well as detecting relatively more aggressive cancer foci. This 
is a substantial improvement for the patient, who will have to undergo fewer biopsies. In 
addition, treatment guidance is improved since more representative areas are discovered 
at biopsy and thus the subsequent diagnostic process can be more accurately performed. 
TRUS remains the primary imaging tool because of its ease-of-use and its role in guiding 
prostate biopsy. However, TRUS accuracies varied widely among studies, in part due to the 
inherent high inter-observer variation, particularly in Doppler imaging.
MRI achieves high accuracy rates, particularly when functional information from dynamic 
contrast-enhanced MR and MRSI are added. A multiparametric approach was shown to 
optimize the diagnostic accuracy. This compensates for the longer examination time and 
the discomfort of the use of an ERC. Nevertheless, on a cost-effectiveness basis, MRI cannot 
be performed in all patients at risk of PC [126]. In patients with one or more prior negative 
TRUS-guided biopsy sessions and continuing suspicion of PC, MRI can provide valuable 
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additional information for PC detection and localization and thereby reduce the future 
number of biopsies the patient must undergo. Direct MRI guided biopsy is a novel method 
of performing targeted prostate biopsy.
CT scanning does not play a role in PC detection or localization because of its low soft-tissue 
resolution and radiation burden. This also applies to PET scanning due to its high costs and 
invasive nature, as well as the availability of alternative imaging modalities. PET scanning 
may possibly be used in instances in which TRUS-guided biopsies are negative and absence 
of evidence of PC on MRI. In addition, combining or fusing PET scanning with, for instance, 
MRI may be of additional value.
Patient at risk of prostate cancer, 
e.g. with elevated PSA (> 3.50 ng/ml) and/or abnormal DRE 
TRUS-guided biopsy  
(lateral sextant + targeted contrast-enhanced Doppler) 
Positive Negative 
Exclusion of disease 
Multiparametric MR imaging 
(1.5T / 3T) 
Suspicion Cancer No suspicion 
cancer 
Active surveillance 
Directed biopsy 
(TRUS or MRI) 
Risk assesment of stage 
Positive Negative 
Figure 5. Proposed scheme for optimal use of imaging in patients at risk of prostate 
having prostate cancer. Abbreviations: PSA, prostate-specific antigen; DRE, digital rectal 
examination; TRUS, transrectal ultrasound; PPA, pelvic phased-array coil.
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PROPOSALS FOR OPTIMAL USAGE OF IMAGING
Scheme
Based on the abovementioned, the authors propose the following scheme for patient care 
in patients at risk for prostate cancer (Figure 5). 
Comparison with AUA and EAU guidelines [127–129]
Both associations recognize that the stage migration during the PSA era necessitates more 
accurate techniques in detecting and localizing prostate cancer. Use of TRUS to guide biopsy 
is regarded the standard of reference. The EAU’s guideline, however, does not mention any 
contrast-enhanced Doppler imaging based biopsy strategies. This is in contrast to the data 
presented in our review. Neither CT scanning nor MRI is recommended or mentioned in 
relation to prostate cancer diagnosis. The latter is in contrast with our proposal in which MRI 
is used in patients in whom no cancer was found on first TRUS biopsy but with persistently 
high or rising PSA levels.
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CHAPTER 3
State-of-the-art uroradiologic imaging 
to determine prostate cancer stage
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In the diagnostic process of prostate cancer (PC), radiologic imaging modalities significantly 
contribute to the determination of extent of the disease. Establishing the exact local disease 
extent in either organ-confined or locally advanced, as well as establishing is highly important 
in determining the optimal patient therapy plan. Within this review, after evaluation of the 
literature, we will discuss the advantages and disadvantages of these imaging modalities in 
clarifying the patient’s clinical status. Bone scintigraphy remains the most sensitive method 
to detect metastatic bone disease but should only be used in high-risk patients. Lymph node 
specific MR contrast agents are promising in nodal staging. However, conventional size and 
shape criteria are still the standard of reference. In determining the local disease stage, MR 
imaging is superior to other imaging techniques. Subsequently, a proposal for optimal use 
of radiologic imaging is presented. 
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With three out of every ten newly diagnosed male cancers being prostate cancer (PC) and 
one in ten male cancer deaths being due to PC [1], the disease burden is considerable. 
After PC has been diagnosed, it is the function of the attending physicians – the urologist, 
radiation therapist, and medical oncologist – as well as the patient and his family, to arrive at 
treatment options that will best serve the patient. It is now believed to be common practice 
that clinicians involved in the treatment of PC patients employ nomograms to determine 
therapeutic options [2-4]. The most frequently used nomogram, the Partin tables, estimates 
the chance of organ-confined disease, extracapsular extension, seminal vesicle invasion 
and lymph node metastasis, based on the results of the traditional triad of digital rectal 
examination, biopsy Gleason score, and prostate-specific antigen (PSA) value [5]. Subsequent 
imaging studies requested by the clinician are based theoretically on the outcomes of such 
nomograms. Likewise, imaging plays an important role in risk stratification. While two 
patients may turn out to have the same PSA level and biopsy Gleason score (a measure 
of cancer aggressiveness scaled from 2 to 10 [6;7]), no two patients will have identical 
transrectal ultrasound (TRUS) or magnetic resonance (MR) imaging findings, an example of 
which is shown in Figure 1.
Each treatment strategy was shown to be associated with distinct patterns of changes in 
quality of life related effects [8]. Additionally, there are factors within the context of the 
patient’s clinical setting that affect the ultimate treatment decision, e.g. expected patient 
longevity, overall health, insurance coverage along with other financial issues, patient 
perceptions of treatment risks, as well as personal preferences [9-11]. Nonetheless, the 
first step in the decision-making process is to answer the crucial question: is the PC organ-
confined or is there spread of cancer beyond the scope of the scalpel, outside of the 
radiation port, beyond the realm of the cryosurgical ice ball, or outside the ultrasound field 
of high intensity focused ultrasound (HIFU)?
This review (1) presents an overview of the currently available imaging modalities to 
determine metastatic spread to the bones and lymph nodes in patients with PC. (2) 
Subsequently, the various imaging modalities for the assessment of local spread are assessed 
with emphasis placed on both the advantages and drawbacks of all methods. (3) From the 
preceding, a scheme is proposed for optimal evidence-based use of imaging in determining 
the PC disease stage.
2.  LITERATURE SEARCH
Relevant articles were retrieved using combinations of both Medical Subject Headings 
(MeSH) and free search terms in the MedLine® (WebSPIRS Version 5.12, Build 20060224, 
Ovid Technologies) and Pubmed (U.S. National Library of Medicine) online search engines. 
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MeSH terms included: “Prostate”, “Anatomy”, “Prostatic Neoplasms”, “Neoplasm Staging”, 
“Ultrasonography”, “Tomography, X-Ray Computed”, “Magnetic resonance imaging”, 
“Magnetic Resonance Spectroscopy”, “Radionuclide Imaging”, and “Positron-Emission 
Tomography”. 
Free search terms included: “prost*”, “cancer”, “detect*”, “localization”, “localisation”, 
“biops*”, “stag*”, “capsul*”, “extracapsular penetration”, “extracapsular extension”, “seminal 
vesicle invasion”, “transrectal ultraso*”, “TRUS”, “computed tomography”, “CT”, “magnetic 
resonance imaging”, “MRI”, “ferumoxtran-10”, “magnetic resonance spectroscopy”, 
Figure 1. An example of two patients (both 61 years of age) with identical PSA levels (5.8 ng/
ml), biopsy Gleason scores (3+3) and normal DRE, but with markedly different MR imaging 
findings. The MR image (A, axial slice) with an endorectal coil (ERC) of patient 1 showed an 
area of low signal intensity (T) in the right peripheral zone towards the base of the prostate 
without signs of extraprostatic extension. Gross pathology (B) and histopathology (not 
shown) confirmed the diagnosis of a Gleason (4+3) tumor (T) (pathological stage T2b, and 
negative surgical margins). Preoperative endorectal MR imaging (C, axial slice) of patient 2 
showed a low signal intensity lesion (T) in the ventral part in the base of the prostate. This 
was accompanied by signs of bulging, indicative of extracapsular extension (arrowheads). 
Gross pathology (D) and histopathology (not shown) revealed a Gleason (3,4) tumor (T) in 
the ventral part of the prostate with capsular penetration (CP) with a radial extent of 0.5 mm 
over an area with a diameter of 4 mm (pathological stage T3a).
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“spectroscopy”, “MRS”, “bone scan*”, “bone scintigraphy”, “positron-emission tomography”, 
“PET”, and “ProstaScint”.
Reference lists of selected articles were further analyzed for relevant articles.
3.  NORMAL PROSTATE ANATOMY IN COMPARISON TO LOCAL,  
 REGIONAL & METASTATIC PROSTATE CANCER 
3.1. Normal Prostate Anatomy 
With the exception of the apex, the whole prostate is surrounded by a thin (2-3 mm) layer of 
fibromuscular tissue, designated as the prostatic capsule [12;13]. Since it is inseparable from 
the prostatic tissue, it is often called a ‘pseudocapsule’. Opposite the apex of the prostate, and 
superior and posterior to the base of the prostate, lie the seminal vesicles (SV) [14] (Figure 
2A). The SV are an accessory gland of the prostate that forms seminal coagulum, modifies 
sperm functions such as motility, and performs phagocytosis of fragments of spermatozoa 
[15]. Via the ejaculatory ducts, the SV empty into the urethra at the verumontanum. The 
dorsolaterally situated neurovascular bundles supply the prostate with blood and nerves 
(Figure 2B). 
SV SV 
A B 
ERC 
Figure 2: MR images of a 53-year-old patient (PSA level 3.74 ng/ml, normal digital rectal 
examination) depicting the anatomy of the prostate related to locoregional spread. (A) The 
seminal vesicles (SV) are cranially located on the base of the prostate and the ejaculatory 
ducts (arrows) drain into the verumontanum. (B) The neurovascular bundle (NVB) (white 
circles) is situated parasagittally to the dorsolateral part of the peripheral zone of the 
prostate. From the NVB, vessels sprout towards the prostate. Abbreviations: ERC: endorectal 
coil. 
40 STATE-OF-THE-ART URORADIOLOGIC IMAGING TO DETERMINE PROSTATE CANCER STAGE
3.2.  PC Anatomy Related to Local, Regional and Metastatic Spread
Predilection sites for local extraprostatic PC spread include the apex, the neurovascular 
bundles, and the SV. Because the (pseudo)capsule is virtually non-existent at the apex, 
this region is vulnerable to extraprostatic spread. In peripheral zone PC, the most common 
location of extracapsular spread is dorsolaterally where the neurovascular bundles 
penetrate the capsule [16]. The SV can be invaded through direct growth of cancer along 
the ejaculatory ducts, by cancer extension outside the capsule and into the SV, or by isolated 
metastasis to the SV without adherence to the primary cancer focus [17]. 
PC is considered locally advanced if it penetrates the prostatic capsule, extends into the 
periprostatic fat, or invades the SV (i.e. TNM stage T3 [18]) or invades other surrounding 
organs, for instance the bladder or rectal wall (stage T4 disease).
PC metastatic degeneration is a lengthy, multistep process [19] and the major locations for 
systemic disease spread are the regional lymph nodes and the bones [20-22]. There is a 
wide variety of lymph drainage paths [23]. However, the nodes in the obturator fossa and 
around the internal iliac vessels appear to be the most frequent route of dissemination, 
occurring in 68% of autopsy patients that have lymph node metastatic disease, although a 
direct spread to the para-aortic lymph nodes has also been described (in 43%) [24-26]. The 
vertebral column, ribs, skull, and proximal ends of the long bones are the most frequent 
locations of metastatic bone disease due to their rich blood supply [27]. Such metastases 
are usually observed at high serum PSA levels (>20 ng/ml), even though they may also be 
present in patients with a high Gleason score (8-10) and relatively low PSA levels, i.e. a low 
PSA leak [28-31]. Only in late-stage PC are metastases to the lungs and liver seen [24]; other 
metastatic sites are anecdotal [25;32].
4.  IMAGING TO EXCLUDE SYSTEMIC AND REGIONAL DISEASE
4.1.  Exclusion of Metastatic Bone Disease
4.1.1.  Conventional X-ray: Too insensitive
A 50% change in bone mineral density is needed for metastatic bone lesions to be visible 
on conventional X-ray images [33] and most PC lesions are sclerotic [24]. Comparing X-ray 
with bone scintigraphy, in 61% of all positive cases, the X-ray examination revealed fewer 
or no lesions compared with scintigraphy [34]. This was concurrent with another study 
which concluded that the X-ray examination detected approximately half of all cases of PC 
metastatic to bone [33]. Therefore, this modality is not sufficiently sensitive for detection of 
metastatic bone disease (Figure 3). It can, however, be used as an adjunctive tool to exclude 
false-positive findings due to conditions such as trauma, degenerative joint disease, or other 
chronic diseases on bone scintigraphy.
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4.1.2.  Computed tomography (CT) scanning: No studies reported
The literature search did not result in identifying any study performing CT scanning for 
determining PC metastatic bone disease.
4.1.3.  Bone scintigraphy: Most Sensitive, Still the Standard of Reference 
The first and foremost diagnostic test to detect or exclude metastatic bone disease is 
technetium-99m-diphosphonate bone scintigraphy. It is difficult to determine its true 
diagnostic performance since most often it is used as standard of reference. In a mixed 
group of cancer types, Charkes et al. validated bone scintigraphy by performing biopsy on 
all lesions observed on scintigraphy and found a detection rate of 79% [35]. Schaffer et 
ERC 
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Figure 3: An example of the sensitivity of MR imaging and bone scintigraphy for detecting 
metastatic bone disease, which went undetected by the conventional X-ray examination. A 
69-year-old man with histologically-proven prostate cancer (PSA level 12.1 ng/ml, Gleason 
score (3+4) in the left side of the prostate, normal digital rectal examination) underwent 
preoperative endorectal MR imaging. A round lesion (white arrows) with low signal intensity 
was observed in the left superior ramus of the ischium on (A) the T1-weighted magnetisation 
prepared rapid gradient-echo series and (B) the T2-weighted axial imaging series. (C) On 
bone scintigraphy, the hot spot (black arrow) was confirmed. (D) On the conventional X-ray 
image, however, no apparent lesion could be detected.
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al. established a 100% sensitivity and 97% specificity with positive and negative predictive 
values of 97% and 100%, respectively [36]. 
A meta-analysis of 23 PC studies found detection rates of 2.3%, 5.3% and 16.2%, for patients 
with PSA levels below 10 ng/ml, between 10 and 19.9 ng/ml, and between 20 to 49.9 
ng/ml, respectively. Above this level the detection rates rose accordingly [37]. In a large 
retrospective study comprising 852 patients, Oesterling et al. found that in patients with 
PSA levels below 20 ng/ml the false-negative rate was less than 2% [38]. In these patients, 
the negative predictive value for bone metastases was 87% [39]. This shows that an in-
depth debate is necessary to determine the precise indications for bone scintigraphy. Bone 
scintigraphy lacks specificity as primary skeletal diseases such as degenerative joint disease, 
traumatic injury to the bones, and, more rarely, Paget’s disease, bone infarcts, and primary 
neoplasms of the bone may cause false positive findings.
4.1.4.  MR Imaging: Radiation-free, Fast, Whole-Body MR Imaging has Future Potential
Until recently, MR imaging of the whole body was impossible within clinically acceptable 
time periods. Today, whole-body MR imaging, which can be performed without having to 
adjust the patient position, appears to be a very sensitive tool for determining PC bone 
metastases. A 30-minute axial skeleton MR screening (a so-called ‘marrow screening’) 
correctly diagnosed 91% of patients, while the 9% of missed metastatic foci were located 
in the peripheral skeleton [40]. A study compromising a heterogeneous group of cancers 
showed that on a patient-by-patient basis, MR imaging scored better than bone scintigraphy 
in detecting metastatic bone disease [41]. A recent study in which axial skeleton MR 
imaging was performed in 66 patients revealed a 100% sensitivity and 88% specificity [42]. 
Advantages of MR imaging are the absence of radiation exposure and the ability to also 
detect non-skeletal metastases.
4.1.5.  Positron Emission Tomography (PET) Scanning: FDG PET Less Sensitive  
 Compared with Bone Scintigraphy But Promising for Therapy Follow-Up
Fluorine-18-labelled deoxyglucose (FDG) – Relatively few studies have performed PET for 
detecting metastatic PC. Bone metastases in PC are primarily sclerotic lesions, and these 
purely sclerotic lesions take up FDG less avidly in comparison to purely lytic or mixed 
metastases [43]. Sensitivity of FDG PET for detecting PC metastatic to bone varied between 
18-75% [20;44-46]. In an analysis of androgen independent PC patients, only 24 of 131 
(18%) sites that were positive on bone scintigraphy displayed increased FDG uptake [45]. 
A biological explanation might be that the metabolism of metastatic cells uses a substance 
different from glucose or that metastatic cells demonstrate a level of metabolism similar to 
normal bone marrow. In another study, FDG PET showed a high positive predictive value of 
98% [44]. A limitation of this study was that most patients with metastatic disease detected 
by FDG PET had PSA levels over 50 ng/ml and metastatic disease was already established 
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or highly likely. Therefore, FDG PET may not be sufficiently accurate in patients with lower 
pre-test risk of metastatic disease. Generally, FDG PET is considered to be inferior to bone 
scintigraphy for PC [47]. Interestingly, however, Morris et al. showed that PET allowed 
earlier detection of a number of bone lesions compared to bone scintigraphy. These authors 
also suggested that FDG PET was able to discriminate between active and dormant lesions 
observed on bone scintigraphy [48]. An advantage of FDG PET over bone scintigraphy is 
its ability to detect also non-skeletal metastatic disease. An important role of PET imaging 
may lie in its ability to detect early treatment response in patients with metastatic disease 
receiving chemotherapy. This could spare patients weeks to months of on-going therapy 
with drugs that are not effective in shutting down cancer metabolism as evidenced by PET 
scan results [20].
Other radiopharmaceuticals – New radiopharmaceuticals are currently under study. A 
double-tracer study comparing FDG with carbon-11-labeled (11C-) methionine PET in 
patients with progressive metastatic PC revealed that these radiopharmaceuticals had 
markedly different sensitivities in detecting bone lesions (48% and 72%, respectively) [20]. 
Heterogeneity of cancer metabolism, which correlates with metabolic transformation to a 
more malignant state, may account for these differences. 
Uptake of 11C-choline in PC foci is higher than FDG and, because it is not excreted via urine, 
does not obscure the prostate gland. In this respect, 11C-choline PET was thought to be 
superior over FDG PET. However, non-specific uptake of 11C-choline in bone marrow may 
lead to false-positive results [49]. A disadvantage of 11C-methionine is the short half-life of 
the radionuclide, thereby restricting its use to study sites with access to a cyclotron.
A lesion-by-lesion comparison between a novel radiolabelled structural analogue of 
5α-dihydrotestosterone, 16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT), which binds to 
androgen receptors, and FDG was performed [50]. In detection of mostly bone metastases 
in castrate patients with laboratory or clinical evidence of disease progression, the detection 
rates were 78% (46/59) for 18F-FDHT and 97% (57/59) for FDG. Therapeutically, 18F-FDHT 
may be applied to analyze the androgen receptor status of the metastases. 
A recent study by Even-Sapir et al. directly compared 18F-fluoride PET, 18F-fluoride PET-CT, 
and bone scintigraphy in a patient population at high risk of bone metastases [51]. On a 
lesion-basis, the sensitivity of 18F-fluoride PET, with or without combined CT scanning, was 
100% in determining metastatic bone disease. While the specificity for 18F-fluoride PET alone 
was only 79%, it increased to 100% when PET was fused with CT scanning. This technique, 
therefore, shows great promise in detection of metastatic bone disease.
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4.1.6.  ProstaScint® Scanning: Better Alternatives Available
One study concluded that the ProstaScint® (Cytogen Corporation, Princeton, NJ, U.S.A.) 
interpretation score did not significantly correlate with the risk of distant metastasis [52]. 
Considering the better performance of the alternative imaging modalities, ProstaScint® is 
not recommended for detecting metastatic bone disease.
4.2.  Exclusion of Metastatic Lymph Node Disease (Table 1)
If the chance of lymph node metastasis is relatively high based on nomograms many 
institutions perform staging pelvic lymph node sampling [53] during radical prostatectomy 
or as a separate intervention before radical prostatectomy. The threshold levels for surgical 
intervention vary among institutions. However, imaging can play a role in selecting patients 
for lymph node sampling.
4.2.1.  Ultrasound: No Role
Ultrasound plays no role in this phase of staging. Although it may possibly aid in 
characterizing superficial lymph nodes [54], deep lying lymph nodes would cause difficulties 
in visualization. A single study from 1988 on this topic showed 0% sensitivity in detecting 
positive PC lymph nodes [55].
4.2.2.  CT Scanning: Size-Only Criteria with Low Sensitivity, But Well-Suited  
 for Biopsy Procedures
CT interpretation of lymph nodes essentially is based on size and to a lesser extent on shape 
criteria. A recent systematic review of the accuracy in staging of lymph nodes in PC showed 
that CT was not sufficiently accurate, particularly in patients with PSA levels below 20 ng/ml 
and relatively well-differentiated cancer on biopsy. While the upper limit of normal lymph 
node size generally is 10 mm [56], some studies used thresholds as small as 6 mm [57]. 
While highly specific (95-100%), sensitivity is too low (0-25%) (Table 1) for it to be useful 
in regular clinical practice for the evaluation of metastatic lymph node disease [58]. Some 
authors advocate restricting the use of CT scanning for high risk patients (e.g. with PSA levels 
above 20 ng/ml) in order for it to be cost-effective [59;60]. In case a suspicious pelvic lymph 
node is observed, CT scanning is the imaging procedure of choice for performing biopsy and 
is associated with relatively few complications [57].
4.2.3. MR Imaging: Only Lymphotropic Contrast Agent Perfects Diagnostic  
 Accuracy, However No Direct Biopsy Possibility Yet
Like CT scanning, conventional MR imaging uses size and shape criteria in assessing lymph 
node status. In a retrospective study of 174 patients, Wolf et al. found a 25% sensitivity of 
detection of positive lymph nodes with a 97% specificity [60] by MR imaging alone. In a 
recent landmark study comprising 80 patients from two centers, a sensitivity and specificity 
of respectively 35% and 90% were achieved on a node-by-node analysis [61]. A recent study 
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found that combining MR imaging of the lymph nodes with local MR imaging features of 
prostate cancer, such as extracapsular extension or seminal vesicle invasion, significantly 
increased the diagnostic accuracy [62]. 
MR lymphography (MRL) using lymphotropic ultrasmall superparamagnetic iron-oxide-
containing (USPIO) nanoparticles that migrate to lymph nodes after intravenous injection 
and subsequent phagocytosis by macrophages [63], has heralded a new era in lymph node 
imaging. These contrast agents visualize nodes by disturbing the magnetic field, thereby 
turning healthy lymph nodes hypointense using an ironsensitive sequence (Figure 4). In 
metastastic lymph nodes, the metastatic deposits displace contrast-laden macrophages. 
Thereby, these areas of metastasis do not display disturbance to the magnetic field and 
therefore remain hyperintense. Using the USPIO agent ferumoxtran-10 (Combidex®/
Sinerem®, Guerbet, France), Harisinghani and Barentsz et al. achieved 97.3% accuracy with 
high sensitivity (90.5%) and specificity (97.8%) on a node-by-node basis [61]. A meta-analysis 
of studies using ferumoxtran-10 in various cancer types showed a significantly improved 
precision in lymph node staging [64]. 
MRL will provide major benefits to non-invasively evaluate the nodal status of patients with 
PC, particularly patients at high risk, and allow many to forego lymph node sampling. This 
will lead to fewer complications [65] and markedly decreased healthcare costs [23;66]. 
Furthermore, MRL should also enable the biopsy of lymph nodes that are outside the 
A B C 
Figure 4: An example of a positive internal iliac region 5.5 mm lymph node in a 66-year-
old patient (PSA: 18 ng/ml, Gleason biopsy score (4+3), and abnormal DRE). (A) CT scan in 
sagittal reformat of a small lymph node of normal size. (B) Post-ferumoxtran-10 T1-weighted 
TSE MR image (which is insensitive to iron) shows one gray normal-sized node (circle). (C) On 
the post-ferumoxtran-10 T2*-weighted MEDIC MR image (which is iron-sensitive) this node 
is white (circle). Histopathology confirmed that the lymph node was completely involved by 
metastatic PC.
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normal anatomical (obturator) area from which urologists routinely obtain samples [23]. 
MRL will improve staging and provide patients with more tailored treatment, which should 
translate into improved survival. 
Inflamed lymph nodes could mimic positive findings. Hyperplastic, reactive lymph nodes 
will turn black after administration of ferumoxtran-10. An additional probable difficulty will 
be that during surgery the urologist may not find all the lymph nodes identified on MRL; 
this due to the small size of the nodes and the disturbed visual plane, a common feature 
during laparoscopic surgery. However, both the Food and Drug Administration (FDA) and 
the European Medicines Agency (EMEA) have not approved ferumoxtran-10 for clinical use. 
In future, proton MR spectroscopic imaging may possibly be of help in differentiating benign 
from malignant lymph nodes [67]. 
4.2.4.  PET Scanning: Metabolic Information with Low Spatial Resolution
 and Risk of False-Positives
Poor anatomical correlation is a major limiting factor in interpreting images with PET. FDG 
PET uptake by positive lymph nodes is insufficiently consistent to be useful for decision-
making [68]. The use of integrated PET-CT scanners improves image interpretation as CT will 
provide the anatomical background for abnormalities identified by PET. 
An advantage of using 11C-choline-PET over FDG-PET is that the urinary activity of 11C-choline 
is negligible [49]. 11C-choline-PET is able to detect lymph node metastases as small as 5 mm. 
Below this size, false-negativity is an important issue. False-positivity may be due to bowel 
motion, bowel uptake, reactive lymph nodes, or non-specific uptake in lymph nodes [69;70]. 
Improvement is required and new tracers are constantly being tested. In a preliminary study, 
18F-fluorocholine showed higher uptake in both primary and metastatic PC than FDG [71]. 
In another preliminary study in recurrence patients, 11C-choline-PET revealed promising 
results with a high PPV of 86%, although the NPV was relatively low (72%) [72]. However, 
the presence of a cyclotron nearby is needed for these radionuclide tracers.
4.2.5.  ProstaScint® Scanning: Costly, with Intermediate Diagnostic Accuracy 
The ProstaScint® (Cytogen Corp., Princeton, NJ) scan uses Indium-111-labelled monoclonal 
antibodies specific for prostate-specific membrane antigen. Sensitivities and positive 
predictive values varied substantially, ranging between 17-75% and 11-79%, respectively, 
while specificities and negative predictive values were less variable between 72-94% (Table 
1). Many studies, however, used the procedure in patients with already established or (very) 
high probability of metastatic disease [73;74]. Disadvantages that preclude its use in the 
routine diagnostic work-up are the high number of false-positives [75], the high costs, and 
the necessity of acquiring several scans over multiple days. 
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5.  Patients in Whom Systemic Spread of Disease Has Been Excluded: Imaging to  
 Exclude Locally Advanced Disease (Table 2, Figure 5)
After exclusion of systemic disease spread, the next clinical question is whether the disease 
is locally advanced or organ-confined. When locally advanced, curative surgery or radiation 
therapy may no longer be a curative option. 
5.1.  TRUS: Wide Range of Accuracies Found, No Strict Diagnostic Criteria
While no strict criteria for determining locally advanced disease have been formulated, 
bulging of the prostatic capsule is most often used. Accuracies of gray-scale TRUS in 
determining the local disease stage varied from 63 to 91%, with sensitivities and specificities 
ranging between 30-84% and 77-96%, respectively (Table 2). In most studies the accuracy 
for identification of SV invasion (81-97%) was higher than that of extracapsular extension 
(57-94%) [76-80].
Particularly, three-dimensional TRUS was found to aid in assessing local disease extension 
for both extracapsular extension and seminal vesicle invasion [78;81]. Also, increased 
capsular flow on color Doppler imaging has been applied as a criterion [82]. However, only 
one study performed staging with Doppler TRUS and showed a rather low (59%) sensitivity 
for detecting locally advanced disease [83].
5.2.  CT Scanning: Radiation Burden and Low Sensitivity
Few recent studies have been published. A pre-radiation therapy staging study of 85 
patients showed that CT staging had only a marginal effect on treatment decisions [84]. Platt 
et al. cautioned against using CT in decision-making for prostatectomy candidates due to 
suboptimal sensitivity (33%) and specificity (60%) for SV invasion, while for periprostatic fat 
invasion, sensitivity and specificity were 75% and 60%, respectively [85]. Hricak et al. found 
a low accuracy of 65% and noted that overstaging was a serious problem [86].
It is important to emphasize that most reports on CT staging studies were performed before 
the routine use of PSA. Thus with stage migration towards smaller volume and earlier-stage 
disease [87], the value of CT is further compromised. Two more recent studies revealed low 
sensitivity (26-29%) with a reasonable specificity (80-89%) [88;89].
5.3.  MR and proton MR spectroscopic imaging (MRSI): High-Resolution  
 Anatomical and Metabolic Information with High Sensitivity and Specificity
The application of MR imaging to determine whether PC is locally advanced remains 
controversial due to varying results across institutions. The most reliable MR signs of 
extracapsular extension are bulging of the prostate into the periprostatic fat, obliteration of 
the rectoprostatic angle, and asymmetry of the neurovascular bundles [90]. Seminal vesicle 
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Figure 5: An example of imaging to detect locally advanced disease. A 63-year-old man with 
biopsy-proven prostate cancer (PSA level 8.2 ng/ml, Gleason biopsy sum score 7 on the 
left side of the prostate, negative digital rectal examination). (A) No abnormalities were 
seen on the CT scan. Note that it is difficult to distinguish the prostate (P) contour from 
the periprostatic venous plexus (v). (B) A TRUS examination showed a lesion (L) with low 
echogenicity in the left peripheral zone of the prostate near the neurovascular bundle. On 
both CT and TRUS the prostate cancer was staged as organ-confined disease. Endorectal 
1.5T MR imaging in the axial (C), sagittal (E) and coronal (F) plane revealed an area of low 
signal intensity (L) in the left peripheral zone. This area extended into the periprostatic fat 
(white arrows, (D) magnified image of the area of capsular penetration) and the cancer was 
staged as locally advanced. Note that the venous plexus was distinguished easily from the 
prostatic capsule. (G) Histopathology confirmed the lesion (T) with a Gleason sum score of 7 
and extracapsular extension (area between the black arrows) with a radial distance of 2 mm. 
Abbreviations: R: rectum, ERC: endorectal coil.
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invasion is usually easily detectable by areas of low signal intensity in the brighter seminal 
fluid.
Two meta-analyses on local staging by MR imaging at 1.5 tesla (T) found combined maximum 
sensitivities and specificities of 71-74%, while sensitivity was 62-69% at a specificity of 80% 
[91;92]. Imaging in more than one plane as well as utilizing an endorectal coil resulted in a 
significantly better staging performance. A large study conducted by Cornud et al. comprising 
336 patients found an overall sensitivity, specificity, positive, and negative predictive value 
of 40%, 95%, 79%, and 76%, respectively [93]. High-specificity MR reading (allowing only 
definite locally advanced cases to be excluded from curative therapy) is now the optimal 
local staging method [94;95]. 
It was established that adding MR imaging with an endorectal coil to clinical data such as 
PSA, biopsy Gleason score, or the Kattan nomogram resulted in a significantly increased 
accuracy of predicting disease stage, extracapsular extension, and seminal vesicle invasion 
[90;96;97]. Recently, it was shown that the presence and the degree of MR imaging predicted 
preradiation therapy extracapsular extension was a predictor of posttherapy outcomes [98].
Experience was found to be an important factor [99]. However, the accuracy of a less 
experienced reader could be increased by applying contrast agent [100]. Likewise, reading 
MR images with multiplanar cross-referencing significantly improved staging accuracy 
compared with reading without cross-referencing [101]. Also, addition of three-dimensional 
MRSI to MR imaging improved staging accuracies, particularly for less experienced readers 
and increased interobserver agreement [102]. A drawback is the longer duration (by 
approximately 15 minutes) of the examination. 
Imaging at higher magnetic field strengths (e.g. 3T) results in higher image resolution. 
Although not yet widely available for clinical work, two studies on local staging at 3T reported 
sensitivities and specificities of experienced readers of 80-88% and 94-100%, respectively 
[103;104]. In the current PSA era, this higher resolution is mandatory as PC is detected at 
earlier stages. Likewise, if extracapsular extension is present, it will most often be minimal.
5.4.  PET Scanning: No Studies Reported
The literature search did not result in identifying any study on the topic of PET to determine 
the local disease stage.
5.5.  ProstaScint® Scanning: No Studies Reported
The literature search did not result in identifying any study directly using ProstaScint® to 
determine the local disease stage. One study did report that when integrating ProstaScint® 
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scores in an artificial neural network, it did not contribute to determining the local disease 
stage [52].
6. CONCLUSIONS
Exclusion of metastatic bone disease – Bone scintigraphy remains the single most sensitive 
method of detecting bone metastases. Targeted conventional X-ray can be used as an 
adjunct to scintigraphy to exclude false-positive findings. The use of bone scintigraphy 
should be limited to prevent its unnecessary use in patients with negligible risk of metastatic 
bone disease. Therefore, it should only be used in patients with PSA levels above 20 ng/ml 
or with biopsy Gleason scores of (4,3) or higher, or in whom the digital rectal examination 
was positive. In the future, whole-body MR imaging may play a role, especially due to the 
ability to detect also non-skeletal metastases within the same examination. Although still 
speculative, FDG-PET may be helpful in facilitating an early assessment of response to 
treatment. This may result in the patient being spared multiple cycles of chemotherapy 
with its inherent toxicity and costs.  
Exclusion of metastatic lymph node disease – Lymph nodes are the first station of 
dissemination for PC and optimal sensitivity (91%) and specificity (98%) is achieved by using 
USPIO-enhanced MR imaging in patients with an intermediate to high risk of metastatic 
disease. FDG-PET scanning suffers from a lack of spatial resolution that is overcome by the 
use of integrated PET-CT, but generally low uptake of the radiopharmaceuticals in metastatic 
PC cells remains an important issue. FDG-PET may again serve as an early predictor of 
treatment response to a particular chemotherapy agent. CT scanning is too insensitive to be 
used in detecting positive lymph nodes but is the modality of choice for pelvic lymph node 
biopsy. With other alternatives available, ProstaScint® scanning should not be part of routine 
staging protocols.
Exclusion of locally advanced disease  – Initial results of TRUS before the introduction of 
the PSA screening test were excellent. However, the subsequent stage migration towards 
less advanced cancers after the introduction of the PSA test necessitates staging modalities 
of higher resolution to assess correctly the extent of PC. MR imaging at 1.5T using an 
endorectal coil combined with a pelvic phased-array coil is currently the optimal clinical 
choice for determining the local disease stage. MRSI and contrast agents can be used to 
increase the staging accuracy for less experienced readers. With endorectal MR imaging at 
3T, the sensitivity of detecting even minimal capsular penetration can be further increased. 
CT scanning is too insensitive to play a role in local disease staging.
A proposed scheme for optimal use of imaging in staging of prostate cancer is shown in 
Figure 6.
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A. High-risk 
                  - PSA > 20 ng/ml 
            or  - GS ≥ 8 
            or  - positive DRE 
1. Is metastatic bone disease present? 
99m-Tc bone scintigraphy 
Positive 
Possible use 
conventional X-
ray 
Negative 
2. Is metastatic lymph node disease present? 
MRL using lymphotropic USPIO 
Positive Negative 
3. Is the disease locally advanced? 
Endorectal mpMR 1.5T with contrast, or,  
Preferably  3T mpMR 
Locally advanced Organ-confined 
RP / RT / Cryo / WW   Work up as in high-risk  CT-guided biopsy or LND ADT or RTx 
B. Low-risk 
 - PSA < 10 ng/ml 
  and  - GS < 7 
  and  - negative DRE 
B. Intermediate risk 
- PSA 10 - 20 ng/ml 
    or  - GS ≥ 7 
    or  - positive DRE 
Figure 6: Proposed scheme for optimal use of imaging in patients in whom prostate cancer 
has been diagnosed. The scheme is based on three basic clinical questions that need to 
be answered and patient risk stratification: 1. Is metastatic bone disease present? 2. Is 
metastatic lymph node disease present? 3. Is the disease locally advanced? Each answer to 
these questions will change the course of therapy and each step can be aided by applying 
diagnostic imaging. A deviation from the AUA and EAU guidelines is indicated with double 
asterisks (**). Abbreviations: PSA: prostate-specific antigen, GS: Gleason biopsy sum score, 
DRE: digital rectal examination, Tc: Technetium, MRL: magnetic resonance lymphography, 
USPIO: ultrasmall paramagnetic iron-oxide containing particles, ADT: androgen deprivation 
therapy, RT: radiation therapy, CT: computed tomography, LND: lymph node dissection, 
WW: watchful waiting, RP: radical prostatectomy, Cryo: cryotherapy.
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CHAPTER 4
Prostate Cancer: Local Staging at 3-T 
Endorectal MR Imaging—Early Experience
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Purpose: To prospectively investigate the local staging accuracy of 3-T endorectal magnetic 
resonance (MR) imaging for prostate cancer by using whole-mount-section histopathologic 
analysis as the standard of reference. 
Materials and Methods: This study was approved by the institutional review board, and 
informed consent was obtained from all patients. In 35 consecutive patients (median age, 
62.3 years) with biopsy-proved prostate cancer, 3-T endorectal MR imaging was performed. 
High-spatial-resolution endorectal T2-weighted fast spin-echo images of the prostate were 
obtained in three planes. MR images were prospectively evaluated by two experienced 
radiologists and a third radiologist who was less experienced with regard to local disease 
extent by using five established extracapsular criteria. Whole-mount-section histopathologic 
analysis was the standard of reference. Evaluation was performed according to octant and 
patient. Sensitivity, specificity, positive and negative predictive values, overall accuracy, and 
interobserver agreement were calculated. 
Results: Thirty-two patients who underwent radical prostatectomy were enrolled in this 
study. Accuracy, sensitivity, and specificity of local staging were 94% (30 of 32), 88% (seven 
of eight), and 96% (23 of 24), respectively, for both experienced radiologists, and these 
values were 81% (26 of 32), 50% (four of eight), and 92% (22 of 24), respectively, for the 
less experienced radiologist. There was substantial agreement between both experienced 
readers (κ = 0.42–0.79) and moderate agreement between the less experienced reader and 
the experienced readers with respect to all extracapsular criteria. In regard to the three 
cases of minimal capsular invasion, two were detected by both experienced radiologists. 
Conclusion: In this study, high accuracy for staging of prostate cancer at 3-T endorectal MR 
imaging, with moderate to substantial observer agreement, was demonstrated. In addition, 
minimal capsular invasion could be detected.
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Prostate carcinoma is the second most frequent cause of cancer-related death in men [1]. 
The increase in the number of the aged, as well as the advent and the ever more frequent 
use of the prostate-specific antigen serum test for detection, has resulted in an increase in 
prostate cancer incidence [2,3]. Determination of the tumor extension in prostate cancer 
is important not only to allow optimal choice between the various therapeutic options but 
also to influence prognosis and treatment [4–6]. 
Presently, the role of magnetic resonance (MR) imaging of the prostate for detection of 
extension beyond the capsule is being debated because of limited availability, high costs, 
and variability in results [7–9]. A large heterogeneity in local staging performance exists 
[4,9–14]. A frequently described limitation is the inability to demonstrate microscopic 
capsular penetration [7]. 
MR imaging at 1.5-T (the standard clinical field strength) with T2-weighted fast spin-echo 
sequences and combined endorectal and phased-array coils has enabled the acquisition of 
MR images of the prostate and its surrounding tissues with high spatial resolution. Although 
a relatively high spatial resolution can be achieved within a clinically acceptable examination 
time, reported accuracy values for staging vary from 54% to 88% [4,7–15]. Jager et al [16] 
stated that staging with MR imaging in the preoperative work-up of prostate cancer is cost 
effective and should be performed with a high specificity (95%). In attaining this specificity, 
however, a low sensitivity (36%) has to be considered [17]. 
For several years, whole-body MR imaging at high magnetic field strengths (>1.5 T) has 
been used for research purposes only. At present, however, high-field-strength MR imaging 
systems are becoming more widely available in routine clinical settings. Generally, use of a 
higher field strength increases the signal-to-noise ratio linear to the magnetic field strength 
[18], thereby affording the possibility of an increase in either the spatial or the temporal 
resolution of MR imaging. Other effects of clinical MR imaging at high field strengths are the 
increased susceptibility differences in tissues that cause magnetic field inhomogeneities, as 
well as possibly shorter T2 along with longer T1 relaxation times.
Preliminary results with endorectal MR imaging at 3 T in patients with prostate cancer 
contributed to increased spatial resolution of T2-weighted imaging with a voxel volume of 
13 μm3 [19]. To the authors’ knowledge, the role of endorectal MR imaging at magnetic 
field strengths of 3 T in the evaluation of local staging in patients with prostate cancer prior 
to radical prostatectomy has not yet been reported. Thus, the purpose of our study was 
to prospectively investigate the local staging accuracy of 3-T endorectal MR imaging for 
prostate cancer by using whole-mount-section histopathologic analysis as the standard of 
reference. 
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MATERIALS AND METHODS
Medrad, Pittsburgh, Pa, supplied the prototypes of balloon-mounted disposable endorectal 
surface coils and interface devices. The authors, however, had control of the data and the 
information submitted for publication. 
Patient Characteristics
From July 2002 until July 2004, 35 consecutive patients with biopsy-proved prostate cancer 
underwent endorectal coil MR imaging examinations at 3 T. Patients who were scheduled for 
radical prostatectomy within 6 weeks (range, 2–42 days; median, 8 days) after MR imaging 
were included in the study. Exclusion criteria were previous hormonal therapy, lymph nodes 
positive for metastases at frozen section analysis during surgery, contraindications to MR 
imaging (eg, cardiac pacemakers, intracranial clips), and contraindications to endorectal coil 
insertion (eg, anorectal surgery, inflammatory bowel disease). The study was approved by 
the institutional review board, and informed consent was obtained from all patients. 
Median patient age was 62.3 years, with a range of 51–72 years. Median prostate-specific 
antigen serum level was 8.9 ng/mL (range, 1–45 ng/mL), and median Gleason score was 
6 (range, scores 4–7), respectively. MR imaging was performed at least 4 weeks after 
transrectal ultrasonographically guided sextant biopsy. 
MR Imaging Acquisition Protocol
All MR images were obtained with a commercially available 3.0-T whole-body scanner 
(Magnetom TRIO; Siemens Medical Solutions, Erlangen, Germany). A quadrature birdcage 
body coil was used for transmission, and prototypes of balloon-mounted disposable 
endorectal surface coils (Medrad) for 3-T MR imaging were used for receiving the MR 
signals. After digital rectal examination, the endorectal surface coil was inserted and inflated 
with demineralized water to a volume of approximately 60 cm3. Peristalsis was suppressed 
in all patients with an intramuscular injection of 1 mg of glucagon (Glucagen; Novo Nordisk, 
Bagsvaerd, Denmark) immediately before the start of the examination. 
The protocol for acquisition consisted of a localizer and two fast turbo gradient spin-echo 
measurements for patient and coil positioning and high-spatial-resolution T2-weighted fast 
spin-echo imaging in three planes. The imaging parameters for the T2-weighted images 
were as follows: repetition time msec/(effective) echo time msec, 4000/109; flip angle, 180°; 
field of view, 280 mm; matrix, 512 × 256; number of sections, 15–18; section thickness, 4 
mm; section gap, zero. The frequency direction was anteroposterior to decrease coil motion 
artifacts over the prostate. In addition, transverse high-spatial-resolution T2-weighted fast 
spin-echo images (matrix, 768–1024 × 512; field of view, 180 mm) were acquired with a voxel 
volume of 13 μm3, and this acquisition exploited the increased signal-to-noise ratio of the 
endorectal coil at 3 T. Possible biopsy-related hematomas were detected with images from 
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a three-dimensional T1-weighted spoiled gradient-echo pulse sequence performed with the 
following parameters: 8.6/4; flip angle, 15°; number of sections, 32; section thickness, 1.5 
mm; field of view, 130 mm; matrix, 128 × 256; and in-plane resolution, 0.51 × 0.51 mm. Total 
examination time for the aforementioned protocol and coil insertion was approximately 
20–25 minutes. 
MR Image Evaluation
Prospectively, all MR images were independently read by three radiologists who were 
aware that patients had biopsy-proved prostate cancer and were scheduled for radical 
prostatectomy. They were unaware of the other clinical findings. The three radiologists 
had different levels of experience in interpretation of findings from prostate endorectal MR 
examinations. Radiologist A (J.O.B.) had 10 years of experience (total of approximately 700 
studies), radiologist B (J.J.F.) had 3 years of experience (total of approximately 250 studies), 
and radiologist C (S.W.T.P.J.H.), who was considered less experienced than radiologists A 
and B, had 6 months of experience (total of approximately 30 studies). MR imaging studies 
were interpreted at a digital workstation (Impax; Agfa, Mortsel, Belgium). MR image 
evaluation was performed in three planes. All MR images were rated for overall quality as 
good, intermediate, or poor. Image quality was considered to be good if the images showed 
high anatomic detail and minimal artifacts and poor if poor anatomic detail or extensive 
artifacts disallowed the evaluation of the images. All other images were considered to be of 
intermediate quality. 
The readers drew lesion and extraprostatic extension locations in standard schemes of the 
prostate for comparison with the whole-mount sections. The prostate capsule was divided 
into octants; that is, the prostate was split in half (from apex to base) and then further 
divided into four areas: right and left peripheral zone and right and left central gland. The 
most likely sites of capsular extension were identified in each octant and numbered on 
the drawings. T1-weighted images were used to rule out false-positive findings caused by 
postbiopsy hemorrhage; if a low-signal-intensity lesion on a T2-weighted MR image matched 
a high-signal-intensity lesion on the corresponding T1-weighted MR image, this area was 
considered to be a hematoma due to biopsy [20]. 
The presence of extracapsular extension was evaluated on the basis of five specific features 
described in the literature as highly indicative of extracapsular extension. These features 
were as follows: neurovascular bundle asymmetry, obliteration of the rectoprostatic angle, 
irregular bulging of the prostatic contour, tumor signal intensity within the periprostatic fat, 
and overt extracapsular tumor [8,21–23]. The criterion used for determination of seminal 
vesicle invasion was abnormal asymmetric low signal intensity within the lumen on T2-
weighted images [11,23]. 
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The readers expressed the likelihood of each criterion -extracapsular extension and 
seminal vesicle invasion- with a five-point scale. A rating with a score of 1 indicated that 
extraprostatic disease was definitely not present; that with a score of 2, that disease was 
probably not present; that with a score of 3, that disease was possibly present; that with a 
score of 4, that disease was probably present; and that with a score of 5, that disease was 
definitely present. When a score of 4 or 5 was assigned, the criterion was considered to be 
present. When a score of 1–3 was assigned, the criterion was considered not to be present. 
Reading was performed at a high-specificity setting [24,25] for extraprostatic disease (ie, 
only if the reader was certain of stage T3 disease, the disease rated as this stage). This was 
done to prevent the withholding of potentially curative therapy because of the classification 
of false-positive stage T3 disease in a patient with actual stage T2 disease.
Histopathologic Analysis
Three urologists, including one author (J.A.W., with 17 years of experience) and two other 
urologists with 11 years and 4 years of experience, who had knowledge of the MR imaging 
results performed the prostatectomy procedures. The prostatectomy specimens were fixed 
overnight in 10% neutral buffered formaldehyde and were coated with India ink. Seminal 
vesicles were separated from the prostate and examined separately. Transverse whole-
mount step sections were created at 4-mm intervals in a plane parallel to the transverse 
plane used to perform the T2-weighted sequence. All sections were routinely embedded 
in paraffin. Tissue sections of 5 μm were prepared and stained with hematoxylin-eosin. The 
presence and extent of cancer were outlined on the glass cover with the tissue section by 
an experienced genitourinary pathologist (C.A.H.) who had 12 years of experience and who 
was blinded to the imaging results. Staging of the prostatectomy specimens was performed 
according to the present TNM classification [26]. 
Data Analysis
The MR imaging–predicted extraprostatic extension was compared with the findings at 
histopathologic analysis by one radiologist (J.J.F., with 3 years of experience) after assignment 
of scores and evaluation of the data were performed. The T2-weighted fast spin-echo MR 
images were aligned with the whole-mount sections. The morphologic characteristics of 
the central gland and peripheral zone—apex and base of the prostate, cysts, calcifications, 
and urethra—were used as landmarks. Aligning of MR images and whole-mount sections is 
considered difficult [10]. Although no literature is available on this subject, to our knowledge, 
we were confident that our alignment was within 8-mm accuracy (eg, two sections). If the 
detected extraprostatic extension in the whole-mount section was within 4 mm from the 
aligned MR image–detected location and on the correct side, this was considered a match. 
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Statistical Analysis
A finding was considered true-positive in a case in which the imaging results were 
correlated with the histopathologic findings, as mentioned previously. The sensitivity, 
specificity, positive and negative predictive values, and overall accuracy for the prediction 
of extraprostatic criteria, tumor stage, extracapsular extension, and seminal vesicle invasion 
were calculated by dichotomizing the readings. When a score of 4 or 5 was assigned, these 
features were considered to be present. When a score of 1–3 was assigned, the features 
were considered not to be present. This analysis was performed according to patient and 
according to octant. 
The statistical analysis included the evaluation of the interobserver agreement by using 
nonweighted κ statistics. The following qualitative terms were used to describe the strength 
of the various values of κ: 0–0.20, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, 
moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1.00, near-perfect 
agreement (27). Two-tailed tests were used to calculate all P values; a P value of .05 or less 
was considered to represent a statistically significant difference. All statistical analyses were 
performed with software (SPSS, version 9.0; SPSS, Chicago, Ill). 
RESULTS
Surgical Specimens
In three patients, performance of the standard of reference was not available because the 
urologist did not remove the prostate as a result of lymph node metastases, and on the basis 
of this finding, the urologist decided not to resect the prostate. These patients subsequently 
underwent a combination of radiation and/or hormonal therapy. One of these three patients 
had clear invasion of the seminal vesicles at MR imaging, and this finding was reported 
to the urologist. The urologist then performed a biopsy of the seminal vesicle, and results 
were positive for cancer. These three patients were excluded from further analysis; thus, 
32 patients were included in our study. Eight of 32 patients had extracapsular extension; in 
three of these patients, seminal vesicle invasion was observed. In the remaining patients, 
disease was confined to the prostate (stage T2a disease in nine patients and stage T2b 
disease in 15 patients). The image quality was good in 29 patients and intermediate in three 
patients. In six patients, postbiopsy artifacts were visible on T1-weighted images; however, 
the artifacts were not in the area of capsular extension or seminal vesicle invasion. 
Staging
The staging results, with scores assigned according to octant, are presented in Table 1. 
Two hundred fifty-six capsular sites were evaluated for extracapsular extension on the MR 
images. Of these 256 sites, 13 had capsular extension at histopathologic evaluation. Of 
these 13 sites, one was not identified as a site of possible capsular extension on MR images 
by all three readers. The penetration depth of this extension was only 0.5 mm. In three sites, 
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the penetration depth of the capsular extension was less than 2 mm (Figure 1). Two of these 
sites were identified by the two experienced readers (readers A and B).
Table 1. Staging and Statistical Analysis Results for Three Readers according to Octant
Note.—Readers A and B were experienced, and reader C was less experienced.
*  Data are numbers of sites with capsular extension.
†  Data are percentages. Numbers in parentheses were used to calculate percentages.
The staging results, with scores assigned according to patient, are shown in Table 2. The 
overall accuracy in prostate cancer staging (T3 disease vs T2 disease) was 94% (30 of 32) 
according to patient for the experienced readers A and B and 81% (26 of 32) for the less 
experienced reader C. No statistically significant difference was present among readers A, 
B, and C. 
Table 2. Staging and Statistical Analysis Results for Three Readers according to Patient
Note - Readers A and B were experienced, and reader C was less experienced.
*  Data are numbers of patients. 
†  Data are percentages. Numbers in parentheses were used to calculate percentages.
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The results of the readers’ observation of diagnostic features of extracapsular extension 
are given in Table 3. The mean sensitivity values for the individual criteria of extracapsular 
extension ranged from 44% to 88%. All readers obtained a high sensitivity for irregular 
bulging (Figure 1) of the prostatic contour. High specificity was established for all criteria 
(Table 3).
In the three patients in whom seminal vesicle invasion was observed, results were confirmed 
with findings at analysis of the specimen removed at prostatectomy. All readers identified 
the invasion of seminal vesicles, and this result yielded an accuracy of 100% (Figure 2).
A B 
C 
Figure 1. Image in a 62-year-old patient with prostate-specific antigen serum level of 8.2 ng/
mL and Gleason score of 6 show histologically confirmed stage T3a prostate carcinoma. (A) 
Transverse T2-weighted fast spin-echo MR image (4000/109) shows suspicious area of low 
signal intensity (open arrows) in the right peripheral zone. Experienced radiologists identified 
this area as irregular border (solid arrows) of the prostate capsule and classified the disease 
as stage T3a. (B) Sagittal T2-weighted fast spin-echo MR image (4124/109) demonstrates 
disrupted prostate capsule in the same patient (arrow). (C) Histopathologic section reveals 
stage T3a disease with minimal capsule penetration (arrow) in the right peripheral zone.
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Interobserver Agreement
The results of the interobserver agreement analysis are displayed in Table 3. Assessment 
of interobserver variability showed moderate to substantial agreement (κ = 0.42–0.79) for 
ratings in regard to extracapsular extension for all three readers. Agreement was best for 
ratings in regard to tumor signal intensity within the periprostatic fat and irregular bulging 
of the prostatic contour, and agreement was the worst for ratings in regard to obliteration 
of the rectoprostatic angle.
DISCUSSION
The most important findings of our study were the high sensitivity of 88% in the staging of 
prostate cancer, the retention of a specificity of 96%, and the detection of minimal capsular 
extension through the prostate capsule by experienced readers. Two of three cases of 
minimal capsular penetration were recognized by the experienced radiologists (readers A 
and B). This finding suggests a role for prostate MR imaging at 3-T. Although we did not 
perform a comparative study between 1.5-T MR imaging and 3-T MR imaging, the results 
Figure 2. Images in a 66-year-old patient with prostate-specific antigen serum level of 4.5 ng/
mL and Gleason score of 6 show seminal vesicle invasion. Coronal and sagittal T2-weighted 
fast spin-echo MR image (4130/109) obtained through the prostate and seminal vesicles. 
Area of low signal intensity is present in base of prostate and extends into seminal vesicle 
(arrows). This finding was confirmed with whole-mount-section histopathologic analysis.
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of this study indicated that with the 3-T technique the accuracy in staging was increased 
to a level that was higher than that reported for 1.5-T imaging, with a range in accuracy of 
54%–88% [8–11,15].
So far, only four studies about in vivo prostate imaging at high field strengths have been 
published, as far as we know. Kim et al [28] used a relatively large external transceive coil for 
prostate imaging without exploring staging and localization performance with MR imaging. 
In our study, we used an endorectal receiver coil for imaging of the prostate, and use of this 
coil resulted in images with a high in-plane resolution and a voxel volume as small as 0.13 
mm3. This resolution and voxel volume would be very difficult to achieve within a reasonable 
time without the use of a local coil. Sosna et al [29] reported results of volume assessment 
of the prostate at 3-T MR imaging with an external phased-array coil. They concluded that 
in vivo volume determinations were very close to ex vivo imaging volume determinations. 
They, however, did not investigate performance of MR imaging for staging. Bloch et al [30] 
showed a proof of principle of MR imaging of the prostate at 3 T with an endorectal coil in a 
limited study with six volunteers.
In a concurrent study by Fütterer et al [19], patients with prostate cancer were examined by 
using an endorectal coil at 3-T MR imaging. It was shown that the increased signal-to-noise 
ratio with an endorectal coil at 3 T has great potential to improve either the spatial or temporal 
resolution of T2-weighted (dynamic) contrast material–enhanced and spectroscopic MR 
imaging of the prostate. In the current study, we applied this signal-to-noise ratio to obtain 
images with high in-plane resolution for clear delineation of the prostate capsule. Because 
of this increased resolution, we were able to display minimal capsular extension in two 
of three cases. Findings in reports from the early 1990s suggested that minimal capsular 
penetration of less than 1 mm does not adversely affect the surgical cure rate [31,32]. No 
recent data in the literature, however, have confirmed these results.
With the demonstrated ability to detect minimal capsular penetration, the question arises 
about whether the progression from stage T2 disease to stage T3 disease should be used 
as the basis on which clinicians should choose between surgical resection of the prostate 
or a combination of radiation therapy and hormonal therapy for treatment. If minimal 
capsular penetration is detected, curative surgery will be withheld in a patient in whom 
the treatment for the disease is potentially curative. Perhaps the reported early detection 
of stage T3 disease, when it is treated as stage T2 disease, does not affect patient outcome. 
The effect of the detection of minimal capsular penetration, as well as possible implications 
in treatment, has to be evaluated in future studies.
In our study, we found a mean sensitivity of 62% (range, 44%–88%) and a high specificity 
for the criteria of extracapsular extension with moderate to substantial interobserver 
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agreement. Outwater et al [23] found only poor accuracy for the extracapsular criteria at 
1.5-T MR imaging. This difference in accuracy could be caused by the increased in-plane 
resolution in our study (voxel volume of 0.61 μm3) versus that of 0.18 μm3 in the study of 
Outwater et al. All the radiologists read the images with the focus on high specificity [24,25]. 
To prevent overstaging, only if the reader was certain of stage T3 disease was the disease 
rated as such.
The results of the current study showed that there was a difference in accuracy according 
to experience of the reader; these results also showed a difference particularly in sensitivity 
(88% vs 50%). This difference was also found in other studies performed at 1.5-T MR imaging 
[14,33]. The sensitivity and specificity at 1.5-T MR imaging found by Yu et al [33] were 17% 
and 94% and 54% and 95% for the less experienced and experienced readers, respectively. 
This difference in sensitivity values was much smaller in the present study, where sensitivity 
and specificity were 50% and 92% and 88% and 96% for the less experienced and experienced 
readers, respectively.
Despite the promising results of our study, some limitations need to be considered. The 
correlation between findings at MR imaging and the findings at corresponding whole-mount-
section histopathologic analysis was difficult to determine in most patients. This difficulty is 
a frequently encountered problem. The angle at which the whole-mount sections were cut 
in the prostate specimens was never exactly the same compared with the angulation of the 
MR images obtained in vivo. After the prostate specimens are fixed in formaldehyde, the 
specimen shrinks and deforms. We tried to overcome these problems by using all whole-
mount sections in the assessment of the corresponding level.
Because prostate-specific antigen serum levels and Gleason scores were low, only four 
patients with seminal vesicle invasion were included in this study. In one patient with 
seminal vesicle invasion who was excluded from this study because no results of analysis 
with the standard of reference were obtained, the urologist changed the treatment on the 
basis of MR imaging findings, and such a change suggests that the technique used in this 
study may influence a decision about treatment and patient outcome. Such a suggestion, 
however, requires confirmation in a future study.
The number of patients included in this study may be considered rather low. In their 
meta-analyses, Engelbrecht et al [12] and Sonnad et al [17] showed that studies with 50 
patients or fewer had more favorable results than did studies with a higher number of 
patients. In an article titled “Clinical Efficacy of MR Needs Rigorous Study” (Diagn Imaging 
1990;12:69,71,161), Kent, however, estimated that 30–70 patients would be required for a 
comparison of the diagnostic accuracy of MR imaging with that of a reference standard. In 
74 PROSTATE CANCER: LOCAL STAGING AT 3-T ENDORECTAL MR IMAGING—EARLY EXPERIENCE
a future study, a multicenter approach has to be used to confirm our promising preliminary 
results.
The role of endorectal MR imaging in local staging of cancer of the prostate is still controversial. 
A number of articles indicated the poor capability of MR imaging in the staging of cancer 
of the prostate [7–9]. May et al [9] even suggested that treatment decisions should not be 
altered as a result of endorectal MR imaging findings. In contrast, Jager et al [16] developed 
an analytic model for decision making that supported the opinion that MR imaging for staging 
in the preoperative work-up of prostate cancer is cost effective and should be performed 
with a high specificity. Langlotz et al [24] and Langlotz [25] emphasized this need for high 
specificity to ensure that as few patients as possible will be unnecessarily turned down for 
potentially curative therapy on the basis of false-positive MR imaging results. D’Amico et al 
[34] suggested using endorectal MR imaging in patients with intermediate risk only; in this 
group, the probability of extraprostatic disease is high enough to warrant the use of MR 
imaging. If the prevalence of extracapsular disease is, for example, 30% and MR imaging is 
performed with a specificity of 97% and a sensitivity of 33%, then only in one of 10 patients 
will MR imaging results affect the treatment. This could be a reason why urologists do not 
use MR imaging as a modality for staging. If the results of our study are reproducible, this 
number could be extrapolated to one of three or four.
With consideration of the thus far published data, results of this study indicate that 3-T 
endorectal MR imaging of the prostate in staging is of additional value in patients with 
prostate cancer. MR imaging of the prostate at 3 T should be performed only in patients 
with intermediate risk of having extraprostatic disease [34], and it should be performed 
with high-specificity readings by experienced genitourinary radiologists [14]. Nonetheless, 
it remains difficult for less experienced readers to interpret MR images of the prostate; 
however, at 3-T MR imaging, it may be anticipated that interpretation will improve.
In conclusion, in this study, high accuracy for staging with moderate to substantial observer 
agreement at 3-T MR imaging was demonstrated. In addition, minimal capsular invasion 
could be detected. These outcomes suggest a future role for high-field-strength MR imaging 
in the staging of prostate cancer.
The authors gratefully acknowledge Vincent Cuijpers, MSc (Department of Pathology), and 
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CHAPTER 5
Prostate Cancer: Body-Array versus Endorectal 
Coil MR Imaging at 3 T—Comparison of Image 
Quality, Localization, and Staging Performance
78 3T PROSTATE MR IMAGING - BODY-ARRAY VERSUS ENDORECTAL COIL
Purpose: To prospectively compare image quality and accuracy of prostate cancer localization 
and staging with body-array coil (BAC) versus endorectal coil (ERC) T2-weighted magnetic 
resonance (MR) imaging at 3 T, with histopathologic findings as the reference standard.
Materials and Methods: After institutional review board approval and written informed 
consent, 46 men underwent 3-T T2-weighted MR imaging with a BAC (voxel size, 0.43 x 0.43 
x 4.00 mm) and an ERC (voxel size, 0.26 x 0.26 x 2.50 mm) before radical prostatectomy. Four 
radiologists independently evaluated data sets obtained with the BAC and ERC separately. 
Ten image quality characteristics related to prostate cancer localization and staging were 
assigned scores. Prostate cancer presence was recorded with a five-point probability scale 
in each of 14 segments that included the whole prostate. Disease stage was classified as 
organ-confined or locally advanced with a five-point probability scale. Whole-mount-section 
histopathologic examination was the reference standard. Areas under the receiver operating 
characteristic curve (AUCs) and diagnostic performance parameters were determined. A 
difference with a P value of less than .05 was considered significant.
Results: Forty-six patients (mean age, 61 years) were included for analysis. Significantly 
more motion artifacts were present with ERC imaging (P < .001). All other image quality 
characteristics improved significantly (P < .001) with ERC imaging. With ERC imaging, the 
AUC for localization of prostate cancer was significantly increased from 0.62 to 0.68 (P < 
.001). ERC imaging significantly increased the AUCs for staging, and sensitivity for detection 
of locally advanced disease by experienced readers was increased from 7% (one of 15) to 
a range of 73% (11 of 15) to 80% (12 of 15) (P < .05), whereas a high specificity of 97% (30 
of 31) to 100% (31 of 31) was maintained. Extracapsular extension as small as 0.5 mm at 
histopathologic examination could be accurately detected only with ERC imaging.
Conclusion: Image quality and localization improved significantly with ERC imaging 
compared with BAC imaging. For experienced radiologists, the staging performance was 
significantly better with ERC imaging.
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Magnetic resonance (MR) imaging can play a role in the diagnosis of prostate cancer. First, 
the characteristic pattern of prostate cancer as a low-signal-intensity lesion on T2-weighted 
MR images makes MR imaging suitable for detection and localization purposes [1,2]. 
However, at standard clinical field strengths of 1.5 T, an endorectal coil (ERC) is necessary 
to obtain a sufficiently high signal-to-noise ratio with subsequent spatial resolution to allow 
reliable cancer delineation [3] in a clinically reasonable time frame. At higher field strengths 
such as 3-T [4], the signal-to-noise ratio increases [5], and the need for an ERC for detection 
or localization of prostate cancer at this field strength has yet to be determined. The use of 
a body-array coil (BAC) alone for signal reception [6] would save time and costs and would 
cause less discomfort for the patient. A clinical application that requires accurate localization 
of cancer is intensity-modulated radiation therapy [7,8]. Accurate localization can further 
aid in preoperative decisions about the status of the neurovascular bundles, in the direction 
of ultrasound-guided biopsy in patients with negative findings at previous biopsy, or in the 
guidance of high-intensity focused ultrasound treatment.
Second, MR imaging can help in the determination of the extent of local disease, specifically 
whether the cancer is organ confined (stage T2) or locally advanced (stage T3). Recently, 
it was shown that MR imaging at 1.5 T with an ERC outperformed staging nomograms [9]. 
Nevertheless, its use for prostate cancer staging is still a matter of debate [10]. Previously, 
it was shown that staging by means of 1.5-T MR imaging had a joint maximum sensitivity 
and specificity of 71% [11]. Researchers in a preliminary study in 32 patients in whom T2-
weighted MR imaging with an ERC at 3 T was performed found a sensitivity for staging of 
88% (seven of eight), with a high specificity of 96% (23 of 24), for experienced readers [12]. 
However, to our knowledge, no studies have been published about prostate cancer staging 
at 3-T MR imaging with the use of only a BAC for signal reception, nor about comparisons 
of the use of a BAC with that of an ERC at 3-T MR imaging. Therefore, it is important to 
determine whether an ERC is still necessary or a BAC could suffice for staging purposes at 
3-T MR imaging.
Thus, the purpose of our study was to prospectively compare image quality and accuracy of 
prostate cancer localization and staging with a BAC versus those with an ERC at T2-weighted 
MR imaging at 3 T, with histopathologic findings as the reference standard.
MATERIALS AND METHODS
Medrad (Pittsburgh, Pa) unconditionally supplied the prototypes of the balloon-mounted 
disposable 3-T surface ERCs and the interface device. The authors had complete control of 
the data and information submitted for publication.
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Patient Characteristics
The study was approved by the institutional review board. Before inclusion, all patients 
gave their written informed consent. From June 2004 to January 2006, consecutive patients 
who met our study criteria and had biopsy-proved and clinically localized prostate cancer 
were scheduled to undergo MR imaging at 3T with both a BAC and an ERC prior to radical 
prostatectomy. Exclusion criteria were contraindications for MR imaging (eg, pacemaker, 
metal cerebral clips) or ERC insertion (eg, prior anorectal surgery, inflammatory bowel 
disease), as well as severe claustrophobia and high anal sphincter tension that prevented 
ERC introduction. For all included patients, the time between the last biopsy procedure and 
MR imaging, as well as the time between MR imaging and surgery, was determined.
MR Imaging Acquisition
All images were obtained by using a 3-T whole-body imager (Magnetom Trio; Siemens 
Medical Solutions, Erlangen, Germany). In the first part of the examination, a commercially 
available eight-element standard BAC was placed around the pelvic area with the patient 
in the supine position. After localizing images were obtained, T2-weighted fast spin-
echo image series in the transverse, sagittal, and coronal planes were obtained, with the 
transverse image series aligned perpendicularly to the anterior rectal wall. Radiofrequency 
power deposition from the spin-echo train was reduced by using hyperechoes [13]. The 
optimized sequence parameters were as follows: repetition time msec/echo time (TE) msec, 
3700/124; field of view, 220 x 100 mm; section thickness, 4 mm; matrix, 512 x 512; voxel 
size, 0.43 x 0.43 x 4.00 mm; number of signals acquired, two; and acquisition time, 4 minutes 
57 seconds. A three-dimensional T1-weighted gradient-echo image series was obtained to 
exclude hemorrhage after biopsy.
In the second part of the examination, after removal of the BAC and performance of a digital 
rectal examination, a prototype ERC (Medrad) was inserted, with the patient in the left lateral 
decubitus position. The balloon was then inflated with either 40-60 mL of demineralized 
water or perfluoro polyether (Fomblin; Solvay Solexis, Milan, Italy). The patient was placed 
in the supine position, and bowel movement was suppressed with an intramuscular injection 
of 1 mg glucagon (Glucagen; Novo Nordisk, Bagsvaerd, Denmark). An ERC localization image 
series was obtained and, if necessary, the ERC position was readjusted. Subsequently, T2-
weighted fast spin-echo images were obtained with the use of hyperechoes in the transverse, 
sagittal, and coronal planes, with the transverse image series aligned perpendicularly to the 
anterior rectal wall. Sequence parameters were as follows: 5000/153; field of view, 200 x 
100 mm; section thickness, 2.5 mm; matrix, 768 x 384; voxel size, 0.26 x 0.26 x 2.50 mm; 
number of signals acquired, one; and acquisition time, 2 minutes 58 seconds. Last, a three-
dimensional T1-weighted gradient-echo image series was obtained. No adverse events were 
reported, and all patients tolerated the examination well.
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MR Imaging Interpretation
Prospectively, four radiologists, two experienced and two less experienced, independently 
read all imaging data sets from which patient identification was removed. The two 
experienced readers, radiologists A (J.J.F.) and B (S.W.T.P.J.H.), had 4 and 2 years of 
experience, respectively, in ERC prostate MR imaging interpretation, which corresponded to 
the previous reading of 400 and 150 ERC MR studies, respectively. The two less experienced 
readers, radiologists C (S.T.) and D (T.H.), both had 3 months of experience in preoperative 
ERC prostate MR image interpretation; this experience corresponded to the reading of 
approximately 20 MR studies each. Radiologist C, however, had 8 years of experience (which 
corresponded to the reading of 100 MR studies) with preoperative prostate cancer MR 
imaging with the use of a pelvic phased-array coil at 1.5 T. Contrary to the experience level 
of radiologist C, radiologist D participated in a short training course about the reading of ERC 
prostate MR images obtained at 3 T prior to assignment of scores. This course comprised 
the reading of MR images obtained in approximately 15 patients with prostate cancer, with 
direct histopathologic feedback. These patients were not included in the current study.
To prevent information bias of either MR study influencing the other, imaging sets obtained 
with the BAC and the ERC in the same patient were never read in the same session, and 
the order was randomized. The authors were in control of the number of sessions and 
time between sessions. The readers knew the patients had histopathologically confirmed 
prostate cancer at biopsy but were blinded to all other clinical data. Readers classified the 
image quality of each set as excellent, sufficient, or insufficient on the basis of the presence 
of any artifacts that affected image interpretation, as well as the signal-to-noise ratio. If 
artifacts or a low signal-to-noise ratio hampered interpretation of the images, sets were 
classified as insufficient. If no artifacts were present and the signal-to-noise ratio was high, 
sets were classified as excellent. All other imaging sets were classified as sufficient. If either 
imaging set was classified as insufficient by two or more readers, the patient was excluded 
from analysis.
First, the readers were asked to assign a score to 10 image quality characteristics derived 
from both the literature [5,14] and the authors’ (J.J.F., J.O.B.) prior experience. Characteristics 
related to localization included the following: the discrimination between the peripheral 
zone and the central gland, visibility of the peripheral zone itself, visibility of the central 
gland itself, visibility of the lesion, and visualization of the internal architecture of the central 
gland. Staging-related characteristics included the following: the delineation of the prostatic 
capsule, visualization of the neurovascular bundle, and visualization of the rectoprostatic 
angle. A general characteristic was the impression of the overall image quality. These nine 
characteristics were assigned scores on a five-point scale as follows: score 1, poor; score 2, 
moderate; score 3, satisfactory; score 4, good; and score 5, excellent. The final characteristic, 
the presence of motion artifacts that affected image interpretation, was assigned a score on 
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the basis of the following five-point scale: score 1, no artifacts were present; score 2, hardly 
any motion artifacts were present; score 3, image quality was satisfactory; score 4, image 
quality was moderately affected, and score 5, image quality was severely affected by motion 
artifacts. All assignment of scores was performed subjectively without specific criteria for 
each of the five points on the scale.
Second, for the purpose of cancer localization, the prostate was divided into apex, mid 
gland, and base regions. Both apex and base were subdivided into quadrants, and the mid 
gland was divided into sextants; thus, the whole prostate was mapped into 14 segments. 
All readers determined the presence of cancer in each segment with a five-point probability 
scale as follows: score 1, definitely absent; score 2, probably absent; score 3, possibly present; 
score 4, probably present; and score 5, definitely present. The criterion for assignment of 
a classification to a segment as cancerous in the peripheral zone was the appearance of 
an area of low signal intensity on T2-weighted fast spin-echo images [2,15]. In the central 
gland, the criterion was the appearance of an area of homogeneously low signal intensity 
with ill-defined margins on T2-weighted fast spin-echo images [16,17]. Areas of low signal 
intensity on T2-weighted fast spin-echo images and areas of high signal intensity on T1-
weighted gradient- echo images were considered indicative of hemorrhage after biopsy (18) 
and were classified as not containing cancer.
Third, the readers assigned a score for the disease stage with a five-point probability scale 
as follows: score 1, definitely stage T2; score 2, probably stage T2; score 3, possibly stage 
T3; score 4, probably stage T3; and score 5, definitely stage T3. Criteria derived from the 
literature for extraprostatic extension included bulging or irregularity of the prostatic 
capsule, obliteration of the rectoprostatic angle or neurovascular bundle, an area of low 
signal intensity within the periprostatic fat, and marked seminal vesicle asymmetry or an 
area of low signal intensity in the seminal vesicles on T2-weighted fast spin-echo images 
[12,14,19,20]. All radiologists were instructed to perform high-specificity staging [21,22] 
to prevent false-positive judgments. Readers assigned the localization of the perceived 
extraprostatic extension to one or more of the 14 segments.
Surgery with Histopathologic Examination as Reference Standard
All radical retropubic prostatectomies were performed by one of two oncologic urologists 
with 18 (J.A.W.) and 5 (B.C.K.) years of experience who were cognizant of the MR imaging 
results.
After excision, prostatectomy specimens were fixed overnight in 10% neutral buffered 
formaldehyde and coated with India ink. Four-millimeter-interval whole-mount sections 
were cut at a plane comparable to that of the transverse MR imaging plane. All sections 
were routinely embedded in paraffin. Tissue sections of 5 mm were prepared and stained 
with hematoxylin-eosin. The exact localization, volume, Gleason score, extent of each 
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cancer focus, and radial distance [23] of each extracapsular penetration were determined 
by a genitourinary histopathologist (C.A.H.) with 13 years of experience who was blinded to 
the MR imaging results. All specimens were assigned to a stage according to the 2002 TNM 
classification [24].
Data Analysis
Cancer locations and extraprostatic extension predicted on MR images were compared with 
histopathologic findings by radiologists A and B after they had completed assignment of the 
scores and evaluation of the data. Landmarks used for the alignment of T2-weighted fast 
spin-echo MR images with whole-mount sections were the morphologic features of the 
peripheral zone, central gland, apex, and base of the prostate, as well as cysts, calcifications, 
the verumontanum, and the urethra [25]. Only cancer foci of 0.5 cm3 or larger were 
considered suitable for matching with findings on MR images. Therefore, all foci smaller than 
0.5 cm3 were excluded from analysis. Each of the 14 segments was classified as containing 
either cancer or healthy tissue. The authors were confident to be within an 8-mm accuracy 
(eg, two sections) [26].
Statistical Analysis
The 10 scores for image quality characteristics for MR images obtained with the BAC and the 
ERC were compared by applying the Wilcoxon rank sum test for paired samples to the mean 
scores of the four radiologists for each patient.
Receiver operating characteristic (ROC) curves were obtained. The localization performance 
was summarized by using the area under the ROC curve (AUC) [27]. The AUCs were 
statistically compared by using nonparametric boot-strap resampling, with the patient 
as the unit of analysis [28,29]. A bootstrap draw either contained a patient, including 
all regions of interest and the readers who were observing the patient, or did not. The 
number of bootstrap replicates was set to 999. The P values for multiple comparisons 
were adjusted by using Bonferroni correction. The plotted ROC curve was the mean over 
all bootstrap curves for a specific factor. In addition, separate analyses were performed 
for peripheral zone and central gland cancer localization. The AUCs of the overall staging 
performance were calculated. The sensitivity, specificity, positive predictive value, negative 
predictive value, and overall accuracy for cancer localization, overall staging, detection of 
extracapsular penetration, and detection of seminal vesicle invasion were calculated by 
using dichotomization of the readings. For high-sensitivity localization and thus prevention 
of false-negative findings, scores of 3 or higher were considered to indicate cancer, whereas 
scores of 1 and 2 were deemed to indicate healthy tissue. For high-specificity staging and 
thereby prevention of false-positive findings [21,22], scores of 4 and 5 were considered 
stage T3 disease, whereas scores of 1–3 were considered stage T2 disease. To compare the 
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diagnostic performance parameters between MR imaging with the BAC and MR imaging 
with the ERC, the McNemar test for matched pairs was performed.
All P values reported were from two-sided tests. A P value of .05 or less was considered to 
indicate a statistically significant difference. Statistical analyses were performed by using R, 
version 2.1.0 (30), and software (Rockit, version 0.9.1B, Charles E. Metz, PhD, Department of 
Radiology, University of Chicago, Chicago, Ill; Prism, version 4.00, Graph-Pad Software, San 
Diego, Calif; SPSS, version 12.0.1, SPSS, Chicago, Ill).Res
RESULTS
Patients and Histopathologic Findings
Six patients were excluded from the study (Figure 1). In three patients, the ERC MR image sets 
were assigned scores for having insufficient quality caused by coupling artifacts of the ERC 
with the body transmit coil or caused by the presence of excessive motion artifacts, which 
precluded accurate image interpretation. In two patients, the ERC could not be inserted due 
to high anal sphincter tension. One patient had gross extracapsular extension on MR images 
and was subsequently treated with radiation therapy instead of surgery. Forty-six patients 
were included in the study (Table 1). For inflation of the balloon of the ERC, water and 
perfluoro polyether were used in 10 and 36 patients, respectively. The mean time between 
the last biopsy procedure and MR imaging was 112 days (range, 21–226 days), and the mean 
time between MR imaging and surgery was 14 days (range, 1– 89 days).
Figure 1: Flow diagram of the study
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Table 1. Characteristics of 46 Male Patients Included in the Study
A total of 124 separate cancer foci were reported at histopathologic examination. Seventy-
two percent (89 of 124) of cancer foci were located in the peripheral zone and 28% (35 of 
124) were located in the central gland. Fifteen (33%) of 46 patients had locally advanced 
(stage pT3) disease. Of them, 13 had extracapsular penetration (stage pT3a), and five had 
seminal vesicle invasion (stage pT3b). Thirty-one patients had organ-confined (stage pT2) 
disease. The mean radial extracapsular penetration at histopathologic examination in the 13 
patients with stage pT3a disease was 1.4 mm (range, 0.5–3.0 mm).
Image Quality Comparison
All image quality characteristics, except motion artifacts, were improved significantly (P < 
.001) with ERC MR imaging compared with BAC MR imaging (Table 2). Significantly more 
motion artifacts were present during ERC imaging compared with BAC imaging (P < .001) 
(Figure 2). No differences in image quality characteristics were found between images 
obtained with the ERC filled with water and those obtained with the ERC filled with perfluoro 
polyether.
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Figure 2. Comparison of image quality of T2-weighted fast spin-echo MR images at 3 T with 
BAC (3700/124) and ERC (5000/153) in a 58-year-old man (prostate-specific antigen level, 
13.9 ng/mL; final Gleason score, 3 + 4; stage, pT3b). (A) Transverse and (B) coronal BAC 
MR images and (C) transverse and (D) coronal ERC MR images. On all images, the cancer 
(arrows) was localized correctly. Note the improved visibility of the internal architecture 
of the central gland (*) and the increased presence of motion artifacts (arrowheads) with 
ERC imaging on C. A right-left phase-encoding direction was chosen to prevent the motion 
artifacts from propagating over the prostate. (E) Corresponding axial whole-mount-section 
histopathologic slice of the mid gland shows the tumor (T) outlined.
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Table 2. Comparison of Image Quality between BAC and ERC MR Imaging at 3 T in 46 Patients 
according to Four Readers
Note.—The two most experienced readers, radiologists A (J.J.F.) and B (S.W.T.P.J.H.), had 4 and 2 years of experience, 
respectively. Radiologists C (S.T.) and D (T.H.) both had 3 months of prior experience in prostate cancer MR imaging 
by using an ERC. Radiologist C had 8 years of experience in MR imaging at 1.5 T with a pelvic phased-array coil. For 
all image quality characteristics, P < .001 for comparison between BAC and ERC MR imaging.
* Values are the means of the scores assigned by four independent readers for image quality: score 1, poor; score 2, 
moderate; score 3, satisfactory; score 4, good; and score 5, excellent.
† Scores were assigned on the basis of a five-point scale: score 1, no artifacts were present; score 2, hardly any 
motion artifacts were present; score 3, image quality was satisfactory; score 4, image quality was moderately 
affected; and score 5, image quality was severely affected by motion artifacts
Prostate Cancer Localization Performance
Sixty-six cancer foci smaller than 0.5 cm3 were excluded from analysis. Of the total of 644 
segments (ie, 46 patients with 14 segments each), 150 were classified as containing prostate 
cancer foci of 0.5 cm3 or larger on the basis of histopathologic findings. One hundred two 
were located in the peripheral zone, whereas 48 were located in the central gland. When the 
data for all readers were pooled, the AUC for localization increased significantly from 0.62 
with BAC MR imaging to 0.68 with ERC MR imaging (P < .001) (Figure 3, Table 3). The AUC 
for localization of peripheral zone cancer foci increased significantly from 0.58 with BAC MR 
imaging to 0.68 with ERC MR imaging (P < .001) (Table 3). Likewise, the AUC for localization 
of central gland cancer foci increased significantly from 0.60 with BAC MR imaging to 0.66 
with ERC MR imaging (P < .001) (Table 3). Improved localization performance was noted 
for ventral prostate cancer foci (Figure 4). For all readers, the sensitivity of localization of 
prostate cancer increased significantly with ERC MR imaging, whereas specificity remained 
stable (Table 4). No significant differences were found between BAC MR imaging and ERC 
MR imaging for localization performance in peripheral zone and central gland cancer foci for 
any reader or for all readers combined (Table 3).
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Figure 3. ROC curves and AUCs of prostate cancer localization for all four radiologists 
combined. At 3 T, the AUC improved significantly from 0.62 with BAC MR imaging to 0.68 
with ERC MR imaging (P < .001). The AUCs for the individual readers are presented in Table 
3. T2BAC = T2-weighted BAC MR imaging, T2ERC = T2-weighted ERC MR imaging.
Table 3. AUCs for Prostate Cancer Localization with BAC and ERC MR Imaging for Four 
Readers
Note.—See Table 2 for the level of experience of the radiologists.
* Value indicates a statistically significant increase (P < .05) with ERC MR imaging, compared with BAC MR imaging.
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Table 4. Diagnostic Performance Parameters for Prostate Cancer Localization with BAC and 
ERC MR Imaging at 3 T in 46 included Patients for 644 Prostate Segments
Note.—All values are percentages. Numbers in parentheses were used to calculate the percentages. See Table 2 for 
the level of experience of the radiologists. NPV = negative predictive value, PPV = positive predictive value.
* Value indicates a statistically significant increase (P < .05) with ERC MR imaging, compared with BAC MR imaging.
A B C 
Figure 4. Example of a 1.8-cm3 prostate cancer focus located in the central gland that was 
localized correctly only with ERC MR imaging in a 64-year-old man (prostate-specific antigen 
level, 6.9 ng/mL; final Gleason score, 3+3; stage, pT2c). (A) All four radiologists missed the 
cancer focus with BAC MR imaging. (B) With ERC MR imaging, three of the four radiologists 
localized the focus (arrows) correctly. (C) Histopathologic examination revealed the ventral 
cancer focus (T) outlined in blue, as well as two small peripheral zone tumor foci (volumes, 
<0.5 cm3) outlined in blue.
Prostate Cancer Staging Performance
For radiologists A, B, and D, the AUCs (Figure 5) for staging increased significantly from 0.76, 
0.61, and 0.55, respectively, with BAC MR imaging to 0.97, 0.97, and 0.79, respectively, with 
ERC MR imaging (P < .05). For radiologist C, the AUCs for BAC MR imaging and ERC MR 
imaging were 0.74 and 0.69, respectively (P < .05).
For all readers, the sensitivity for detection of locally advanced disease increased with ERC 
MR imaging (Table 5). For the most experienced radiologists, readers A and B, sensitivity 
increased significantly from 7% to 73%–80% (P < .05). For radiologist C, it increased from 7% 
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to 13%, and for radiologist D, it increased from 13% to 33% (P < .05). All readers achieved a 
high specificity of 94%–100% with ERC MR imaging.
Table 5. Diagnostic Performance of Prostate Cancer Staging for Stage pT3 versus Stage pT2 
Disease with BAC and ERC MR Imaging at 3 T in 46 Patients Included in the Study
Note.—All values are percentages. Numbers in parentheses were used to calculate the percentages. See Table 2 for 
the level of experience of the radiologists. NPV = negative predictive value, PPV = positive predictive value.
* Value indicates a statistically significant increase (P < .05) with ERC MR imaging, compared with BAC MR imaging.
A B 
Figure 5. (a) ROC curves and AUCs of prostate cancer staging for the experienced radiologists 
A (J.J.F.) and B (S.W.T.P.J.H.) with 4 and 2 years of experience, respectively, in prostate MR 
imaging. The AUCs for both radiologists improved significantly (P < .05) with the ERC. (b) 
ROC curves and AUCs of prostate cancer staging for radiologists C (S.T.) and D (T.H.) with 3 
months of experience. Radiologist C had 8 years of experience in MR imaging at 1.5 T with 
a pelvic phased-array coil. The AUC for radiologist D, who participated in a short training 
course about reading endorectal prostate MR images obtained at 3 T prior to assignment of 
scores, increased significantly (P < .05).
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The sensitivity for detection of extracapsular penetration (stage pT3a disease) also improved 
for all readers with the use of an ERC (Figure 6). For the two most experienced radiologists, 
this increase was significant (P < .05). The sensitivity values for radiologists A, B, C, and D 
with BAC MR imaging were 8% (one of 13), 0% (0 of 13), 8% (one of 13), and 8% (one of 13), 
respectively, whereas specificity was 100% (33 of 33), 97% (32 of 33), 100% (33 of 33), and 
91% (30 of 33), respectively. The respective accuracy values were 74% (34 of 46), 70% (32 
of 46), 74% (34 of 46), and 67% (31 of 46). For ERC MR imaging, the sensitivity values for 
radiologists A, B, C, and D were 77% (10 of 13), 69% (nine of 13), 8% (one of 13), and 31% 
(four of 13), respectively, with specificity values of 94% (31 of 33), 97% (32 of 33), 94% (31 
A B 
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Figure 6. Example of a tumor with 2-mm radial distance of extracapsular extension (prostate-
specific antigen level, 8.6 ng/mL; final Gleason score, 3 + 4; stage, pT3a) that was detected 
only with ERC MR imaging in a 61-year-old man. (A, B) Two consecutive transverse BAC 
T2-weighted fast spin-echo MR images (3700/124) show an area of low signal intensity in 
the left peripheral zone (arrow in a) that displayed no signs of locally advanced disease. 
(C, D) Corresponding consecutive transverse ERC T2-weighted fast spin-echo MR images 
(5000/153) show the area of low signal intensity with irregular bulging and obliteration 
of the rectoprostatic angle (arrows in C). (E) After wide excision at the left lateral side 
and resection of the neurovascular bundle on the left side, histopathologic examination 
confirmed the presence of tumor (T), outlined in blue, and the 2-mm radial extracapsular 
extension (ECE++ 2mm) (arrow) with surgical margins negative for tumor.
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of 33), and 97% (32 of 33), respectively. The respective accuracy values were 89% (41 of 46), 
89% (41 of 46), 70% (32 of 46), and 78% (36 of 46).
Of all six patients with extracapsular penetration with a radial distance (as determined by 
using histopathologic findings) of 0.5 mm or less, radiologists A, B, C, and D identified five, 
four, one, and two, respectively, with ERC MR imaging. Only one patient with extracapsular 
penetration of 0.5 mm or less was identified with BAC MR imaging by reader C, whereas the 
other readers did not identify any patient.
The sensitivity and specificity for detection of seminal vesicle invasion (stage pT3b 
disease) for radiologist A with BAC MR imaging were 0% (zero of five) and 100% (41 of 41), 
respectively, whereas for radiologist B these values were 20% (one of five) and 90% (37 
of 41), respectively. The ERC MR imaging results were the same for radiologists A and B: 
Sensitivity and specificity values were 40% (two of five) and 100% (41 of 41), respectively. 
For BAC imaging, radiologists C and D had a sensitivity of 0% (zero of five) and 20% (one of 
five), respectively, with a specificity of 100% (41 of 41) and 88% (36 of 41), respectively. For 
ERC MR imaging, radiologists C and D had sensitivity values of 20% (one of five) and 0% (zero 
of five), respectively, with a specificity of 100% (41 of 41).
DISCUSSION
Results of our study show that, compared with BAC MR imaging at 3 T, ERC MR imaging 
at 3 T significantly improved image quality and, combined with higher spatial resolution, 
significantly increased the localization and staging performance for the experienced 
radiologists and the less experienced radiologist who participated in a short training 
course about reading images of the prostate obtained with ERC MR imaging at 3 T prior to 
assignment of scores.
The significant improvement in image quality is supported by an initial study in healthy 
volunteers in which the researchers concluded that several details of the prostate seen with 
endorectal MR imaging at 3 T could not be seen with endorectal MR imaging at 1.5 T or 3 T 
without the ERC [31].
Localization performance results of our study are similar to those obtained at 1.5 T for MR 
imaging with an ERC by investigators who found AUCs for localization by using T2-weighted 
imaging that varied between 0.67 and 0.83 when the results were compared with findings 
at radical prostatectomy [32]. This point illustrates that localization on T2-weighted MR 
images alone remains difficult without addition of functional MR imaging techniques. 
Dynamic contrast material–enhanced MR imaging and proton MR spectroscopic imaging 
have been reported to increase the localization performance of MR imaging at 1.5T [33–
35]. Addition of these techniques at 3 T [5] may enhance the capability for localization of 
3T PROSTATE MR IMAGING - BODY-ARRAY VERSUS ENDORECTAL COIL 93
5
prostate cancer, also in areas of hemorrhage after biopsy, and for staging of the disease [26]. 
In our study, we classified areas of low signal intensity on T2-weighted fast spin-echo images 
with corresponding areas of high signal intensity on T1-weighted gradient-echo images as 
negative because biopsy artifacts precluded interpretation. Thus, cancer foci could have 
been missed since hemorrhage after biopsy does not exclude the presence of cancer.
The significant increase in capsular delineation, visualization of the neurovascular bundle 
and rectoprostatic angle, and visibility of the lesion with endorectal MR imaging, caused by 
higher spatial resolution, improved staging performance. This finding explains the increase in 
sensitivity for detection of locally advanced disease for all readers. The significant increase in 
AUC for staging by the reader who participated in a short course with direct histopathologic 
feedback may indicate the need for such a course for radiologists with little experience with 
endorectal imaging at 3 T. Our results are congruous with earlier results by Mullerad et 
al [36] who re- ported a substantially improved staging performance for radiologists who 
specialized in urogenital radiology compared with general body radiologists. In our study, 
the radiologists who had 2 or more years of experience in prostate MR imaging obtained 
the highest AUCs and sensitivity values for staging. The differences in results between the 
experienced and less experienced readers were particularly large with the use of the ERC, 
thereby providing evidence for the particular expertise necessary to interpret endorectal 
MR images obtained at 3 T. This finding also is supported by the fact that reader C, who had 
experience with pelvic phased-array coil MR imaging at 1.5 T, performed better with the 
BAC than with the ERC at 3 T. It thus appears that in order to obtain accurate high-specificity 
staging with ERC MR imaging at 3 T, experience is an important factor.
It is difficult to compare our results with those of studies from the 1980s or early 1990s, 
because, currently, patients are identified earlier, and also, therefore, the number of patients 
with extraprostatic disease spread is lower and the spread is likely to be smaller as well. 
In our patient population, the average extraprostatic spread was 1.4 mm (range, 0.5–3.0 
mm), and six of 13 patients had an extension of 0.5 mm or less. With BAC MR imaging, this 
small extension is extremely difficult to depict and determine with certainty. This difficulty in 
depiction, coupled with high-specificity reading, could explain the low sensitivity values for 
BAC imaging in the staging of patients. Comparison with previous studies is difficult because 
in none has the exact amount of the extraprostatic extent been described. Nevertheless, the 
spatial resolution of BAC imaging is too low for detection of the small extraprostatic extent 
that one can depict with ERC MR imaging.
Our staging results are in accordance with those obtained from an initial study of staging 
with 3-T ERC MR imaging, which show consistent high diagnostic performance with ERC 
imaging [12]. These results exceed those obtained at 1.5 T. Particularly when the
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ERC is used at 3 T, minimal capsular penetration can be detected more accurately. In a large 
(n = 336) published study about ERC MR imaging at 1.5 T, only extensive locally advanced 
disease could be detected accurately: A sensitivity of only 40% (45 of 113) with a specificity 
of 95% (211 of 223) was obtained by two radiologists reading in consensus [37]. Nakashima 
et al (38) found a sensitivity of 62% (18 of 29) in the detection of locally advanced disease. 
With ERC 1.5-T MR imaging, two independent readers with 5 and 2 years of experience 
achieved sensitivity values of 54% (13 of 24) and 17% (four of 24), respectively, for the 
detection of extracapsular penetration [19].
Although specificity values for determination of seminal vesicle invasion were high (88%–
100%) for all readers with both BAC MR imaging and ERC MR imaging, the sensitivity values 
were low (0%– 40%). Other researchers in studies with imaging at 1.5 T also found rather 
low sensitivity values (38). With the same cutoff point as used in our study, Sala et al (20) 
also found high (97%–99%) specificity with lower (50%– 63%) sensitivity with ERC 1.5-T MR 
imaging in 354 patients with a prevalence of seminal vesicle invasion of 14% (51 of 354). 
The small number of patients with seminal vesicle invasion limited the interpretation of 
the results of our study, and the diagnostic performance for detection of seminal vesicle 
invasion at 3 T needs to be investigated in larger patient populations. By its low prevalence 
(five patients in our study), it appears that readers are less likely to detect seminal vesicle 
invasion. Continuous training with imaging sets obtained in patients who had seminal vesicle 
invasion may increase the performance.
A general limitation of ERC MR imaging is that it is technically more challenging and may not 
be performed in all patients. In our study, in five of the six excluded patients, the reason for 
the exclusion was related to the ERC.
A limitation of our study is the relatively low prevalence (15 of 46, 33%) of patients with 
locally advanced disease. Also, extracapsular penetration was small (mean penetration 
distance, 1.4 mm). Nevertheless, these factors reflect the current patient population in 
general urologic clinics because of the widespread use of the prostate-specific antigen level 
for screening [39].
Furthermore, by applying bowel movement suppression only before ERC MR imaging, we 
may have artificially increased ERC image quality. However, the introduction and presence 
of the ERC in the rectum itself causes bowel discomfort and reactionary bowel movement, 
as can be deduced from the higher motion artifact scores with ERC imaging.
Thus, bowel suppression actually may have enhanced objective comparison between BAC 
MR imaging and ERC MR imaging.
3T PROSTATE MR IMAGING - BODY-ARRAY VERSUS ENDORECTAL COIL 95
5
In our study, the choice of the TE for both BAC MR imaging and ERC MR imaging was restricted 
by a combination of the specific absorption rate, matrix size, and echo train length. To fully 
use the high signal-to-noise ratio of the ERC, a large matrix size was applied. As shortening 
of the radiofrequency pulses was precluded by the specific absorption rate limit, the larger 
matrix size increased the inter-TE and thereby also the TE of the image series. Thus, our TEs 
were longer than the established mean T2 value of the entire prostate at 3 T [40]. However, 
using TEs beyond the T2 of the prostate is common practice at 1.5 T (eg, TE of 96–132 msec 
vs T2 of 88 msec) (16,26), as the difference in signal intensity between healthy prostate 
tissue and cancerous prostate tissue is important. At longer TEs, this difference is more 
profound, provided the tissue with shortest T2 still has adequate signal-to-noise ratio. With 
novel radiofrequency pulse techniques, however, it is advised that TEs of approximately 100 
msec are used when the signal is acquired.
Readers could not be blinded to whether they were reviewing BAC MR images or ERC MR 
images, since the presence or absence of the ERC and the prostate shape already would have 
indicated the type of image. This could possibly have led readers to systematically provide 
lower scores for BAC images. To minimize bias, BAC and ERC image sets were evaluated 
separately and randomly. Furthermore, readers were instructed to perform a certain type 
of reading (high-sensitivity localization and high-specificity staging). This specification 
of the type of reading could have influenced our results, particularly the sensitivity in 
staging. Possibly, this factor influenced BAC MR imaging more than it did ERC MR imaging. 
Nevertheless, in preoperative prostate cancer staging, it is common practice to perform 
high-specificity reading.
The limitation of a possible discrepancy and potential difficulty in comparing both BAC MR 
imaging and ERC MR imaging findings with histopathologic examination findings because 
of the changed alignment of the prostate after insertion of the ERC was minimized by using 
anatomic landmarks of the prostate [25] to correlate results of T2- weighted fast spin-echo 
imaging with histopathologic findings.
Endorectal MR imaging can play a role in accurate delineation of cancer foci in the planning 
of intensity-modulated radiation therapy and enable radiation boosting to areas within 
the prostate. Moreover, it can facilitate nerve-sparing decisions with determination of 
the proximity of the cancer to the neurovascular bundle [41]. Likewise, since the clinical 
implications of small extracapsular penetration are being debated as to whether this 
penetration has an effect on patient survival, prior knowledge of its localization may aid 
urologists in obtaining negative surgical margins.
In conclusion, MR image quality of the prostate improved significantly with the use of an ERC. 
For prostate cancer localization, performance with ERC MR imaging was significantly better 
than was that with BAC MR imaging. Also, when we used the ERC, the staging performance 
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improved significantly in the two experienced readers and the less experienced reader 
who participated in a short course about endorectal prostate MR reading at 3 T prior to 
assignment of scores. Therefore, also at 3 T, the ERC is necessary for accurate localization 
and staging of prostate cancer.
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CHAPTER 6
Changes in Prostate Shape and Volume and 
Their Implications for Radiotherapy after 
Introduction of Endorectal Balloon as 
Determined by MRI at 3T
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Purpose: To determine the changes in prostate shape and volume after the introduction of 
an endorectal coil (ERC) by means of magnetic resonance imaging (MRI) at 3T.
Methods and materials: A total of 44 consecutive patients with biopsy-proven prostate cancer 
underwent separate MRI examinations at 3T with a body array coil and subsequently with 
an ERC inflated with 50 mL of fluid. Prospectively, two experienced readers independently 
evaluated all data sets in random order. The maximal antero-posterior, right-to-left, and 
craniocaudal prostate diameters, as well as the total prostate and peripheral zone and 
central gland volumes were measured before and after ERC introduction. The changes in 
prostate shape and volume were analyzed using Wilcoxon’s test for paired samples.
Results: The introduction of the ERC significantly changed the prostate shape in all three 
directions, with mean changes in the anteroposterior, right-to-left, and craniocaudal 
diameters of 15.7% (5.5 mm), 7.7% (3.5 mm), and 6.3% (2.2 mm), respectively. The mean 
total prostate, peripheral zone, and central gland volume decreased significantly after ERC 
introduction by 17.9% (8.3 cm3), 21.6% (4.8 cm3), and 14.2% (3.4 cm3), respectively. 
Conclusion: ERC introduction as observed by 3T MRI changed the prostate shape and 
volume significantly. The mean anteroposterior diameter was reduced by nearly one-sixth of 
its original diameter, and the mean total prostate volume was decreased by approximately 
18%. This could cause difficulties and should be considered when using ERC-based MRI for 
MRI-computed tomography fusion and radiotherapy planning.
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INTRODUCTION
Advanced imaging techniques that provide both anatomic and functional information are 
being gradually introduced into clinical practice. In radiation oncology, prostate magnetic 
resonance imaging (MRI) techniques can be fused with planning computed tomography (CT) 
scans and have been shown to enable improved target delineation [1, 2].
Functional MRI techniques, such as dynamic contrast-enhanced MRI [3, 4] and proton MRI 
spectroscopic imaging [5–9], can lead to more accurate localization and staging of prostate 
cancer [4, 10, 11] and are established methods for the early evaluation of the radiotherapy 
(RT) effect [12, 13]. These advanced MRI techniques can also detect so-called intraprostatic 
dominant lesions and have opened the way for advanced “dose-painting” RT delivery in 
both brachytherapy [14–17] and external beam RT [18, 19]. The integration of the anatomic 
prostate on MRI with the CT-MRI marker-based fusion method described by Huisman et 
al. [20] has been implemented into our daily clinical practice. The use of the endorectal 
coil (ERC) increases the resolution and improves the localization and staging compared 
with application of external coils alone [21, 22]. Compared with 1.5T, imaging at high-field 
strengths such as 3T improves the resolution. Performing imaging without an ERC would 
have a number of advantages, including less patient discomfort, lower costs, and better 
correlation with RT planning, if the latter has been performed without an endorectal balloon 
(ERB). However, the use of an ERB in localized prostate RT has been proved advantageous 
[19, 23–26] and well tolerated [27, 28]. For RT planning and during RT sessions, ERBs that 
are similar to the ERC in construction and shape can be used. Nevertheless, the introduction 
of an ERC causes changes in both the shape and possibly the volume of the prostate [29, 30].
The purpose of this study was to determine the exact changes in prostate shape by comparing 
the prostate diameters and volumes before and after the introduction of an ERC using MRI 
at a field strength of 3T and to discuss the possible implications for RT.
METHODS AND MATERIALS
Patient characteristics
The institutional review board approved this prospective study. Before inclusion, all patients 
provided written informed consent. Between September 2004 and December 2005, 44 
consecutive patients with biopsy-proven prostate cancer who had not received any form 
of hormonal therapy, surgery, or RT were scheduled to undergo MRI. The exclusion criteria 
were contraindications to MRI (e.g., the presence of a pacemaker or metal cerebral clips), 
severe claustrophobia, or contraindications to ERC insertion (e.g., previous anorectal 
surgery, inflammatory bowel disease, high anal sphincter tension). For all included patients, 
the interval between the last biopsy procedure and MRI was determined.
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MRI acquisition
All images were obtained using a 3T whole-body scanner (Magnetom TRIO, Siemens 
Medical Solutions, Erlangen, Germany). Before the examination, patients were asked to void 
to empty the bladder as much as possible. First, T2-weighted images in three planes with 
an external body array coil were obtained [22]. Second, after removal of the body array coil 
and a digital rectal examination, an ERC (Medrad, Pittsburgh, PA; Figure 1) was inserted, 
and, subsequently, the balloon was inflated with 50 mL of fluid. The fluids used were either 
demineralized water or perfluoropolyether (Fomblin, Solvay Solexis, Milan, Italy). Bowel 
motion was suppressed by an intramuscular injection of 1 mg of glucagon (Glucagen, Novo 
Nordisk A/S, Denmark). T2-weighted images in three planes were obtained [22].
Figure 1. (A) Overview of commercially available 3T endorectal coil (Medrad, Pittsburgh, PA). 
(B) Detailed view of diameters of endorectal coil balloon tip before filling.
MRI measurements
To prevent an information bias, the readers never scored the imaging sets of the same 
patient in the same session and the order of reading was randomized.
Image quality determination. Two of us, a radiologist (S.W.T.P.J.H.) with 3 years of experience 
in endorectal prostate MRI interpretation corresponding to previously having read 250 
endorectal MRI studies, and an MRI spectroscopist (T.W.J.S.) with 4.5 years of experience in 
reviewing prostate MRI examinations (approximately 300 previous studies), independently 
reviewed all imaging sets. Both readers scored the image quality of each set according to the 
presence of motion artifacts affecting image interpretation, particularly the visualization of 
the prostate contours. If either imaging set was scored as insufficient by one of the readers, 
the patient was excluded from additional analysis.
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Prostate size. Both readers assessed the prostate size in three directions on a digital 
workstation (Agfaweb Impax, Agfa, Mortsel, Belgium). The largest medial anteroposterior 
and right-to-left diameters were measured in the axial plane, and the largest craniocaudal 
diameter was assessed in the coronal plane.
Prostate volume. The prostate volume was calculated by manually determining the prostate 
outline on every axial T2-weighted MRI slice. One reader (S.W.T.P.J.H.) drew a freehand 
contour around the prostate on each imaging slice on a commercially available workstation 
(Syngo VX49B, Leonardo VD10B, Siemens AG, Berlin, Germany). For each slice, the number 
of pixels within the contour was automatically established, and, with the known in-plane 
resolution and slice thickness, the prostate volume was calculated. Subsequently, a separate 
contour was drawn around the peripheral zone alone to obtain its volume. By subtracting 
the peripheral zone volume from the total volume, the volume of the central gland (i.e., 
transition zone, central zone, and periurethral area) was obtained. Finally, the relative 
volume changes (expressed as percentages of the volume before ERC introduction) were 
calculated.
Statistical analysis
The diameters as determined by both observers were compared by calculating the mean 
differences between the readers in absolute terms and as a percentage of the readers’ 
mean. Likewise, of the total number of 264 observations (44 patients x 2 imaging settings 
x 3 diameters), the absolute differences were analyzed to determine the interobserver 
variation. Subsequently, 95% confidence intervals of the means were calculated.
The changes in prostate diameter and prostate volumes were compared using Wilcoxon’s 
signed rank test for paired samples. To investigate whether the original size of the prostate 
influenced the changes in diameters and volumes, changes in large prostates (clinically 
deemed enlarged; i.e., 40 cm3 before ERC introduction) and small prostates (< 40 cm3) were 
evaluated separately by applying the t test for unpaired samples. The diameter and volume 
changes were visualized on Bland-Altman plots.
All p values reported were from two-sided tests, with p ≤ 0.05 considered statistically 
significant. Statistical analyses were performed using MedCalc, version 8.1.0.0 (MedCalc 
Software, Mariakerke, Belgium).
RESULTS
Patient characteristics
Both readers scored the image quality of all individual patients as sufficient; therefore, the 
data from all 44 analyzed patients were included in the study. The mean age, mean prostate-
specific antigen level, and median Gleason biopsy score was 61 years (range, 51–70), 7.77 
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ng/mL (median, 6.07; range, 3.48–24.63), and 6 (range, 5-9), respectively. The average 
interval between biopsy and MRI was 112 days (range, 21–226).
Observer variations
In 133 (50%) of 264 observations, the difference between the two readers was ≤ 1 mm, 
and in 186 (70%), the difference was ≤ 2 mm. The mean of the differences between the 
diameter scores of the readers before ERC introduction was 1.87 mm (mean difference 
as a percentage of the mean score, 4.9%, 95% confidence interval, 3.9–5.9%). After ERC 
introduction, the mean of the differences was 2.34 mm (mean difference as a percentage of 
the mean score, 6.1%, 95% confidence interval, 5.0–7.2%).
Changes in prostate diameters
All three prostate diameters changed and the change was statistically significant (p <0.05) 
after ERC introduction (Table 1 and Figures 2 and 3). On average, the anteroposterior 
prostate diameter decreased by 5.4 mm, corresponding to a reduction of 15.7% from the 
original diameter. The mean right-to-left and craniocaudal diameter increased by 3.5 mm 
(8%) and 2.2 mm (7%), respectively. No differences were observed between the water and 
perfluoro polyether filling of the ERC.
Table 1. Comparison of prostate diameters before and after endorectal coil introduction
mm (7%), respectively. No differences were observed between the water and perfluoro 
polyether filling of the ERC. 
 
Table 1. Comparison of prostate diameters before and after endorectal coil introduction 
 ERC insertion  Mean difference as 
percentage before 
ERC insertion  
(95% CI) 
 
Mean prostate  
diameter* (mm) 
 
Before 
 
After 
Mean difference 
(95% CI) 
P 
AP 35.03 29.66 -5.38 (-3.88--6.87) -15.7 (-11.1--20.3) <0.05 
RL 48.67 52.16 +3.49 (1.34-4.73) +7.69 (4.39-11.0) <0.05 
CC 39.90 42.14 +2.24 (0.38-4.10) +6.28 (1.16-11.4) <0.05 
Abbreviations: ERC = endorectal coil; CI = confidence interval; AP = anteroposterior; RL = right-to-left; CC = 
craniocaudal. 
∗ All data presented as mean of two independent readers. 
 
Figure 2. Example of MR images obtained with (A,C,E) external surface coils and (B,D,F) endorectal 
coil (ERC) filled with demineralized water. (C,D) Maximal prostate diameter change after 
introduction and inflation of ERC in anteroposterior direction decreased by 18.5% and right-to-left 
diameter increased by 6.1%. (E,F) Maximal craniocaudal diameter increased by 11.5%. 
 
Figure 3. Bland-Altman plots of absolute change in (a) anteroposterior (AP), (b) right-to-left (RL), 
and (c) craniocaudal (CC) diameters of the prostate after endorectal coil (ERC) introduction. 
Abbreviations: ERC = endorectal coil; CI = confidence interval; AP = anteroposterior; RL = right-to-left; CC = 
craniocaudal.
* All data presented as mean of two independent readers.
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Figure 2. Example of MR images obtained with (A,C,E) external surface coils and (B,D,F) 
endorectal coil (ERC) filled with demineralized water. (C,D) Maximal prostate diameter 
change after introduction and inflation of ERC in anteroposterior direction decreased by 
18.5% and right-to-left diameter increased by 6.1%. (E,F) Maximal craniocaudal diameter 
increased by 11.5%.
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Figure 3. Bland-Altman plots of absolute change in (a) anteroposterior (AP), (b) right-to-
left (RL), and (c) craniocaudal (CC) diameters of the prostate after endorectal coil (ERC) 
introduction.
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Changes in prostate volume with introduction of ERC
The mean total prostate volume decreased significantly (p < 0.05) from 50.4 cm3 before 
ERC introduction to 42.2 cm3 after (Table 2 and Figures 4 and 5). The change in volume 
ranged from 0.3 to 23.9 cm3. For the peripheral zone alone, the mean volume decreased 
significantly (p < 0.05) from 21.9 cm3 to 17.0 cm3, with a range of volume change of 0.3–11.2 
cm3. Also, the mean central gland volume decreased significantly (p < 0.05) from 28.6 cm3 
to 25.2 cm3 (volume change range, 0–13.3). The mean relative change in the volume of the 
peripheral zone (21.6%) was significantly (p < 0.05) greater than that of the total prostate 
volume (17.9%) and central gland volume (14.2%).
Table 2. Comparison of prostate volumes before and after endorectal coil introductionTable 2. Comparison of prostate volumes before and after endorectal coil introduction 
 ERC insertion  Mean difference as 
percentage before 
ERC insertion  
(95% CI) 
 
Mean prostate  
Volume (cm3) 
 
Before 
 
After 
Mean difference 
(95% CI) 
P 
Total prostate gland 50.44 42.18 -8.26 (-6.53--9.98) -17.9 (-14.7--21.1) <0.05 
Peripheral zone 21.85 17.03 -4.83 (-3.94--5.72) -21.6 (-18.3--24.8) <0.05 
Central gland 28.58 25.15 -3.43 (-2.37--4.50) -14.2 (-10.2--18.2) <0.05 
Abbreviations as in Table 1. 
∗ Defined as total prostate gland volume minus peripheral zone volume and thus including transition zone, 
central zone, and periurethral area. 
 
Figure 4. Determination of prostatic volume using example determination in one slice with 
(A) body-array coil and (B) endorectal coil (ERC) filled with perfluoropolyether (Fomblin, 
Solvay Solexis, Milan, Italy). After drawing region of interest around prostate, number of 
pixels calculated automatically. With known slice thickness and in-plane resolution, volume 
per slice could be determined: 4.0 cm3 (5407 × 0.43 × 0.43 × 4 mm3) for slice with body-array 
coil and 3.3 cm3 (16149 × 0.26 × 0.26 × 3 mm3) for slice with endorectal coil. 
 
 
Figure 5. Bland-Altman plots of absolute change in volume of (a) entire prostate, (b) 
peripheral zone, and (c) central gland after introduction of endorectal coil (ERC). All mean 
volumes changed significantly (p < 0.05). PZ = peripheral zone; CG = central gland. 
Abbreviations as in Table 1.
* Defined as total prostate gland volume minus peripheral zone volume and thus including transition zone, central 
zone, and periurethral area.
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Figure 4. Determination of prostatic volume using example determination in one slice with 
(A) body-array coil and (B) endorectal coil (ERC) filled with perfluoropolyether (Fomblin, 
Solvay Solexis, Milan, Italy). After drawing region of interest around prostate, number of 
pixels calculated automatically. With known slice thickness and in-plane resolution, volume 
per slice could be determined: 4.0 cm3 (5407 × 0.43 × 0.43 × 4 mm3) for slice with body-array 
coil and 3.3 cm3 (16149 × 0.26 × 0.26 × 3 mm3) for slice with endorectal coil.
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Figure 5. Bland-Altman plots of absolute change in volume of (a) entire prostate, (b) 
peripheral zone, and (c) central gland after introduction of endorectal coil (ERC). All mean 
volumes changed significantly (p < 0.05). PZ = peripheral zone; CG = central gland.
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The relative prostate volume change for larger (>40 cm3) and smaller (<40 cm3) prostates did 
not differ significantly (p > 0.05) at 17.0% and 18.8%, respectively.
No differences were observed between the water and perfluoro polyether ERC filling.
DISCUSSION
Our results have demonstrated that the ERC causes significant changes in the prostate 
diameters and a significant volume decrease. The main advantage of using an ERC is the 
greater imaging resolution. However, our study has shown that the changes between 
situations without and with the ERC or ERB are substantial, and we believe that RT planning 
and procedures should be performed in the same setting in which the MRI has been 
performed.
Our results show that the introduction of an ERC at 3T significantly changes all three prostate 
diameters, most markedly in the anteroposterior direction, compressing the prostate by 
nearly 16% of its original diameter. A significant decrease in volume was observed for both 
the peripheral zone and the central gland and, thereby, for the entire prostate. Because 
biologic materials are generally considered to be incompressible [31], we hypothesized that 
this decrease in prostate volume originated from expulsion of fluid. Seminal fluid and fluids 
within the ducts could be extruded by application of pressure, similar to what happens 
during ejaculation. Also, blood vessels could be compressed by the substantial pressure of 
the balloon, resulting in a decrease in blood volume.
Our results regarding the prostate diameter changes are in line with those of a previous 
study of 10 prostate cancer patients by Kim et al. [30] that demonstrated that an expandable 
1.5T ERC caused more prostate deformation than did a rigid coil. They found a mean 
anteroposterior diameter compression of 4.1 mm (our study, 5.4 mm) and a mean right-
to-left diameter expansion of 3.8 mm (our study, 3.5 mm). The change in the craniocaudal 
diameter was not analyzed in-depth; however, it was reported to be <3 mm in all patients 
(our study, mean change of 2.2 mm). The investigators, however, did not describe the 
volume to which the ERC was inflated, making direct comparisons with our results more 
difficult. Also, the prostate volumes were not analyzed in that study. In contrast, our study 
was performed at 3T. Therefore, our imaging spatial resolution was greater than theirs at 
1.5T imaging, thereby increasing the accuracy in determining the diameters in our study.
Because the setup, shape, and expansive characteristics of the 3T ERC do not differ 
substantially from that of the 1.5T ERC, it can be assumed that the presented results 
obtained at 3T can be generalized to those of 1.5T ERC-based MRI. In our study, patients with 
a wide range of prostate-specific antigen levels and biopsy Gleason scores were included. 
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Therefore, we are confident that our results can be generalized to the whole population of 
prostate cancer patients with biopsy-proven prostate cancer who are undergoing RT.
Our observations could have several implications for RT planning. First, registration (or 
fusion) of MRI studies, obtained with an ERC, and CT images, performed without an ERB 
similar to the ERC in construction and shape, could cause substantial difficulties and result in 
less accurate delineation of the pelvic structures. To overcome these problems, algorithms 
have been developed [14, 16] or MRI-defined volumes have been manually entered into 
the planning system and the gland distortion only addressed visually [15, 17]. A recently 
presented MRI-CT fusion study for high-dose intraprostatic dominant lesion–intensity-
modulated RT, in which an ERB identical to the MRI ERC was used for CT scanning [19], 
resulted in almost equal deformation of the prostate gland on the MRI and CT studies, 
and thereby obtaining an accurate intraprostatic dominant lesion projection onto the CT 
images. The iterative closest point method, in which the gold marker surface models are 
automatically registered, yielded an MRI-CT fusion precision of 1.1 mm in a data set of 21 
patients, using five operators [20]. However, it is unclear whether the extensive prostate 
deformations due to the introduction of the ERC that were found in our study might be 
sufficiently compensated for by any algorithm.
Second, the clinical use and tolerability of an ERB during treatment has been extensively 
described [19, 23–28]. The use of the ERB adds only few (range, 3–5) minutes to the whole 
RT procedure. Although an ERB does not reduce the day-to-day interfraction prostate 
displacements completely [32, 33], it is advisable to use the ERB in combination with a 
prostate position verification and correction protocol.
Third, by using an ERC and ERB, the target volume for RT will be decreased. Thus, the overall 
volume that is subjected to the radiation dose will be decreased, particularly in larger 
prostates. A reduction in the target volume might also reduce the volumes of neighboring 
organs exposed to high dose levels and consequently reduce the toxicity.
Fourth, most prostate cancer foci arise in the peripheral zone of the prostate [34], which 
showed the largest relative decrease in volume. Hypothetically, the increased pressure on 
the rectal wall and prostatic tissue could cause compression of the vasculature, possibly 
leading to a degree of acute hypoxia within the tissue, in turn affecting the RT [35]. 
Theoretically, this might affect either the radiosensitivity of the rectal wall mucosa (which 
would be advantageous) or the prostate tumor cells (which would be disadvantageous). 
Data on both issues do yet not exist; however, no clinical evidence to date has shown the 
balloon resulted in a decrease in the clinical outcome [36].
114 CHANGES IN PROSTATE SHAPE AND VOLUME AFTER 3T ENDORECTAL COIL INTRODUCTION
Fifth, RT planning using fusion between CT and MRI at 1.5T with an ERC has previously 
been established [19, 37]. By using an ERC at a field strength of 3T, prostate delineation 
might even be more accurate because of the greater spatial resolution achieved at this field 
strength.
Our study had a number of limitations. First, by having both imaging sets read by two 
readers, we might have introduced an information bias. This was minimized by reading 
the imaging sets of the same patient in our substantial (n = 44) patient group in separate 
sessions. Second, by applying bowel motion suppression only before ERC-based MRI, we 
might have introduced a bias toward better image quality obtained with the ERC-based MRI. 
In a previous study [22], however, it was shown that even with bowel suppression, more 
motion artifacts were present using ERC-based MRI vs. the body array coil. Third, by using 
the greater signal-to-noise ratio of the ERC, the in-plane spatial resolution of ERC-based 
MRI was greater. This increased the accuracy in delineating the prostate structures and 
might have caused more accurate volume determination with ERC-based MRI. It is unclear 
whether this would have resulted in systematically lower or greater determined volumes.
CONCLUSION
Our results have shown that the introduction of a 3T ERC, similar to an ERB, caused 
significant changes in all prostate diameters and a significant mean absolute and relative 
reduction in prostate volume of the total prostate gland, peripheral zone, and central gland, 
which could cause problems using ERC-based MRI scans for MRI-CT image fusion. The use of 
algorithms or applying an ERB, similar in volume to the ERC, for CT scanning and treatment 
might overcome these problems.
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CHAPTER 7
Prostate and Lymph Node Proton Magnetic 
Resonance (MR) Spectroscopic Imaging with 
External Array Coils at 3 T to Detect Recurrent 
Prostate Cancer After Radiation Therapy
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In a patient suspected of having recurrent prostate cancer after radiation therapy, we 
demonstrate the feasibility of noninvasive proton magnetic resonance spectroscopic 
(1H-MRS) imaging of the prostate and a lymph node at 3 T using a matrix of external surface 
coils. Written informed consent was obtained from the patient. With 1H-MRS imaging, high 
choline with low citrate signal was observed in the prostate, and in the lymph node a signal 
of choline-containing compounds was identified. The tissue level of the compounds in the 
enlarged lymph node was estimated to be 8.1 mmol/kg water. Subsequent histopathological 
analysis of systematic transrectal ultrasound-guided prostate biopsy and computed 
tomography-guided biopsy of the lymph node confirmed the presence of prostate cancer 
in both.
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Presently, 1 in 3 new cases of cancer in the male population [1] of the United States is 
prostate cancer. As part of the primary diagnostic process the urologist and radiation 
oncologist as well as the medical oncologist calculate the risk of extraprostatic disease 
spread and positive lymph nodes based on the serum prostate-specific antigen (PSA) level, 
the digital rectal examination findings, and the Gleason score at biopsy [2].
After treatment with curative intent, a rise in the PSA level may be indicative of recurrence. 
Although differentiation between a local or systemic recurrence is difficult, the PSA doubling 
time may help to discriminate between these [3]. However, also imaging can play a role 
in establishing recurrent disease in both the prostate and lymph nodes. By establishing 
(early) local recurrence, potentially curative salvage therapies such as radical prostatectomy 
or cryotherapy may be performed. Recently, the first prostate cancer studies of magnetic 
resonance (MR) imaging with and without an endorectal coil and proton MR spectroscopic 
imaging (1H-MRS) with an endorectal coil at 3 T in preoperative patients have been published 
[4-8]. No studies have yet been published that performed 1H-MRS with external surface 
coils only.
The transformation of healthy cells toward malignancy was reported to change the 
membrane choline phospholipid metabolism [9]. In prostate cancer, using an endorectal 
coil for signal reception, it was shown that an increase in the choline signal along with a 
concurrent decrease in the citrate signal, was indicative of malignancy [10–13]. Thereby, 
choline compounds are important tumor biomarkers. The purpose of this case report is 
to demonstrate the feasibility of noninvasive 1H-MRS using a matrix of external surface 
coils to detect recurrent cancer in the prostate and to detect metastatic prostate cancer by 
quantifying the total choline-containing compounds (tCho) in an enlarged lymph node.
MATERIALS AND METHODS
Case
A 77-year-old man with a PSA level of 30 ng/mL and an adenocarcinoma with a Gleason 
score of 3 + 5 = 8 on prostate biopsy, underwent an initial staging MR imaging examination 
at 1.5 T (MAGNETOM Sonata, Siemens Medical Solutions, Erlangen, Germany) with a pelvic 
phased-array coil because of the patient’s intolerability of the endorectal coil. T2-weighted 
imaging [repetition time (TR)/echo time (TE): 4400/132 milliseconds] was performed in 3 
planes and revealed cancer encompassing the whole peripheral zone of the prostate from 
apex to base with signs of extraprostatic spread (Figure 1A) and seminal vesicle invasion. 
On the T1- weighted series (TR/TE: 1570/3.9 milliseconds) that covered the region between 
the prostate and aortic bifurcation, no pathologically enlarged lymph nodes were reported. 
Bone scintigraphy did not reveal any bone metastases. Successive limited pelvic lymph node 
dissection, harvesting 10 nodes, showed no metastatic nodal disease. Therefore, the cancer 
was staged as T3bN0M0. After neoadjuvant hormonal therapy, ie, maximum androgen 
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blockade, the radiation therapy consisted of irradiation of the entire prostate plus seminal 
vesicles with a dose of 70 Gy, in 35 daily fractions of 2 Gy using a 4-field “box” conformal 
technique, from November 21, 2002 to January 9, 2003. Before the radiation treatment, the 
PSA level was below 0.10 ng/mL and remained at that level until July 2003. Subsequently, 
it gradually started to rise to 6.34 ng/mL in October 2005. In November 2005, a repeat 
1.5 T MR imaging examination (MAGNETOM Avanto; Siemens Medical Solutions, Erlangen, 
Germany) using a pelvic phased-array coil for local recurrence showed a homogeneously 
low signal intensity in the entire prostate. On the T1-weighted 3-dimensional gradient-echo 
sequence (TR/TE: 8.6/4.2 milliseconds; acquisition time: 7 minutes 52 seconds) covering 
the region from the prostate up toward the aortic bifurcation taken before the contrast 
administration, a single enlarged lymph node with a maximal diameter of 2.5 cm was seen 
ventral of the internal iliac artery (Figure 2). Based on its size, the lymph node was reported 
as suspicious for metastatic disease. Retrospectively, this node was not enlarged on the 
T1-weighted images of the MR imaging examination performed before radiation therapy. 
Additionally obtained bone scintigraphy was negative.
T T 
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R R L L 
Figure 1. (A) Axial T2-weighted spin-echo MR image at 1.5 T before therapy from the 
midgland of the prostate of a 77-year- old man with a PSA level of 30 ng/mL and biopsy-
proven Gleason 3 + 5 = 8 prostate cancer using a pelvic phased-array coil (TR/TE: 4400/132 
milliseconds). A large area of low signal intensity indicative of tumor (T) covering the whole 
peripheral zone of the prostate from apex to base was observed. Signs of capsular bulging 
(arrow) and seminal vesicle invasion (not shown) are present. (B) Two and a half years after 
radiation therapy, the axial T2-weighted fast spin-echo image (TR/TE: 3100/135 milliseconds) 
at 3 T with combined body and spine matrix coils reveals a homogeneously low signal in the 
entire prostate, indicative of postradiation therapy effects. L, left; R, right; T, tumor.
Proton MR Spectroscopic Imaging Combining Multiple External Surface Coils at 3 T
After written informed consent, the patient agreed to undergo 1H-MRS of both the prostate 
and the enlarged lymph node at 3 T (MAGNETOM Trio with total imaging matrix; Siemens 
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Medical Solutions, Erlangen, Germany) using a matrix of external surface coils for signal 
reception followed by biopsy of the prostate and lymph node. 
Proton MR Spectroscopic Imaging of the Prostate
Immediately before the start of the examination, bowel peristalsis was suppressed by a 
1-mg intramuscular injection of glucagon (Glucagen; Novo Nordisk A/S, Denmark). First, T2-
weighted fast-spin echo imaging in 3 planes was performed (TR/TE: 3230/108 milliseconds; 
hyperechoes [14]; field of view (FOV): 256 x 256 mm; matrix size: 512 x 512; 15 slices; 
slice thickness: 4 mm; no gap; 2 averages; acquisition time: 3 minutes 43 seconds, Figure 
1B). Subsequently, 3-dimensional 1H-MRS imaging covering the entire prostate (Figure 
3A) was performed combining the signal of multiple external surface coils [15]. The pulse 
sequence used was similar to the one used for prostate 1H-MRS imaging at 1.5 T [16] with 
some adaptations to assure an optimal spectral shape of the citrate signal at 3 T [17]. Scan 
parameters: TR/TE: 750/145 milliseconds; acquisition bandwidth: 1250 Hz; 512 spectral 
data points; FOV: 84 x 70 x 70; matrix size: 12 x 10 x 10; number of weighted averages: 6; 7 
saturation slabs were applied. The voxel resolution (before apodization) was 7 x 7 x 7 mm3 
within a total acquisition time of 8 minutes 15 seconds. A radiologist (S.W.T.P.J.H.) and an 
MR spectroscopist (T.W.J.S.) analyzed the spectral data. Throughout most of the prostate 
(Figure 3B, C), choline displayed a higher signal than citrate, indicative of locally recurrent 
disease [18].
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Figure 2. Coronal reconstruction image of the T1-weighted 3-dimensional gradient-echo 
sequence at 1.5 T (TR/TE: 8.6/ 4.2 milliseconds) showing the single enlarged lymph node 
(arrows) located ventral of the internal iliac artery. The maximal diameter of the lymph node 
was 2.5 cm. L, lumbar spine; B, bladder; P, prostate; F, femoral head.
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Figure 3. (A) Example of the voxels within an axial partition from the 3-dimensional 1H-MRS 
imaging acquisition (TR/TE: 750/145 milliseconds) overlaid on T2-weighted imaging, 
showing the field of view (outer white box) and the volume of interest (inner white box). 
Within the volume of interest, a number of voxels is selected (dark box) for visualization of 
individual spectra. 
(B) Spectral map of selected voxels (ppm range 2.0–3.7). All selected voxels revealed high 
tCho signals with lower citrate signals. One voxel was chosen for enlarged display (light box). 
(C) tCho, creatine (Cr) and citrate (Ci) signals were observed, with tCho displaying a higher 
signal than citrate.
Proton MR Spectroscopic Imaging of the Lymph Node
To localize the enlarged lymph node, an axial T2-weighted multislice fast-spin echo imaging 
series (TR/TE: 3100/135 milliseconds; voxel size: 1 x 1 x 4 mm3; acquisition time: 3 minutes 
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34 seconds, Figure 4A) and a T1-weighted 3-dimensional gradient-echo sequence (TR/
TE: 6.47/2.54 milliseconds; FOV: 250 x 250 x 225 mm3; matrix: 320 x 320 x 288; parallel 
imaging acceleration factor: 2; acquisition time: 5 minutes 58 seconds) covering the region 
from the prostate up toward the aortic bifurcation were obtained. Subsequently, an 1H-MR 
spectrum was obtained from a single voxel of 15 x 17 x 13 mm3 positioned inside the node 
using an echo time averaged point resolved spectroscopy sequence (PRESS (19,20) TR 1500 
milliseconds, 256 averages; acquisition time 6 minutes 24 seconds). Water and lipid signals 
were suppressed 2-fold. A combination of 2 dual-frequency selective refocusing pulses and 
crusher gradients around the second 180-degree PRESS pulse suppressed both water and 
lipid resonances [21]. In addition, the TE of the PRESS sequence was stepped up from 136 to 
272 milliseconds in 64 steps (each averaged 4 times) to cancel residual coupled lipid signals 
(echo time averaging [22]). Supervised automatic shimming and automatic adjustments of 
frequency and transmit power took approximately 5 minutes. With an integrated 1-minute 
normalization scan the contribution of the different coil elements to the signal intensity 
of the voxel was calculated. In Figure 4B the location of the voxel inside the lymph node is 
visualized as well as the corresponding 1H-MR spectrum from 1.0 to 5.5 ppm. In the absence 
of lipid resonances in the 0.5–2.5 ppm range we attribute the visible resonance at about 
3.20 ppm to the methyl protons of choline, phosphocholine, and glycerophosphocholine. In 
vivo, these multiple resonances cannot be spectrally resolved at 3 T. Thus, they appear as 
a single peak, termed total choline-containing compounds (tCho). To estimate the amount 
of tCho in this node we also acquired an unsuppressed, fully relaxed spectrum of the same 
voxel (TR/TE: 5000/30 milliseconds; 4 averages), in which the tCho signal was also clearly 
visible. Neglecting T1 saturation of the water and tCho spins at this long TR, using the T2 
of choline proton spins to be 220 milliseconds [17] and assuming T2 of water spins to be 
94 milliseconds in cancer tissue [23], we estimate a tCho content of 8.1 mmol/kg water, 
dividing the integral of a Gaussian line fit to the tCho resonance (9 protons) by the integral 
of a Lorentzian line fit to the water resonance (2 protons), and taking into account the 
molecular weight of water.
To validate that the choline signal was confined to the lymph node, a 3-dimensional 1H-MRS 
imaging measurement (TR/TE: 1500/100 milliseconds; FOV: 100 x 100 x 100 mm3; matrix 
size: 10 x 10 x 10; acquisition time: 7 minutes 31 seconds) with dual frequency selective 
water and lipid suppression was performed with the volume-of-interest covering the 
enlarged lymph node and adjacent lipid tissue (Figure 4C, D). Due to filtering of the signal 
before Fourier transformation in the spatial dimensions, the true size and shape of a voxel 
is a sphere with a diameter of approximately18 mm. The shown size of a voxel in Figure 4C, 
D is only 6 x 6 mm2, therefore locations just outside the lymph node still show a small tCho 
resonance (the underlined peaks), originating from the node itself. Residual lipid signals are 
visible outside the node and are associated with surrounding adipose tissue.
Histopathological Confirmation (Standard of Reference)
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Systematic 8-core (3 peripheral zone and central gland cores bilaterally) transrectal 
ultrasound-guided biopsy was performed. No complications were reported. Histopathology 
confirmed the presence of locally recurrent Gleason 3 + 4 prostate cancer in all 8 prostate 
biopsy cores (Figure 5A).
The patient underwent computed tomography (CT)-guided histologic biopsy of the enlarged 
lymph node (SOMATOM Sensation 16 slice; Siemens, Erlangen, Germany). The patient was 
placed in the supine position and the enlarged lymph node visualized on MR imaging was 
correlated with CT imaging. During repetitive CT scanning the biopsy needle was positioned 
against this node and histologic biopsy was performed with a 20-gauge needle using a 
coaxial system (Bard, Covington, GA). No complications were reported. Histopathology 
revealed the presence of adenocarcinoma with cribriform growth pattern that stained with 
a PSA antibody, conclusive for prostate cancer, in all lymph node biopsy cores (Figure 5B).
Because the elevated PSA level remained stable and due to the absence of any abnormality 
on bone scintigraphy and the absence of any clinical symptoms, the then-81-year-old 
patient, the patient’s family, and physicians decided to delay hormonal therapy and to keep 
the patient under further active clinical and PSA surveillance.
DISCUSSION
In this technical note and case report we demonstrated that noninvasive 1H-MRS imaging 
combining the signals of multiple external surface coils at 3 T is feasible in the prostate to 
detect local recurrence and in a lymph node to detect prostate cancer by quantifying tCho. 
1H-MRS of the Prostate
It has been established that tCho is a marker for the phospholipid turnover in the cell 
membrane [24]. Previous 1H-MRS studies of the prostate have demonstrated that the ratio 
of tCho + creatine as compared with citrate is an indicator of prostate cancer within the 
prostate gland [12,13]. Also, there was a trend towards increasing tCho + creatine/citrate 
ratios in more aggressive prostate cancer foci [25]. Our results, showing generally high tCho 
peaks with relatively lower citrate signals, are concurrent with previous studies performed 
at 1.5 T with an endorectal coil in prostate cancer treated with hormonal therapy [26] in 
which responsive prostate tissue experienced “metabolic atrophy” while any residual 
cancer exhibited a high tCho peak [18,26,27]. Thus, the feature of choline as an indicator of 
the presence of recurrent prostate cancer has been well established and it would be logical 
that metastatic disease could display a tCho peak on 1H-MRS.
We did not perform 1H-MRS of the prostate during the period after radiation therapy in 
which the PSA level was within the clinical range of normal. Although potentially we cannot 
exclude that the high tCho peak may have also been present prior to recurrence, it is 
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Figure 4. (A) Axial T2-weighted fast spin-echo image (TR/TE: 3100/135 milliseconds) 
at 3 T with combined body and spine matrix coils for localization of the enlarged lymph 
node (arrows). (B) The phase-corrected 1H-MR spectrum (without baseline correction) 
obtained from the TE-averaged and combined water and lipid-suppressed single voxel 
MR spectroscopy measurement. A peak at 4.7 ppm for residual water spins and a peak 
at about 3.2 ppm assigned to the methyl groups of choline-containing compounds (tCho) 
were observed. Note the absence of lipid signals from 1 to 2.5 ppm. The coronal reference 
image from the T1-weighted 3-dimensional gradient-echo sequence (TR/TE: 6.47/ 2.54 
milliseconds) and the axial T2-weighted fast spin-echo image are shown to indicate the voxel 
placement. (C) An axial spectral map of all voxels inside the volume-of-interest from the 
1H-MR spectroscopic imaging measurement (TR/TE: 1500/ 100 milliseconds) in which the 
tCho resonances are underlined. Outside the lymph node, large lipid signals are present; the 
tCho signal is only present inside. (D) Interpolated coronal and axial tCho color-coded maps 
constructed using the integral of a Gaussian fit to the tCho signal.
A 
M 
M 
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Figure 5. (A) Microscopy (hematoxylin-eosin stain, original magnification X 100) of the 
prostate needle biopsy revealed recurrent Gleason 3 + 4 prostate cancer. (B) Microscopy 
(antibody against PSA stain, original magnification X100) of the needle biopsy shows normal 
lymphatic tissue (L) along with metastasis (M) of an acinar adenocarcinoma with cribriform 
growth pattern and prominent nucleoli, characteristic for prostate carcinoma.
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generally assumed that metabolic and biochemical response are related and that metabolic 
atrophy is present when the PSA level is at nadir level [28].
Proton MRS imaging of the prostate has previously been performed with the use of an 
endorectal coil at both 1.5 T [12,13,29] and 3 T [5]. In our case report we demonstrated that 
it is feasible to perform 1H-MRS of the prostate without an endorectal coil at 3 T. Particularly 
in patients that have undergone radiation therapy, introduction of the endorectal coil can 
cause discomfort due to radiation treatment effects on the rectum and adjacent structures. 
Other advantages of not having to use an endorectal coil are the lower costs and time gained 
by not having to introduce the coil and check its position.
To obtain a sufficiently high spectral signal to noise ratio within clinically reasonable scanning 
times, the voxel size was larger than at both 1.5 and 3 T with an endorectal coil. Using our 
voxel size, small cancer foci may be missed. However, it is unclear if detecting small cancer 
foci has clinical consequences. In recurrence detection the aim is to detect clinically relevant 
recurrence in the prostate. Our technique may also be used in other clinical settings, such 
as in a screening population or radiation therapy planning. In a screening population, the 
preferential detection of larger, more aggressive cancer foci over smaller, less aggressive 
ones would be required since most relatively low-grade, small-volume cancer foci will not 
determine the patient’s morbidity and mortality [30,31]. In intensity-modulated radiation 
therapy planning, by identifying and correctly localizing the areas of the most aggressive 
prostate cancer foci (the dominant intraprostatic lesions), a radiation therapy dose boost 
up to 90 Gy can be administered to this region [32]. Since it is hypothesized that most 
recurrences occur at the localization of the primary cancer [33] this may aid in preventing 
recurrent disease.
In patients with breast cancer, 1H-MRS has been shown to aid in diagnosis and treatment 
follow-up [34-36]. Previously, a quantitative approach using single voxel 1H-MRS at 4 T was 
used in breast cancer patients. It was concluded that the amount of tCho per kilogram of 
water was a predictor of malignancy [34]. In a recent preliminary study, the addition of 
1H-MRS to MR imaging of breast lesions was shown to be of possible help to improve the 
radiologist’s ability to distinguish benign from malignant breast lesions [35].
1H-MRS of the Lymph Node
In an earlier publication, Yeung et al established the feasibility and high diagnostic 
performance of detecting choline in axillary lymph nodes in 39 breast cancer patients at 1.5 
T using either a surface or breast coil with fine-needle aspiration as standard of reference 
[37]. The authors found high sensitivity 82% (14 of 17 nodes) with perfect specificity 
(100%, 14 of 14). They reported that the false negative results were due to small (2–4 mm) 
metastases with an inherently low signal-to-noise ratio and, therefore, undetectable tCho 
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signal. Furthermore, the authors determined only whether a tCho peak could be assigned, 
but did not quantify the amount of choline.
The amount of tCho present in the positive lymph node in our case report is similar to the 
largest values reported in malignant breast lesions (up to 8.5 mmol/kg water) [34,38,39]. 
Quantification of the tCho concentration has also been performed in other tumors. For 
gliomas, it was established that the average tCho concentration was 2.86 mmol/L and this 
increased to 3.21 mmol/L if only grade III gliomas were included in the analysis [40]. In 
another study, tCho concentrations between 1.5 and 2.7 mmol/mL were found for various 
types of brain tumors [41]. In 4 patients with hepatocellular carcinoma, tCho concentrations 
between 3.4 and 14.0 mmol/L have been found [42]. In lymph nodes and in breast tumors, 
the 1H-MRS voxel is likely to include adipose tissue.
Proton MRS imaging using multiple external surface receiver coils is a noninvasive technique. 
Another novel technique, MR lymphography using ultrasmall paramagnetic iron-oxide 
containing particles such as ferumoxtran-10 [43,44], if approved for clinical use, may be an 
alternative to investigate the state of lymph nodes. A clear advantage of MR lymphography 
is that it is able to detect much smaller metastatic lymph nodes than 1H-MRS. However, 
the former technique is not yet available and is more invasive than 1H-MRS. In future, we 
need to assess the minimal volume necessary for 1H-MRS to detect sufficiently high tCho 
signals within a lymph node. Performing 1H-MRS at field strengths of 4 T or higher [45] may 
enable us to reduce the volume necessary to perform single voxel measurements and use 
1H-MRS in smaller lymph nodes. In addition, diffusion weighted whole-body MR imaging 
with fat suppression has potential for detection of metastatic lymph nodes. The feasibility 
to visualize pathologic lymph nodes has been shown in 11 patients with, among others, 
malignant lymphoma and breast cancer [46].
We need to consider several limitations. First, our techniques will have to be applied to 
more patients and in patients who have not undergone prior therapy to determine heir 
applicability in the general prostate cancer population. Likewise, prospectively, the 
technique will also have to be compared directly with endorectal 1H-MRS of the prostate at 
1.5 T or 3 T to assess its clinical applicability. Second, as for the lymph node, we do not have 
any reference value as to whether tCho is also present in healthy lymph nodes or nodes 
reactive to inflammation. In general, these nodes are considerably smaller than the one we 
have performed 1H-MRS on, resulting in too little tCho to detect with this instrumental set-
up. Future studies should perform 1H-MRS on enlarged, healthy lymph nodes to determine 
the amount of tCho, if at all, present in these nodes. Analogous to 1H-MRS in breast lesions, 
the calculated concentration of tCho may provide a possibility to differentiate benign from 
malignant lymph nodes.
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Our technique shows promise in aiding radiation oncologists to determine the presence of 
recurrence in both the prostate and lymph nodes. It may also be applied in patients before 
undergoing radiation therapy to determine the exact localization of prostate cancer within 
the prostate gland, for instance for performing dose boosting in dominant lesions with 
intensity-modulated radiation therapy [32]. Up to now 1H-MRS at a field strength of 1.5 T 
was only possible using an endorectal coil to achieve clinically relevant spatial information on 
cancer localization. Nevertheless, also at 1.5 T the technique combining multiple external-
surface coils may be applied. To achieve a sufficiently high signal-to-noise ratio, the voxel 
volume will have to be considerably larger compared with that in our study at 3 T or that 
with an endorectal coil at 1.5 T.
In conclusion, we demonstrated that in a patient suspected of having recurrent prostate 
cancer it was feasible to noninvasively detect local recurrence of prostate cancer within 
the prostate and to detect and quantify the total choline-containing compounds in a lymph 
node metastasis located deep inside the body, with proton MR spectroscopic imaging at 3 
T by combining the signals of multiple external matrix coils. This technique may aid in the 
diagnosis of local recurrence and regional metastatic lymph node disease. Future studies in 
a larger patient population will have to be performed to determine the clinical applicability.
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CHAPTER 8
Three-dimensional Proton MR Spectroscopy 
of Human Prostate at 3 T without 
Endorectal Coil: Feasibility
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Purpose - To evaluate sensitivity and specificity of proton magnetic resonance (MR) 
spectroscopy of the prostate with external surface coil elements at 3 T for differentiation of 
cancer from healthy tissue within an acceptable measurement time, by using histopathologic 
findings as the reference standard.
Materials and Methods - The study was approved by the institutional review board; 
informed consent was obtained. Forty-five men (age range, 51–70 years) underwent 3-T MR 
imaging with external radiofrequency surface coils for signal reception. MR spectroscopy 
was performed with acquisition-weighted three-dimensional water- and lipid-suppressed 
point-resolved spectroscopy pulse sequence. Voxels were classified into healthy peripheral 
zone, central gland, and periurethral zone and cancer tissue. Cancer voxels were classified 
according to cancer size and certainty in matching histopathologic findings with MR images. 
After visual inspection of automated fitting of classified voxels, the choline plus creatine–to-
citrate (Cho + Cr/Cit) ratio was calculated for all tissues. Area under the receiver operating 
characteristic curves (Az) values were used to assess accuracy of discrimination of cancer 
from healthy tissues. P < .05 indicated a significant difference.
Results - After exclusion of four patients with no voxels that passed visual inspection of the 
automated fit, a median of 82% of the classified voxels per patient was used in the analysis. 
Mean Cho + Cr/Cit ratios for healthy tissues were 0.22 +/- 0.12 (standard deviation) for 
peripheral zone, 0.34 +/- 0.14 for central gland, and 0.36 +/- 0.20 for periurethral area; all 
were significantly different from that of cancer (P < .001). Az for discrimination of probable 
and definite cancer tissue from healthy tissue for the peripheral zone (0.84) was significantly 
higher than that for the central gland (0.69) (P < .05).
Conclusion - Three-dimensional proton MR spectroscopy of the prostate, with a combination 
of only external radiofrequency surface coils at 3 T, can be used to discriminate cancer from 
healthy tissue.
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Proton magnetic resonance (MR) spectroscopy of the human prostate has proved to be 
a valuable addition to conventional MR imaging in the localization of prostate cancer [1]. 
Signals of citrate, creatine, and choline can be detected throughout the prostate, with 
increased levels of choline and decreased levels of citrate being indicative of cancer tissue 
[2,3]. A major issue in MR spectroscopy of the prostate is the use of an endorectal coil, either 
rigid or inflatable. Apart from the discomfort to the patient caused by this coil, its insertion 
and the necessary evaluation of its position take up valuable MR imaging time. Although 
the local sensitivity reached with the use of an endorectal coil can never be reached by 
using only conventional external array coils, it is worthwhile to explore the possibilities of 
not using the endorectal coil: hydrogen 1 (1H) MR spectroscopic examinations without an 
endorectal coil would be easier, faster, less expensive, and truly noninvasive. It would make 
this technique eligible for more wide-spread use in a clinical environment.
MR spectroscopy of the prostate without an endorectal coil has previously been performed at 
a magnetic field strength of 1.5 T with a single spine-array coil element [4]. The possibility of 
coherently adding the signals from multiple coil elements into one spectrum for every voxel 
of a spectroscopic imaging grid [5] has enabled the use of a combination of multiple coils at 
1H MR spectroscopy of the prostate. The drawback of using surface coils is their larger size 
and further distance from the prostate, which leads to a decrease in signal-to-noise ratio. 
By using 3 T, part of this loss in signal-to-noise ratio is recovered. The optimal timing for 1H 
MR spectroscopic imaging by using point-resolved spatially localized spectroscopy (PRESS) 
[6] of the prostate at 3 T has been presented recently, which makes the technique suitable 
for use in patients [7]. Because the chemical shift (in hertz) of different resonances increases 
linearly with magnetic field strength, one would expect better separation of the creatine 
and choline methyl-proton resonances than that in spectra obtained at a field strength of 
1.5 T. However, resonances of strongly coupled proton spins from polyamines (spermine, 
spermidine, among others) or ethanolamine and phosphoethanolamine could be present 
between 3.0 and 3.3 ppm [8], which prevents the spectrum from reaching the spectral 
baseline between the creatine and choline signals. Thus, the purpose of our study was to 
evaluate the sensitivity and specificity of 1H MR spectroscopy of the prostate performed 
with a combination of external surface coil elements at 3 T for differentiation of cancer from 
healthy tissue throughout the prostate within a clinically acceptable measurement time, by 
using histopathologic findings as the reference standard.
MATERIALS AND METHODS
One author (S.A.R.) is employed by Siemens Medical Solutions (Erlangen, Germany). All 
other authors had control of inclusion of any data and information that might present a 
conflict of interest.
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Patients
The study was approved by our institutional review board, and written informed consent was 
obtained from all patients. From September 2004 to December 2005, 45 consecutive men 
with biopsy-proved prostate cancer who underwent radical prostatectomy within 6 weeks 
after MR imaging and 1H MR spectroscopic imaging at 3 T were eligible for inclusion in our 
study. A patient exclusion criterion was previous hormonal therapy. Patient age ranged from 
51 to 70 years (mean age, 60 years). Mean prostate-specific antigen level was 9.6 ng/mL 
(range, 3.6-79.2 ng/mL), and the mean Gleason score, based on findings in prostatectomy 
specimens, was 6.6 (range, 5–9). The median time between transrectal ultrasonographically 
guided eight-core sextant biopsy and MR examination was 107 days (range, 21–246 days), 
and that between MR examination and surgery was 7 days (range, 1– 89 days).
MR spectroscopic imaging data were routinely obtained from the entire prostate of all 
patients. The total examination time of 25–30 minutes consisted of the following parts: 
12–15 minutes for all anatomic T2-weighted imaging (transverse, sagittal, and coronal), 4 
minutes for shimming, and 9 minutes for spectroscopic imaging measurements.
MR Imaging Acquisition
MR imaging was performed with a 3-T whole body unit (Magnetom Trio; Siemens Medical 
Solutions), with an eight-element body-array coil (31 patients) and the total imaging matrix 
concept (Siemens) (14 patients) for signal reception. In the latter case, the user selected 
the appropriate one or two three-element coil arrays from the supine coil matrix (eight 
arrays of three coil elements on the patient table) and one or two three-element coil arrays 
from the body matrix coil placed on top of the patient. Peristalsis was suppressed with an 
intramuscular injection of 1 mg glucagon (Glucagen; Novo Nordisk, Bagsvaerd, Denmark) 
immediately before the start of the examination.
With the patient inside the imager, a quick series of three orthogonal gradient-echo images 
(field of view, 400 x 400 mm; matrix size, 128 x 256; echo time, 5 msec; section thickness, 10 
mm) was obtained for localization, after which the prostate anatomy and surrounding tissues 
were depicted with T2-weighted fast spin-echo MR imaging in three planes. Radiofrequency 
power deposition was reduced by using hyperechoes: Instead of a train of 180° pulses, the 
spin echoes were obtained with a train of low-power pulses with modulated flip angles to 
produce a full spin echo at the effective echo time [9]. The parameters for the T2-weighted 
images were as follows: repetition time msec/effective echo time msec, 3500-5000/124; 
field of view, 220 mm; matrix size, 512 x 512; 13-17 sections; section thickness, 4 mm; 
intersection gap, 0.4 mm; number of signals acquired, two; and acquisition time per plane, 
4-5 minutes.
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MR Spectroscopic Imaging
After automatic and, if necessary, additional manual shimming (optimization of the main 
magnetic field homogeneity) of the prostate volume, a 1H MR spectroscopic imaging PRESS 
pulse sequence was performed to acquire proton MR spectra from every voxel of a three-
dimensional (3D) excited subvolume containing the prostate. Because the two protons of 
the citrate resonance at 2.60 ppm are a strongly coupled spin system, the spectral shape 
of this resonance depends on magnetic field strength and pulse sequence timing [10]. For 
an optimal shape of the citrate resonance at a magnetic field strength of 3 T, we used an 
echo time of 145 msec, at which the signal of citrate appears with large positive in-phase 
A B 
C D 
Figure 1. T2-weighted MR imaging (3500/124) and 1H MR spectroscopic data in 61-year-
old patient with prostate cancer. (A–C) T2-weighted MR images in transverse, coronal, and 
sagittal orientation, respectively, show placement of PRESS box (box around prostate) and 
outer volume saturation slabs (crosshatched bands). (D) Enlarged transverse image with one 
partition of 3D interpolated 1H MR spectroscopic matrix of 16 × 16 × 16 voxels (outer box). 
Outer volume saturation slabs extend into PRESS-selected volume of interest (inner box).
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inner lines [7]. This echo time is long enough for possible residual lipid signals to decay but 
is still short enough to depict the metabolites of interest. Water and lipids were suppressed 
with outer volume saturation slabs (Figure 1) and two 12.6-msec dual-frequency selective 
Mescher-Garwood pulses with crusher gradients [11,12].
A combination of an elliptic weighted averaged k-space acquisition scheme, zero filling to 
the nearest power of two, and 3D filtering of the signal in k-space was used [13] to reduce 
intervoxel signal contamination. Imaging parameters were as follows: 750/145; acquisition 
bandwidth, 1250 Hz; and 512 spectral data points. Field of view, matrix size, and number 
of signals acquired were adjusted in every prostate to achieve a nominal voxel resolution 
(before apodization) of 7 x 7 x 7 mm within a total acquisition time of approximately 9 
minutes. After apodization, a voxel could best be approximated as a sphere with a diameter 
of 12.5 mm and a volume of 1.0 cm3 [13].
Before Fourier transformation, the signals from the individual coil elements of the body-
array coils were zero-order phased on the basis of the first point of the free induction decay 
and were added with the amplitude of that point as a weight factor [5].
To investigate the appearance of the strongly coupled resonances of polyamines between 3.0 
and 3.3 ppm, a two-dimensional MR spectroscopic PRESS measurement of a phantom with 
a buffered solution of citrate, creatine, choline, and spermine at physiologic concentrations 
(90.0, 12.0, 9.5, and 18.0 mmol/L, respectively) was performed with the same pulse 
sequence timing as that used for in vivo spectroscopic imaging (echo time, 145 msec; time 
from 90° to first 180° pulse, 25.0 msec [7]; field of view of 96 x 96 mm, matrix of 12 x 12, 
section thickness of 10 mm, nominal voxel resolution before apodization of 8 x 8 x 10 mm, 
and acquisition time of 1 minute 52 seconds).
Histopathologic Analysis
Prostatectomy specimens were fixed overnight (in 10% neutral buffered form- aldehyde) 
and coated with India ink. The prostate was sliced at 4-mm intervals in a plane parallel to 
the transverse T2-weighted sequence. All slices were routinely embedded in paraffin. Tissue 
slices of 5 mm thickness were prepared and stained with hematoxylin-eosin. The presence 
and extent of cancer were outlined on the glass cover and marked on photographs of the 
corresponding slice by a genitourinary pathologist (C.A.H., 13 years of experience) who was 
blinded to imaging results. All prostatectomy specimens were assigned a stage according to 
the 2002 TNM classification [14].
Spectroscopic Imaging Voxel Classification
On the basis of histopathologic findings and T2-weighted images in three directions with the 
overlaid spectroscopic imaging voxel matrix, a radiologist (S.W.T.P.J.H., 3 years of experience) 
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in consensus with an MR spectroscopist (T.W.J.S., 4 years of experience) assigned 1–4 
voxels of the 1H MR spectroscopic imaging matrix to each of the following tissues: healthy 
peripheral zone, healthy central gland (consisting of combined transition zone and central 
zone), healthy periurethral zone, and prostate cancer. Both reviewers were blinded to 1H 
MR spectroscopic imaging spectra. The inclusion of the periurethral zone as tissue separate 
from the central gland enabled us to study this region as a possible confounder in identifying 
cancer. The ejaculatory ducts, connecting the seminal vesicles through the central zone of 
the prostate to the urethra, can have high intensity signals from the ejaculatory ducts around 
3.2 ppm. The voxels were assigned to different tissues on the basis of anatomic landmarks 
in the prostate visible on T2-weighted images (enabling distinction between central gland, 
peripheral zone, and urethra), rather than on the basis of hyper- or hypointensity of the tissue 
itself. Matching between histopathologic slices and T2-weighted images was estimated to 
be within an accuracy of one image section thickness (4 mm) in the craniocaudal direction 
[15].
For each assigned prostate cancer voxel, the size of the corresponding cancer focus as 
determined by using histopathologic findings was classified by the radiologist (S.W.T.P.J.H.) 
and spectroscopist (T.W.J.S.) in consensus as larger than 2 1H MR spectroscopic imaging 
voxels, between one and two 1H MR spectroscopic imaging voxels, or smaller than 1 1H 
MR spectroscopic imaging voxel. To acknowledge the difficulties in aligning MR images and 
histopathologic slices [16], we assigned a certainty score to each selected cancer voxel, 
noted as a score of 1, possibly inside the cancer; a score of 2, probably inside the cancer; 
and a score of 3, definitely inside the cancer.
Data Processing and Analysis
For evaluation and quantification of all individual spectra, a software package (PRISMA; 
University of Bremen, Bremen, Germany, and Siemens Medical Solutions) was used. 
This software package uses a basis set of metabolic time signals of choline, creatine, and 
citrate, which are simulated by using literature values of chemical shifts and coupling 
constants. Especially for the complicated shape of citrate, this is an advantage, because 
the whole spectral shape is used in the fit [7]. The reported amplitude of the citrate 
resonance is amplitude fitted to the model time signal, which can differ from the integral 
of the citrate resonance in the spectrum because its shape comprises both positive and 
negative signal intensities. After a frequency shift and residual water removal, the complex 
fit to the spectroscopic data in the time domain was performed, which included baseline 
artifact handling by truncation and remodeling of the first five data points. For every fitted 
metabolite, a Cramer-Rao lower bound was calculated, and a visual inspection of the original 
spectrum together with the curve fit and residual plot was performed by the spectroscopist 
(T.W.J.S.). Voxels with a correct automatic choice of the resonances (ie, PRISMA-produced 
signal fits at the correct parts-per-million positions), without lipid signal contamination 
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and severe baseline distortions and with minimal intensity in the residual plots, passed the 
visual inspection. From these voxels, the choline-plus-creatine-to-citrate (Cho + Cr/Cit) ratio 
was calculated by dividing the sum of the fitted amplitudes in the free induction decay of 
choline and creatine by the fitted amplitude of the citrate signal.
Because the pathologist (C.A.H.) indicated the Gleason score for every outlined cancer focus 
in the histopathologic slices, we were able to investigate a possible relation between the 
Gleason score and the Cho + Cr/Cit ratio for every classified cancer voxel.
Statistical Analysis
The area under the receiver operating characteristic (ROC) curve (Az) for discrimination 
between cancer and healthy tissue was calculated by using the classified voxels as 
independent values. ROC curves were calculated with cancer voxels that had a matching 
certainty score of 2 or 3 (probably or definitely inside cancer). Separate analyses were 
performed for peripheral zone, central gland, and periurethral cancer localization. Sensitivity 
and specificity at different threshold values for the different tissues were calculated.
P values for comparisons of different tissues were calculated with the Bonferroni multiple 
comparison test after a one-way analysis of variance; a P value of .05 or less was considered 
to indicate a significant difference. P values for differences in ROC curves were calculated 
with two-sided paired t tests. The Spearman rank correlation test was used to calculate r 
values. Statistical analyses were performed by using software (MedCalc, version 8.1.0.0, 
MedCalc Software, Mariakerke, Belgium; Prism, version 4.00, GraphPad Software, San 
Diego, Calif; SPSS, version 12.0.1, SPSS, Chicago, Ill).
RESULTS
Phantom Measurement and in Vivo 1H MR Spectroscopic Imaging
In a representative 1H MR spectroscopic imaging data set accompanied by histopathologic 
findings of the corresponding resected prostate, signals of citrate, choline, and creatine 
were depicted throughout the entire prostate (Figure 2). In many spectra in all patients, the 
choline and creatine resonances could not be clearly separated: Polyamine signals were still 
present at the used pulse-sequence timing, as is illustrated with the spectrum of a voxel 
inside the phantom with a solution of relevant prostate metabolites (Figure 3). Although the 
line width of the signals in this spectrum is quite small (4 Hz), the signals from the strongly 
coupled protons of spermine overlap with both creatine and choline signals. Therefore, in 
all voxels of the in vivo measurements with larger line widths and possibly other polyamines 
present, the complete region from approximately 3.0 to 3.2 ppm, reflected in a fit of two 
resonances to this region, was summed and used as the numerator of the marker ratio for 
prostate cancer.
3D PROSTATE MR SPECTROSCOPY WITH EXTERNAL COILS AT 3T 143
8Figure 2. Histopathologic findings and corresponding 3D 1H MR spectroscopic data (750/145) 
of prostate in 64-year-old patient with prostate cancer (prostate-specific antigen level, 6.86 
ng/mL; final Gleason score, 3 + 4; stage, pT2c). Top: Photographs of histopathologic findings 
from apex to midgland in transverse slices. Arrows = areas of specimen that correspond to 
location of spectra and images below. Middle: Spectra from in vivo prostate. Left to right: 
healthy peripheral zone, cancer in peripheral zone, cancer in central gland, and healthy 
central gland. Scale is adjusted for each spectrum. Bottom: Transverse T2-weighted MR 
images of three of 16 sections of 3D 1H MR spectroscopic data from apex to midgland 
overlaid with corresponding spectral maps (range, 2.0–3.5 ppm). True size and location of 
voxels of which spectra are shown in middle row are indicated with circles. CP±? = possible 
capsular penetration, RV++ = positive resection margins.
Voxel Classification and Metabolite Ratios
In total, 375 voxels were selected on the basis of histopathologic findings and assigned to 
one of the four tissues in all 45 patients: 87 voxels to cancer, 118 voxels to healthy peripheral 
zone, 115 voxels to healthy central gland, and 55 to healthy periurethral tissue. All selected 
voxels were processed with the automatic signal fit of the PRISMA software package (Figure 
4). In four patients (26 voxels) (Figure 5), none of the classified voxels contained useful 
spectra. With the exclusion of these four patients, the average percentage per patient of 
voxels that passed the visual inspection of the automated fit procedure was 74% (median, 
82%).
144 3D PROSTATE MR SPECTROSCOPY WITH EXTERNAL COILS AT 3T
Figure 3. MR spectrum of voxel in phantom with buffered solution of citrate, creatine, choline, 
and spermine at physiologic concentrations (90.0, 12.0, 9.5, and 18.0 mmol/L, respectively). 
Spermine, one of the polyamines, has relatively broad relevant signal intensities in 3.0–
3.2-ppm range at the used pulse timing. If line widths increase and other polyamines are 
also present, which is often the case in vivo, it is difficult to reliably quantify resonances of 
choline, creatine, and polyamines separately.
A C B 
Figure 4. Spectral fits and calculations of Cho + Cr/Cit (CC/C) ratio by using PRISMA software 
with data of three locations in prostate of 64-year-old patient with prostate cancer. Spectra 
originate from (a) healthy peripheral zone, (b) transition zone cancer with Gleason score of 2 
+ 4, and (c) peripheral zone cancer with Gleason score of 3 + 4. From top to bottom for each 
fit in (a–c) measured spectrum (black line) overlaid with fit (upper gray line) and baseline, 
metabolite fit (lower gray line), and residual between data and fit.
Figure 5. Flowchart of study profile. PCa = prostate cancer.
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From 257 included spectra, both mean and median Cho + Cr/Cit ratios of the voxels from 
healthy tissues significantly differed from those of cancer tissue (Figure 6) (P < .001). The 
mean Cho + Cr/Cit ratio in the peripheral zone was significantly different from that in central 
gland and periurethral tissue (P < .05), whereas there was no statistical difference between 
ratios in the central gland and periurethral tissue (P = .90).
Figure 6. Graph of Cho + Cr/Cit (CC/C) ratio of tissues in prostate. Mean values, indicated 
with a horizontal line, for Cho + Cr/Cit ratio are 0.22 ± 0.12 (standard deviation) for peripheral 
zone (PZ), 0.34 ± 0.14 for central gland (CG), 0.36 ± 0.20 for periurethral area (U), and 1.3 ± 
3.7 for cancer tissue. For display purposes, 6 voxels with Cho + Cr/Cit ratio greater than 1.5 
are shown as 1.5.
However, some voxels in the periurethral area had the highest Cho + Cr/Cit ratios among 
healthy tissues. Focusing on voxels from cancer tissue only and using the additional 
classifications concerning cancer size and matching certainty, we found an increase in mean 
and median Cho + Cr/Cit ratios with both increasing cancer size and matching certainty 
(Figure 7).
ROC curves were calculated for tissues by using only cancer voxels that were probably 
or definitely inside cancer (matching certainty scores of 2 and 3), thereby excluding the 
category possibly inside cancer. In seven patients, only cancer voxels with a matching 
certainty score of 1 were classified, so ROC curves were constructed with cancer voxels from 
34 patients and voxels in healthy tissues from 41 of 45 patients. Because the Cho + Cr/Cit 
distribution between the central gland and the periurethral area did not differ significantly, 
we combined the Cho + Cr/Cit distributions from the central gland and the periurethral area 
into a single ROC curve (Figure 8). The Az for the tissues were 0.84 (95% confidence interval: 
0.76, 0.90) for the peripheral zone and 0.69 (95% confidence interval: 0.62, 0.76) for the 
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combined central gland and periurethral area (P = .002). In the Table, the sensitivity and 
specificity at two threshold values for the Cho + Cr/Cit ratio for peripheral zone and central 
zone tissues are summarized.
Figure 8. ROC curves summarize accuracy of discrimination of cancer from healthy peripheral 
zone and central gland tissue at 1H MR spectroscopy with only external surface coils at 3 T.
Although we used only the Cho + Cr/Cit ratio of those voxels that were classified as definitely 
inside cancer (class 3 only) to relate to cancer aggressiveness (Figure 9), we did not find a 
correlation between the Cho + Cr/Cit ratio and Gleason score (r = 0.17).
A B 
Figure 7. Graphs of valid cancer voxels classified by size and matching certainty score. (A) Cho 
+ Cr/Cit (CC/C) ratio is plotted against size: class A = larger than 2 1H MR spectroscopic voxels 
(approximately 2 cm3), class B = between 1 and 2 1H MR spectroscopic voxels (between 1 
and 2 cm3), and class C = smaller than 1 1H MR spectroscopic voxel (approximately 1 cm3). 
(B) Relationship with matching certainty score is shown: class 1 = possibly inside cancer, 
class 2 = probably inside cancer, and class 3 = definitely inside cancer. For display purposes, 
Cho + Cr/Cit ratios greater than 1.5 are shown as 1.5.
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Table. Sensitivity and Specificity of 1H MR Spectroscopy for Discrimination of Cancer from 
Healthy Peripheral Zone and Central Gland Tissue at Cho + Cr/Cit Thresholds
Figure 9. Graph shows that correlation between Cho + Cr/Cit (CC/C) ratio of cancer voxels 
assigned with high matching certainty and total Gleason score of corresponding cancer 
focus at histopathologic examination was not found (r = 0.17).
DISCUSSION
Our study results demonstrate that 1H MR spectroscopic imaging of the prostate with the 
use of external surface coils at 3 T is feasible. The examinations -including MR imaging- 
were noninvasive and relatively short (<30 minutes). The number of classified voxels that 
passed visual inspection of the quality of the fit and that were chosen at random in tissues 
throughout the prostate of every patient can be used as an estimate of what percentage 
of the voxels of the data set were useful. With the exclusion of four patients because of 
inadequate shimming values and/or low signal-to-noise ratio, the median amount of 82% of 
useful voxels per patient reflects the robustness of the pulse sequence, the combination of 
signals from multiple coil elements, and the automatic fit routine. From these useful voxels, 
the Cho + Cr/Cit ratio could be calculated, which resulted in a Cho + Cr/Cit threshold value 
of 0.41. At 0.41, the sensitivity and specificity, respectively, of discrimination of cancer from 
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healthy tissue were 66% and 95% for the peripheral zone and 66% and 73% for the central 
gland.
Although we used a different repetition time, echo time, and magnetic field strength, the 
mean and standard deviation of the Cho + Cr/Cit ratio of voxels in the healthy peripheral zone 
(0.22 +/- 0.12) were almost identical to values reported previously with similar combined 
water and lipid suppression at 1.5 T with an endorectal coil (0.22 +/- 0.13) [17]. Apparently, 
differences in pulse sequence timing equalize with differences in metabolite relaxation 
times. On one hand, choline and creatine signals are lower than citrate signal because of a 
slight increase in saturation of these signals at 3 T (T1 of choline in the prostate at 3 T has 
been reported to be 1.6 seconds +/- 0.5 compared with 0.47 second +/- 0.14 for citrate) [7]. 
On the other hand, this is compensated by the smaller loss of signal at an echo time of 145 
msec because T2 relaxation for choline (T2 of 0.24 second +/- 0.09) [7] is higher than that of 
citrate (T2 of 0.17 second +/- 0.05) (7) at 3 T.
With complete coverage of the whole prostate at 3D 1H MR spectroscopic imaging, we 
could differentiate Cho + Cr/Cit values of the peripheral zone from values of the central 
gland. Another study [18] at 1.5 T on differentiation between central gland and peripheral 
zone at two-dimensional 1H MR spectroscopic imaging, with use of an endorectal coil and 
somewhat different MR parameters, revealed slightly deviating mean Cho + Cr/Cit values of 
healthy tissues (0.38 +/- 0.15 for peripheral zone and 0.43 +/- 0.16 for central gland) but a 
similar overlap of Cho + Cr/Cit values in cancer with those in healthy tissue. Mean Cho + Cr/
Cit values for voxels in cancer tissue are difficult to compare between studies because the 
distribution in Cho + Cr/Cit values is far from Gaussian: A single or small number of very high 
Cho + Cr/Cit values dominate the mean value.
Because the mean Cho + Cr/Cit ratio of the central gland is higher than that of the peripheral 
zone, the overlap with voxels from cancer tissue is larger and the power of using the ratio 
to discriminate healthy tissue from cancer tissue is smaller, as is reflected in the lower Az of 
the ROC curve for the central gland than that for the peripheral zone. For a separate analysis 
of cancer in the central gland and the peripheral zone, the amount of matched voxels of 
cancer tissue in the central gland was too small. Therefore, voxels of cancer tissue were not 
subdivided according to their location in the prostate in the analysis.
The shape of the citrate signal at 3 T at the applied pulse timing calls for a postprocessing 
method that calculates more than the integral of signals in the spectrum only. The integral 
of the citrate signal varies with its line width and can approach zero when positive and 
negative lobes of the phased signal cancel each other. This problem was overcome by 
fitting a complex signal amplitude to a model function in the time domain. As mentioned 
earlier, the increase in spectral resolution obtained at 3 T compared with that at 1.5 T did 
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not necessarily increase the accuracy of fitting choline and creatine resonances separately, 
because polyamine resonances between these two metabolites often still appeared to be 
present. Adding the integrals of these metabolites, thereby quantifying the complete group 
of resonances from 3.0 to 3.2 ppm and dividing them by the integral of citrate (represented 
by the fitted amplitude of the time domain signal), which is a general approach with spectra 
at 1.5 T, provided a more robust measure for quantifying tissues. A general problem with this 
approach remains partial cancellation of the sum of resonances by a decrease in polyamine 
signals together with an increase in choline signals in cancer tissue.
Difficulties in matching histopathologic slices with T2-weigthed MR images were 
acknowledged with the additional classification we made for the cancer voxels: Both 
smaller foci and foci that were matched with lower confidence had smaller Cho + Cr/Cit 
ratios. Furthermore, as a result of apodization to reduce voxel bleed [13], the true size of 
a voxel (approximately 1 cm3) was larger compared with what is called a clinically relevant 
cancer focus volume (> 0.5 cm3) [19,20] and also was larger than voxel sizes reported at 
1.5 T (0.24 – 0.7 cm3 [1] and 0.6 – 0.8 cm3 [18], both without apodization). This introduces 
partial volume effects. In smaller cancers, voxels could contain both cancer and healthy 
tissue with a corresponding lower Cho + Cr/Cit ratio, which is also reflected in the decrease 
in median Cho + Cr/Cit ratio with decreasing cancer size. Because the highest Cho + Cr/ Cit 
values of healthy tissues were present around the urethra, we cannot rule out the urethra 
and ejaculatory ducts as possible confounders for cancer. However, the size of the voxels 
and the corresponding partial volume effects when defining a voxel around the urethra 
could be a reason why we did not find significant differences between the Cho + Cr/Cit 
ratio of the periurethral area and that of the healthy central gland. Throughout the central 
gland, including the urethra, the Cho + Cr/Cit ratio is generally larger than that of the healthy 
peripheral zone. Benign diseases of the central gland that increase the signals from 3.0 to 
3.2 ppm or anatomic differences, such as less ductal tissue in which citrate is accumulated, 
could be reasons for this.
Although such findings were revealed in prostate cancer studies at 1.5 T [15], we were not 
able to detect a trend between the Cho + Cr/Cit ratio of a voxel in cancer tissue and the 
corresponding Gleason score at histopathologic analysis. A possible explanation could be 
that our patients were eligible for prostatectomy and therefore did not have the highest 
Gleason scores (predominantly 5-7). Consequently, we could not cover the complete range 
of Gleason scores proportionally with our patient population.
Our study had limitations. Without an endorectal coil, the signal-to-noise ratio inside the 
prostate was limited, which forced us to use a voxel size of 1.0 cm3, with its corresponding 
partial volume effects. If an endorectal coil had been used, the signal-to-noise ratio in the 
peripheral zone of the prostate would have been four to 10 times higher, depending on the 
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actual distance from the voxel to the coil conductors. With increasing distance to the coil 
conductors (in central gland tissues), the benefit of an endorectal coil is less [21].
Not all voxels of all prostates were evaluated in our study. Although the classified voxels 
were chosen at random locations within the tissues of the prostate, they are a subset of 
the total number of voxels. But, because the classification was performed on the basis 
of histopathologic and MR imaging findings, with reviewers blinded to MR spectroscopic 
results and with the incorporation of both large and smaller cancer foci, we do not expect 
a bias in quantification with this subset. Furthermore, the MR spectroscopic findings were 
studied without an extensive comparison with sensitivity and specificity for distinguishing 
benign from malignant tissue with T2-weighted MR imaging alone at 3 T. Therefore, we are 
unable to estimate the incremental value of MR spectroscopic imaging over T2-weighted 
MR imaging -which has been found for 1.5 T [22]- for a field strength of 3T.
Another limitation of our study was its relatively small number of patients. We did not 
assign a prospective score, or radiologic certainty score, to tissue for the presence of cancer, 
as has been proposed by Jung et al [23]. We also did not take into account possibly elevated 
choline or decreased polyamine levels as separate parameters, which can have additional 
value. We investigated the quantitative value of the Cho + Cr/Cit ratio itself, without the 
experience of radiologic input but also without the possible bias of radiologic input, as a 
basis for either radiologic assignment or pure quantitative assessment of future prospective 
work.
In summary, on the basis of only the numbers of the Cho + Cr/Cit ratio, which originated from 
1.0-cm3 voxels and was measured in less than 10 minutes, 3D proton MR spectroscopy at 3 
T with only external array coils had a high specificity for the discrimination of cancer from 
healthy tissues; therefore, this technique shows potential for the metabolic identification of 
prostate cancer. Further and larger studies are needed, however, for confirmation.
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CHAPTER 9
Initial Results of 3-Dimensional 1H-Magnetic 
Resonance Spectroscopic Imaging in the 
Localization of Prostate Cancer at 3 Tesla: 
Should We Use an Endorectal Coil?
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Purpose: The purpose of this study was to compare the diagnostic performance of 3 Tesla, 
3-dimensional (3D) magnetic resonance spectroscopic imaging (MRSI) in the localization of 
prostate cancer (PCa) with and without the use of an endorectal coil (ERC).
Materials and Methods: Our prospective study was approved by the institutional review 
board, and written informed consent was obtained from all patients. Between October 2004 
and January 2006, 18 patients with histologically proven PCa on biopsy and scheduled for 
radical prostatectomy were included and underwent 3D-MRSI with and without an ERC. The 
prostate was divided into 14 regions of interest (ROIs). Four readers independently rated 
(on a 5-point scale) their confidence that cancer was present in each of these ROIs. These 
findings were correlated with whole-mount prostatectomy specimens. Areas under the 
receiver-operating characteristic curve were determined. A difference with a P < 0.05 was 
considered significant.
Results: A total of 504 ROIs were rated for the presence and absence of PCa. Localization of 
PCa with MRSI with the use of an ERC had a significantly higher areas under the receiver-
operating characteristic curve (0.68) than MRSI without the use of an ERC (0.63) (P = 0.015).
Conclusion: The use of an ERC in 3D MRSI in localizing PCa at 3 Tesla slightly but significantly 
increased the localization performance compared with not using an ERC.
3T PROSTATE MR SPECTROSCOPY WITH AND WITHOUT ENDORECTAL COIL 155
9
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous form of cancer in 
men and is the second largest cause of cancer-related mortality in this population [1]. Like 
many cancers, PCa is treated most effectively if localized and staged correctly. Thus, reliable 
knowledge of the location and spatial extent of the disease within and beyond the gland is 
crucial.
The most frequently used diagnostic tools in daily clinical practice (eg, digital rectal 
examination, prostate-specific antigen [PSA] level, and transrectal ultrasound [TRUS]-guided 
biopsy) are often inaccurate or inadequate. Digital rectal examination misses a substantial 
proportion of cancers, PSA alone cannot accurately stage an individual patient, and TRUS 
suffers from major sampling errors [2-6].
Magnetic resonance (MR) imaging is a noninvasive examination, which can provide 
anatomic, functional, and metabolic information. MR spectroscopic imaging (MRSI), that 
generates metabolic spectra, has been investigated before for cancer localization. Some 
promising results have been reported with sensitivities and specificities of 63% to 80% 
and 75% to 84%, respectively [7,8]. In addition, MRSI and MR imaging are still evolving 
techniques where recent insights about new metabolic markers such as polyamines [9,10], 
and new approaches with dynamic contrast-enhanced and diffusion-weighted MR imaging 
could further improve its localization ability [11-14].
The use of an endorectal coil (ERC) as an essential part of the optimal prostate MR imaging 
protocol is still a matter of debate. The obvious advantage of using the ERC is the increase 
in signal-to-noise ratio compared with non-ERC MR imaging. Even though several authors 
have demonstrated the advantages of the use of such an ERC for localizing and staging PCa 
on T2-weighted MR imaging [15,16], the direct comparison between ERC and non-ERC MR 
examinations has not been investigated for PCa localization with three-dimensional (3D) 
MRSI.
We hypothesized that the use of an ERC will increase the diagnostic performance of MRSI 
in localizing PCa. Therefore, the purpose of this study was to compare the diagnostic 
performance of 3 Tesla (3T), 3D MRSI in the localization of PCa with and without the use of 
an ERC.
MATERIALS AND METHODS
Patients
Our prospective study was approved by the institutional review board, and written informed 
consent was obtained from all patients. During the time period in which 3D MRSI at 3T was 
firstly initiated and performed at our institution (between October 2004 and January 2006), 
18 consecutive patients with histologically proven PCa on biopsy and scheduled for radical 
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prostatectomy were included and underwent 3D-MRSI (at least 3 weeks after biopsy) with 
and without an ERC. Patient characteristics were as follows: median age 66 years (range, 
56–75 years), median PSA 4.9 ng/mL (range, 3.6–24.6 ng/mL), median time between TRUS 
guided biopsy and MR examination 64 days (range, 21–104 days), median time between 
MR examination and radical prostatectomy 7 days (range, 1–89 days), and median Gleason 
score, based on prostatectomy specimens, 6.5 (range, 5–9). Exclusion criteria were previous 
hormonal therapy and contraindications to MR imaging (eg, cardiac pacemakers, intracranial 
clips, prior anorectal surgery).
MR Imaging Protocol
MR imaging of the prostate was performed using a 3T whole-body MR system (Siemens 
Trio Tim, Erlangen, Germany) with the spine array and body array coil elements, with a total 
examination time of between 45 and 50 minutes. Bowel peristalsis was suppressed with an 
intramuscular injection of 1 mg of glucagon (Glucagen, Novo Nordisk, Bagsvaerd, Denmark). 
At first, patients were imaged without the use of an ERC according to the following MR 
imaging protocol sequences: T2-weighted fast spin echo sequence in 3 orthogonal planes, 
with the field of view of the axial plane obtained perpendicular to the rectal wall, (repetition 
time/ echo time [TR/TE], 3700/124 milliseconds; field of view, 220 x 220 mm; matrix size, 512 
x 512; slice thickness, 4 mm; number of averages, 2; total acquisition time per plane, 4 –5 
minutes), followed by 3D 1H-MRSI of the entire prostate with a point-resolved spectroscopy 
pulse sequence15 (TR/TE, 750/145 milliseconds; acquisition bandwidth, 1250 Hz; voxel 
resolution, 7 x 7 x 7 mm; total acquisition time, approximately 9 minutes).
Subsequently, in the same patient an ERC was inserted rectally and filled with 40 mL 
perfluorocarbon liquid (Fomblin, Solvay-Solexis, Milan, Italy). After a quick series of images 
obtained to depict ERC position and ERC adjustment if necessary, a T2-weighted fast spin 
echo sequence in 3 planes (TR/TE, 5000/153; field of view, 200 x 100 mm; matrix size, 768 
x 384; slice thickness, 2.5 mm; number of averages, 1; total acquisition time per plane, 2–3 
minutes) was obtained, with the field of view of the axial plane obtained perpendicular to 
the rectal wall, followed by 3D 1H-MRSI (TR/TE, 750/145 milliseconds; acquisition bandwidth, 
1250 Hz; voxel resolution, 6 x 6 x 6 mm; total acquisition time, approximately 9 minutes).
Data Postprocessing
Semi-automatic postprocessing of all voxels within the prostate was performed with a 
software work-in-process package (Metabolite report, Siemens, Erlangen, Germany). A 
basic set of simulated complex model signals of choline, creatine, and citrate was fitted to 
the time domain signals of the voxels after a frequency shift, residual water removal, and 
remodeling of the first 5 data points to handle baseline artifacts. The amplitudes of the 
individually fitted signals were used to calculate the choline+creatine-to-citrate ratio (CC/C) 
and the choline-to-creatine ratio (C/C). A similar approach has been used before (17).
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Scoring and Evaluation of Data
All MRSI datasets were evaluated overlaid on the T2- weighted datasets. The prostate was 
divided into 14 regions of interest (ROIs) (Figure 1). 
Figure 1. A schematic overview of the 14 regions of interest in which the prostate was 
divided.
The T2-weighted images were only used for transfer of the 14 ROIs to the MRSI data 
and subsequently correlating this with pathology. Four readers (reader I, Radiologist; II, 
Radiologist; III, Radiologist; and IV, Spectroscopist with 0, 4, 6, and 8 years of experience in 
MRSI data evaluation, respectively) independently rated cancer presence in each of these 
ROIs on a 5-point scale, using a standardized scoring system.18 This scale was based on the 
CC/C and C/C ratios for the peripheral zone and the central gland determined before by 
Scheenen et al [19] (Table 1).
Table 1. Five-point scale
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Table 1. Five-point scale 
 PZ CC/C 
ratio 
CG CC/C 
ratio 
C/C ratio  
adjustment Score and score definition 
1. Definitely benign tissue ≤ 0.34 
> 0.35 - 0.46 
> 0.47 - 0.58 
> 0.59 - 0.70 
≥ 0.71 
≤ 0.48 If C/C ratio ≥ 2, then:  
adjust 3 and 2 into 4 
 
If C/C ratio < 2, then:  
adjust 5 into 4 and 4 into 3 
2. Probably benign tissue > 0.49 - 0.62 
3. Possibly malignant tissue > 0.63 - 0.76 
4. Probably malignant tissue > 0.77 - 0.90 
5. Definitely malignant tissue ≥ 0.91 
Adapted from Radiology 2007;245:507–516 [19] 
PZ indicates peripheral zone; CG, central gland; CC/C, choline-creatine-to-citrate; C/C, choline-to-
creatine. 
 
All datasets were anonymized, and readers were blinded to all clinical parameters. They were 
only aware of the fact that all patients were histopathologically diagnosed with PCa. First, all 
Adapted from Radiology 2007;245:507–516 [19]
PZ indicates peripheral zone; CG, central gland; CC/C, choline-creatine-to-citrate; C/C, choline-to-creatine.
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All datasets were anonymized, and readers were blinded to all clinical parameters. They 
were only aware of the fact that all patients were histopathologically diagnosed with PCa. 
First, all MRSI examinations without the ERC were rated. For each ROI, all spectra were read 
and interpreted and the final score for that ROI was based on the highest CC/C present 
within the ROI, and adjusted based on the C/C ratio for the corresponding voxel (Table 1). 
Second, after a period of 4 weeks, during a different reading session, MRSI with the ERC was 
rated likewise. Readers were allowed to rate ROIs as nonrateable if ratios were not reliably 
fitted because of low signal-to-noise ratios of the metabolite spectra (more than 50% of the 
voxels within a certain ROI).
Histopathological Analysis
Prostatectomy specimens were fixed overnight in 10% neutral buffered formaldehyde and 
coated with India ink. These prostatectomy specimens were sliced at 4-mm intervals at a 
plane parallel to the axial T2-weighted images (perpendicular to the rectal wall). All slices 
were routinely embedded in paraffin. Tissue sections of 5 µm thickness were prepared from 
the slices and stained with hematoxylin and eosin. A single genitourinary histopathologist 
(C.A.H. van de K.) with 18 years of experience who was blinded to the MR imaging results 
determined the exact localization, extent, Gleason score, and volume of each cancer focus.
Data Analysis
After evaluating and scoring all MRSI data, one spectroscopist (T.W.J.S.) and two of the 
radiologists (J.J.F. and D.Y.) in consensus transferred the histopathologic evaluation (standard 
of reference) of the prostatectomy specimens to the 14-segment prostate ROI scheme. This 
transfer was realized by matching the pathologic slice to the level of the T2-weighted images 
by its location between the apex and the base of the prostate. Subsequently, landmarks such 
as benign prostatic hyperplasia nodules and the urethra were used to match cancer foci to 
their corresponding ROIs. The T2-weighted images were only used for correlating pathology 
to the cancer region relative to the 14-segment ROI-scheme. An ROI was considered true-
positive if cancer was present and if this cancer focus was 0.5 cm3 or larger in volume [20]. 
All smaller cancer foci were excluded from further analysis. Each of the 14 ROIs for every 
prostate were classified as containing either cancer or healthy tissue.
Statistical Analysis
For statistical analysis (SPSS version 16.0), the sensitivity, specificity, negative predictive 
value (NPV), and positive predictive value were calculated by dichotomizing (cut-off point 
of 3 and above was considered malignant) the readings. Areas under the receiver-operating 
characteristic curve (AUC) and comparison between these AUCs were determined by using 
an ROI-ROC analysis [21], with a bootstrap estimation of diagnostic accuracy [22] and a 
Bonferroni correction. These statistical methods have been used before in studies that 
collected data according to the ROI paradigm [8,15].
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All P values reported were derived at one-sided tests. P values of 0.05 or less were considered 
significant.
RESULTS
In all, 18 patients were included. A total of 504 ROIs (18 patients with 14 ROIs each, 252 ROIs 
with and 252 ROIs without ERC) were rated for the presence and absence of PCa (Figure 
2). From the histopathologic standard of reference, 81 of 252 (32%) ROIs were assigned 
as containing PCa. Of these 81 ROIs, 31 containing PCa, were excluded due to low cancer 
volume (<0.5 cm3). Of the remaining 50 ROIs classified as containing PCa, 72% (36/50) 
comprised peripheral zone cancers, whereas 28% (14/50) comprised central gland cancers. 
These remaining cancer foci had a median volume of 1.1 cm3 (range, 0.5–12.9 cm3) (Figure 
3).
Figure 2. Presentation of how readers were able to evaluate and score the data in 1 view. 
MR images of a 73-year-old man with a PSA of 5.0 ng/mL. From left to right: Overlaid on 
transverse T2-weighted multiple-spin-echo image (TR/TE 3700/124) spectral fits (A), 
choline+creatine-to-citrate ratio (CC/C) (B), and choline-to-creatine ratio (C/C) (C). Magnified 
view of metabolite spectrum of the voxel at the red arrow (D), which had the highest CC/C 
ratio of region of interest (ROI) number 10. Measured spectrum (white line), overlaid with fit 
(red line), and residual between data and fit (green line). This voxel had a CC/C ratio of 0.83 
in the peripheral zone of the prostate. The C/C ratio was 1.06 so, according to Table 1 this 
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voxel, representing segment 10, was classified as probably malignant tissue. Histopathology 
revealed prostate cancer in this segment with a Gleason score of 3+3 (E).
Figure 3. Cancer foci volume distribution on histopathology. Median tumor volume, 1.1 cm3; 
range, 0.5 to 12.9 cm3.
Overall, there were significantly more ROIs nonrateable on MRSI with ERC, 14% (146/1008), 
than without ERC, 12% (121/1008), (P = 0.007) for all readers together (Table 2). Descriptive 
statistics of PCa localization with and without an ERC per reader was summarized in Table 
3. For the more experienced readers (ie, readers II, III, and IV) MRSI with an ERC had a high 
specificity (82%–92%), but a low sensitivity (20%–57%). For the novice reader (reader I), 
MRSI with the use of an ERC had a high sensitivity (80%) and a low specificity (34%). For all 
readers, the NPVs were high (82%– 89%), whereas the positive predictive values were low 
(20%–45%) for both imaging with and without ERC.
Table 2. Number of nonrateable ROIs
 
 
Overall, there were significantly more ROIs nonrateable on MRSI with ERC, 14% 
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Table 2. Number of nonrateable ROIs 
 MRSI– MRSI+ 
 
Reader I 3% (6/252) 
18% (50/252) 
8% (20/252) 
18% (45/252) 
0% 
Reader II 22% (62/252) 
Reader III 14% (36/252) 
Reader IV 19% (48/252) 
P = 0.007 
MRSI– indicates MR spectroscopic imaging without an endorectal coil; MRSI+ indicates MRSI with 
an endorectal coil; ROIs: regions of interest. 
 
Table 3. Diagnostic Performance in Localizing Prostate Cancer With MRSI With and Without an 
ERC 
 
 
 
P = 0.007
MRSI– indicates MR spectroscopic imaging without an end re tal coil; MRSI+ i dicates MRSI with an endore t l coil; 
ROIs: regions of interest.
3T PROSTATE MR SPECTROSCOPY WITH AND WITHOUT ENDORECTAL COIL 161
9
Table 3. Diagnostic Performance in Localizing Prostate Cancer With MRSI With and Without 
an ERC
The AUCs increased with the experience of the reader (Table 4). The most experienced 
reader (reader IV) had the highest AUC (0.72) for localization of PCa with MRSI with an ERC. 
Overall AUCs were calculated for reader II, III, and IV together. Localization of PCa with MRSI 
with the use of an ERC had a significantly higher AUC (0.68) than MRSI without the use of an 
ERC (0.63) (P = 0.015) (Figure 4).
Table 4. AUC’s for Localizing Prostate Cancer With MRSI With and Without an ERC
The AUCs increased with the exp ri nce of the reader (Table 4). Th  most experienced reader 
(reader IV) had the highest AUC (0.72) for l calization of PCa with MRSI with an ERC. 
Overall AUCs were calculated for reader II, III, nd IV together. Localization of PCa with 
MRSI with t e use of an ERC ad a significantly higher AUC (0.68) than MRSI without the 
use of an ERC (0.63) (P = 0.015) (Figure 4). 
 
Table 4. AUC’s for Localizing Prostate Cancer With MRSI With and Without an ERC 
 MRSI– 
AUC 
MRSI+ AUC P 
Reader I 0.55 0.61 0.047* 
Reader II 0.62 0.65 0.151 
Reader III 0.59 0.68 0.014* 
Reader IV 0.67 0.72 0.056 
Overall (II, III and IV) 0.63 0.68 0.015* 
* Considered significant 
MRSI– indicates MR spectroscopic imaging without an endorectal coil; MRSI+ indicates MRSI with 
an endorectal coil; AUC: area under the curve; ROIs: regions of interest. 
 
Figure 4. ROI-receiver operating characteristic curves for the experienced readers for 
localizing prostate cancer with MR spectroscopic imaging without an endorectal coil (MRSI-) 
(A), and with an endorectal coil (MRSI+) (B). 
 
 
DISCUSSION 
 
In the localization of PCa with MRSI at 3T, the use of an ERC provided a significantly (P = 
0.015) higher AUC (0.68) for experienced readers compared with not using an ERC (AUC, 
0.63) (Figure 4). Despite the fact that this difference was statistically significant, such a small 
increase in the AUC should make one think whether using the ERC is worth the effort, cost, 
and patient discomfort. 
 
When calculating the general AUCs for all readers together, we excluded the results from 
reader I. This was done because of the vastly different level of experience of this reader (no 
experience) for evaluating MRSI data compared with the other three readers (at least 4 years 
of experience), as evidenced by the contrasting descriptive statistics compared with the other 
readers. All other readers had high specificities and low sensitivities, whereas reader I had a 
high sensitivity and a low specificity. 
 
A B 
* Considered significant
MRSI– indicates MR spe troscopic imaging without an endorectal coil; MRSI+ indicat  MRSI 
with an endorectal coil; AUC: area under the curve; ROIs: regions of interest.
A B 
Figure 4. ROI-receiver operating characteristic curves for the experienced readers for 
localizing prostate cancer with MR spectroscopic imaging without an endorectal coil (MRSI-) 
(A), and with an endorectal coil (MRSI+) (B).
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DISCUSSION
In the localization of PCa with MRSI at 3T, the use of an ERC provided a significantly (P = 
0.015) higher AUC (0.68) for experienced readers compared with not using an ERC (AUC, 
0.63) (Figure 4). Despite the fact that this difference was statistically significant, such a small 
increase in the AUC should make one think whether using the ERC is worth the effort, cost, 
and patient discomfort.
When calculating the general AUCs for all readers together, we excluded the results from 
reader I. This was done because of the vastly different level of experience of this reader 
(no experience) for evaluating MRSI data compared with the other three readers (at least 4 
years of experience), as evidenced by the contrasting descriptive statistics compared with 
the other readers. All other readers had high specificities and low sensitivities, whereas 
reader I had a high sensitivity and a low specificity.
In general, the AUCs for localization with or without the use of an ERC were low compared 
with earlier published studies in localizing PCa with MR imaging [7,8]. Only one previously 
published multicenter study on the localization of PCa with MRSI at 1.5T presented even 
lower AUCs compared with our study [23]. Some of their main arguments for such low 
AUCs, such as low image quality and limited experience in obtaining data are somewhat 
shared by us. The results of our study were based partly on MRSI data that were obtained 
in 2004 when we had just commenced acquiring MRSI on a 3T system. A large number of 
nonrateable ROIs (Table 2) clearly illustrated this limited experience in 3T data acquisition. 
With matured technology (improved shimming), better coils and more experienced 
technicians, current data quality in clinical practice is expected to be improved, possibly 
resulting in an increased signal to-noise-ratio of the spectra and less nonrateable regions 
in the prostate. Furthermore, in our study, the experience level of the reader was also 
shown to be of influence by the fact that the highest AUC (0.72) was achieved by the most 
experienced reader (reader IV). Altogether this emphasizes the importance of experience 
in both acquiring and reading spectroscopic data. Future studies should therefore focus on 
training radiologists to read spectroscopic data (with possible pitfalls such as false positives 
because of high choline signals from seminal vesicles, and unreliable fits because of low 
signal-to-noise ratios) as well as technicians in obtaining high image quality data.
Nonetheless, it is important to note that the main purpose of our study was to compare the 
performance of MRSI in the localization of PCa with and without an ERC. The low overall 
AUCs did not interfere with our conclusion that the use of the ERC only marginally, but 
significantly, improves localization performance.
More ROIs were judged nonrateable on MRSI with the use of an ERC than in the set of 
images without the use of an ERC. In one other study [15], the authors established that 
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there was a higher presence of motion artifacts in the ERC group (compared with the non-
ERC group), which could explain the higher amount of non-rateable ROIs in the ERC group 
(compared with the non-ERC group) in our study. It is very difficult to assess motion during 
the MRSI measurements. As the MRSI part of the protocol is performed after T2w MRI in 3 
directions (larger time gap from pre-examination glucagon injection), and takes longer than 
one T2w series alone, motion during MRSI cannot be ruled out and may indeed be a source 
of error. Even the absence of these artifacts on T2w MRI cannot rule out motion during 
MRSI. Also, this difference in nonrateable ROIs in favor of the ERC group could be accounted 
for by decreased signal-to-noise ratio at distances further away from the coil, in the ventral 
part of the prostate.
Limitations of this study were initially, the low number of patients included, although this 
was partially compensated for by the 14 ROIs per prostate that were used and the multiple 
number of readers that were involved. Second, poor SNR and therefore the high number 
of nonrateable ROIs in these patients, because of this being the first patient cohort. Third, 
in this study, we did not use T1-weighted images to assess the amount of hemorrhage 
after biopsy in the prostate gland. Instead, to diminish this hemorrhage effect as much as 
possible, the time between biopsy and MR examination was kept to a minimum of 3 weeks 
[25]. Worth noting, any still existing hemorrhage effect would have affected the endorectal 
group as well as the nonendorectal group equally. Fourth, the readers rating these data 
were able to see which set of images concerned the MRSI data with the use of an ERC as 
well as without the use of an ERC. Ideally, data in comparative studies should be presented 
in a blinded manner. Blinding the use of an ERC is problematic, because it is very difficult to 
hide the increased SNR, especially at the dorsal aspect of the prostate, and the deformed 
prostate/rectum from a good radiologist or spectroscopist.
In conclusion, the use of an ERC in 3D MRSI in localizing PCa at 3T slightly but significantly 
increased the localization performance compared with not using an ERC.
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CHAPTER 10
Richtlijn prostaatcarcinoom 2007
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INLEIDING
Prostaatcarcinoom is, naast longcarcinoom, de meest voorkomende kanker bij mannen. Het 
prostaatcarcinoom heeft in Nederland een incidentie van ongeveer 95 op de 100.000 mannen 
per jaar (Kankerregistratiegegevens 20031). Dit betekent dat in Nederland jaarlijks meer dan 
7900 nieuwe patiënten met prostaatcarcinoom worden gediagnosticeerd. Opvallend is de 
toename van het incidentiecijfer van prostaatcarcinoom in het begin van de jaren negentig. 
De toename tussen 1989 en 1994 bedroeg ongeveer 40%. Daarna volgde een stabilisatie 
van het incidentiecijfer op een hoog niveau, maar in 2003 is het incidentiecijfer opnieuw 
met 6% gestegen. De meest voorkomende vorm is het adenocarcinoom, uitgaande van de 
klierbuisjes. Vooral de diagnose van een gelokaliseerd prostaatcarcinoom wordt steeds vaker 
gesteld. Dit gaat samen met een daling van de gemiddelde leeftijd waarop de ziekte wordt 
vastgesteld. Een en ander wordt in verband gebracht met het op steeds ruimere schaal 
toepassen van onderzoek naar de prostaatspecifieke merkstof ‘prostaat specifiek antigeen’ 
(PSA), waarmee vroege stadia van prostaatcarcinoom kunnen worden opgespoord. Er is dus 
waarschijnlijk nauwelijks sprake geweest van een reële stijging van de incidentie. De sterfte 
ten gevolge van prostaatcarcinoom daalde vanaf de tweede helft van de jaren ‘90. De laatste 
jaren is vooruitgang geboekt bij de detectie en de behandeling van prostaatcarcinoom, dat 
kan verklaren dat de sterfte aan prostaatcarcinoom een dalende trend vertoont. 
Vanaf het veertigste jaar neemt de incidentie per leeftijdscategorie geleidelijk toe. Op hoge 
leeftijd komt het prostaatcarcinoom zeer frequent voor. Op basis van vergrijzing en groei 
van de bevolking is de verwachting dat het aantal mannen bij wie prostaatcarcinoom wordt 
geconstateerd in de periode 2000-2020 zal toenemen met circa 64% (Van Oers 20022). 
Een rationele behandeling van prostaatcarcinoom wordt in zekere zin bemoeilijkt door het 
veelal ontbreken van goed uitgevoerd onderzoek. De meeste informatie over de behandeling 
wordt ontleend aan analyses van de behandelingsresultaten van een enkel instituut. Er is 
nogal wat verschil van mening over de waarde van de diverse behandelingsmogelijkheden. 
In verband met de hoge incidentie van prostaatcarcinoom en ook vanwege de vele 
behandelingsmogelijkheden, bestaat de noodzaak om tot een gezamenlijke nationale 
richtlijn te komen.
Voor de diagnostiek en behandeling van prostaatcarcinoom bestond in Nederland nog geen 
nationale richtlijn. Derhalve heeft de Nederlandse Vereniging voor Urologie het initiatief 
genomen een multidisciplinaire, evidence-based richtlijn te ontwikkelen over zowel de 
diagnostiek als de behandeling van het prostaatcarcinoom. Het Kwaliteitsinstituut voor de 
Gezondheidszorg CBO verleende hieraan methodologische expertise en logistieke steun. De 
Vereniging van Integrale Kankercentra coördineerde het proces en voerde het secretariaat. 
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DOELSTELLING 
Deze richtlijn geeft aanbevelingen ter ondersteuning van de dagelijkse praktijkvoering, 
gericht op optimaal medisch handelen en gebaseerd op de resultaten van wetenschappelijk 
onderzoek en aansluitende meningsvorming. Er wordt aangegeven wat in het algemeen de 
beste zorg is voor patiënten met prostaatcarcinoom.
Deze richtlijn geeft aanbevelingen over de diagnostiek, de behandeling, de follow-
up en begeleiding van patiënten met prostaatcarcinoom. Er worden geen uitspraken 
en aanbevelingen gedaan over screening vanwege het ontbreken van voldoende 
wetenschappelijk bewijsmateriaal. De richtlijn beoogt vooral een leidraad te zijn voor 
de dagelijkse praktijk en is van toepassing op alle patiënten met prostaatcarcinoom, 
ongeacht het stadium. De richtlijn kan ook worden gebruikt bij het geven van voorlichting 
aan patiënten. Daarnaast biedt de richtlijn aanknopingspunten voor bijvoorbeeld lokale 
(instituuts of regio-) protocollen en/of transmurale zorgafspraken, ter bevordering van de 
implementatie.
SAMENSTELLING WERKGROEP
Voor het ontwikkelen van de richtlijn werd een multidisciplinaire werkgroep samengesteld, 
bestaande uit vertegenwoordigers van alle relevante specialismen die met de diagnostiek en 
behandeling van prostaatcarcinoom te maken hebben. Er werd rekening gehouden met de 
geografische spreiding van de werkgroepleden en een evenredige vertegenwoordiging van 
de verschillende verenigingen, ‘scholen’ en academische achtergrond. De werkgroepleden 
waren gemandateerd door hun vereniging en hebben een belangenverklaring ingevuld 
en ondertekend. De samenstelling van de werkgroep als geheel is goedgekeurd door alle 
deelnemende wetenschappelijke verenigingen. Bij het opstellen van aanbevelingen werd 
ook een afgevaardigde van de patiëntorganisatie (Stichting Contactgroep Prostaatkanker) 
betrokken. De werkgroepleden zijn gezamenlijk verantwoordelijk voor de tekst van deze 
richtlijn.   
Kernredactie en voorzitters subwerkgroepen
- Dr. Th.M. de Reijke, uroloog, Academisch Medisch Centrum, Amsterdam, vice-voorzitter 
tot september 2004; voorzitter vanaf september 2004
- Prof. Dr. J.J. Battermann, radiotherapeut, Universitair Medisch Centrum Utrecht, vice-
voorzitter vanaf september 2004
- Prof.dr. S. Horenblas, uroloog, Antoni van Leeuwenhoek ziekenhuis, Amsterdam, voorzitter 
tot september 2004
- Dr. I.J. de Jong, uroloog, Universitair Medisch Centrum Groningen
- Dr. R.J.A. van Moorselaar, uroloog, VU Medisch Centrum Amsterdam
- Dr. G.O.N. Oosterhof, uroloog, Academisch Ziekenhuis Maastricht
- W. IJzerman, uroloog, Gelre Ziekenhuis, Apeldoorn
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- Dr. P.F.W.M. Rosier, arts, Kwaliteitsinstituut voor de Gezondheidszorg CBO, Utrecht, 
adviseur tot januari 2005
- Dr. J.S. Burgers, programmaleider, Kwaliteitsinstituut voor de Gezondheidszorg CBO, 
Utrecht, adviseur vanaf januari 2005
- Mw. Dr. P.J.J. Wauben-Penris, hoofd patiëntenzorg, Integraal Kankercentrum Limburg, 
Maastricht, procesbegeleider namens de VIKC
- Mw. H.W.G. Hamelers-Paulus, secretaresse, Integraal Kankercentrum Limburg, Maastricht 
namens de VIKC
Overige werkgroepleden
- Dr. G. van Andel, uroloog, Onze Lieve Vrouwe Gasthuis Amsterdam
- Mw. J. Arnts, oncologieverpleegkundige radiotherapie, Universitair Medisch Centrum 
St. Radboud Nijmegen
- Prof.dr. J.O. Barentsz, radioloog, Universitair Medisch Centrum St. Radboud Nijmegen
- Dr. A.C.M. van de Bergh, radiotherapeut, Universitair Medisch Centrum Groningen
- Dr. R.F.M. Bevers, uroloog, Leids Universitair Medisch Centrum Leiden
- Prof.dr. M.A. Blankenstein, hoofd klinische chemie, VU Medisch Centrum Amsterdam
- Mw. Dr. F.C.J.M. van Gils, radiotherapeut, Maastro Clinic, Heerlen
- Dr. A.J.M. Hendrikx, uroloog, Catharina ziekenhuis Eindhoven
- Drs. S.W.T.P.J. Heijmink, radioloog i.o, Universitair Medisch Centrum St. Radboud, 
Nijmegen
- Mw. Dr. C.A. Hulsbergen-van de Kaa, patholoog, Universitair Medisch Centrum St. 
Radboud, Nijmegen
- Mw. Drs. H.K. de Jager-Nowak, radiotherapeut, Haga ziekenhuis, Den Haag
- Dr. P.C.M. Koper, radiotherapeut, Daniel den Hoed Kliniek, Rotterdam (tot juni 2005)
- Prof.dr. Th. van der Kwast, patholoog, University Toronto, Canada (tot oktober 2004)
- Dr. R.C.M. Pelger, uroloog, Leids Universitair Medisch Centrum, Leiden
- J.A. van Spil, nurse practitioner, Universitair Medisch Centrum Groningen
- Drs. Th. Twerda, contactpersoon Stichting Contactgroep Prostaatkanker Utrecht (vanaf 
september 2005)
- Dr. A.P. Visser, psycholoog, namens NVPO, Helen Dowling Instituut, Utrecht
- Mw. Drs. E.M. de Wit, radiotherapeut, Ziekenhuis Medisch Spectrum, Enschede
- Dr. R. de Wit, medisch oncoloog, Daniel den Hoed kliniek, Rotterdam
BEELDVORMEND ONDERZOEK
Echografie
Bij welke patiënten is het zinvol om transrectale grijswaarde echografie te verrichten voor 
het stellen van de diagnose prostaatcarcinoom en voor het stageren van de aandoening?
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Het aspect van prostaatcarcinoom op het grijswaardebeeld van de transrectale echografie 
is sterk wisselend. Sinds de invoering van PSA-meting en systematische biopten is het aantal 
carcinomen dat in een hypo-echogene laesie alleen wordt aangetoond afgenomen. Onur 
et al. 2004 [23] beschrijven in een prospectieve studie ruim 3900 patiënten. Ondanks de 
hogere prevalentie van prostaatcarcinoom in prostaten waarin een hypo-echogene laesie 
werd gezien, bleek deze laesie niet frequenter maligne en werd per biopt een identiek 
percentage tumoren aangetoond in hypo- en iso-echogene gebieden (respectievelijk 
9,3% en 10,4%). Heijmink et al. 2006 [22] vonden in een systematische review met een 
gemiddelde prostaatcarcinoomprevalentie van 25-33% waarbij hypo-echogene foci werden 
gebiopteerd, een positief voorspellende waarde tussen 18 en 53%.
Wat is de aanvullende diagnostische waarde van color Doppler, power Doppler en 
contrastversterkte transrectale ultrasonografie (TRUS) voor het stellen van de diagnose 
prostaatcarcinoom en voor het stageren van de aandoening?
Doppler beeldvorming, met of zonder contrastversterkende middelen, kan mogelijk helpen 
prostaatcarcinoomfoci te identificeren aangezien Doppler de doorbloeding van het weefsel 
zichtbaar maakt. Prostaatcarcinoom kenmerkt zich door een toegenomen aantal nieuwe 
bloedvaten of een toegenomen capaciteit van reeds bestaande bloedvaten (Wilson, 
2004 [32]). ‘Color Doppler’ geeft informatie over zowel de richting als de snelheid van 
de doorbloeding. ‘Power Doppler’ registreert alleen de sterkte van het signaal dat wordt 
afgegeven door de perfusie, waardoor deze modus kleinere bloedvaten kan weergeven. 
Cornud et al. 2000 [24] vonden met color Doppler beeldvorming een grote overlap tussen 
hypo-echogeniciteit en Doppleraankleuring.
Kravchick et al. 2003 [27] stelden dat hoogsensitiviteitsinstellingen een beter resultaat 
halen dan hoogspecifieke Dopplerinstellingen en dat Doppler een aanvulling kan zijn op 
de sextantbiopsie. Kravchick et al. 2004 [28] onderzochten vervolgens 120 opeenvolgende 
patiënten met color Doppler gerichte biopt en vergeleken dit met sextantbiopsie. Alle focale 
laesies op grijswaardebeeldvorming en alle gebieden met verhoogd color Dopplersignaal 
werden gebiopteerd. Bij 71 patiënten werd een hypervasculaire focus gevonden en bij 43 
patiënten werd prostaatcarcinoom gediagnosticeerd. 
Sextantbiopsieën detecteerden kanker bij 23 patiënten, color Doppler bij 30 patiënten. Van 
de 37 hypo-echogene laesies in 32 patiënten waren 14 biopten positief. Met color Doppler 
werden 13 patiënten meer gedetecteerd dan met sextantbiopsie. Er werd geen kanker 
gedetecteerd in hypo-echogene laesies die geen abnormale flow bij color Doppler hadden. 
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Remzi et al. 2004 [30] verrichtten power Doppler-geleide biopten bij 101 patiënten tijdens 
de eerste ronde biopten en bij 35 patiënten tijdens een herhalingsbiopt indien eerdere 
biopten negatief waren. De auteurs concludeerden dat power Doppler weinig additionele 
waarde had vergeleken met systematische biopten.
Een nieuwe ontwikkeling bij prostaatbiopten is het gebruik van echocontrastmiddel 
om met name kleinere tumorvaten beter zichtbaar te maken. Frauscher et al. 2002 [25] 
vonden in een studie bij 230 patiënten, bij wie het detectiepercentage van maximaal 5 
contrastechogeleide TRUS-biopten in aankleurende gebieden werd vergeleken met 10 
systematische biopten, een significant hoger percentage biopten dat prostaatcarcinoom 
bevatte voor contrastgeleide biopten dan voor systematische biopten (10,4% respectievelijk 
5,3%).
Pelzer et al. 2005 [29] vergeleken 10 systematische biopten met een contrastversterkt color 
Doppler geleide biopt van maximaal twee biopten per aankleurende laesie bij 380 patiënten 
met een PSA >4,0 ng/mL. Hoewel het aantal patiënten gedetecteerd met prostaatcarcinoom 
gelijk was, was het percentage per naaldbiopt voor contrastgeleide biopten significant 
hoger. Minder agressieve tumoren (Gleasonscore <6) werden niet gedetecteerd door 
contrastgeleide biopten.
Halpern et al. 2005 [26] vergeleken diverse typen contrastversterkte geleide TRUS-biopten 
met serie biopten bij 301 mannen met een PSA >4 ng/mL of een verdacht rectaal toucher. Het 
aantal positieve biopten was significant hoger bij gebruik van contrastversterkte echografie 
dan bij serie biopten: 15,5% respectievelijk 10,4%. Op patiëntniveau was er echter geen 
significant verschil. Met name in de apex werden met contrastversterkte biopten veel 
tumoren gemist.
Voor lokale stagering met behulp van color Doppler beeldvorming en contrastversterkte 
beeldvorming zijn nog geen studies gepubliceerd. Power Doppler beeldvorming kan mogelijk 
hulp bieden bij het bepalen van het lokale stadium door de bloedvaten die door het kapsel 
naar de tumoren lopen zichtbaar te maken (Sauvain et al. 2003 [31]).
Computer tomografie (CT)
Bij welke patiënten dient een CT-scan te worden gemaakt voor het stellen van de diagnose 
prostaatcarcinoom en voor de stagering van de aandoening?
Diagnose. Prando en Wallace (2000 [35]) toonden bij 25 patiënten met prostaatcarcinoom 
aan dat van alle met TRUS-geleide biopten bevestigde foci van prostaatcarcinoom, 
contrastmiddelversterkte CT slechts 58% van de tumoren in de perifere zone aantoonde. 
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Prostaatcarcinoomfoci in de transitie zone konden niet van benigne prostaathyperplasie 
onderscheiden worden.
De meest recente studie over CT-gebaseerde lokale stagering dateert uit 1996. Tarcan et al. 
1996 [37] voerden een pre-operatieve CT-scan zonder contrastmiddel uit bij 30 patiënten met 
middels TRUS-geleide biopten vastgesteld prostaatcarcinoom. Eén radioloog beoordeelde 
alle CT-scans. De sensitiviteit voor detectie van lokaal uitgebreid prostaatcarcinoom 
was laag (29%). Het grootste probleem van CT bij lokale stagering in deze studie was de 
onderstagering: 50% van de patiënten werd ondergestageerd. 
Lymfeklierstagering. Tiguert et al.1999 [38] beschreven in een retrospectieve studie dat 
bij prostaatcarcinoom de grootte van een lymfeklier niet correleerde met de aanwezigheid 
van een metastase. De onderzoekspopulatie bestond uit 980 patiënten die een radicale 
prostatectomie met lymfeklierdissectie hadden ondergaan waarvan bij 63 patiënten 
lymfekliermetastasen waren vastgesteld. Lymfeklierdissectie was de referentie-standaard. 
Bij 48 patiënten was histopathologisch materiaal beschikbaar voor onderzoek. Bij geen 
enkele patiënt met lymfekliermetastasen werd met behulp van CT-onderzoek een vergrote 
(>15 mm) lymfeklier gevonden. Histopathologisch onderzoek wees uit dat driekwart (74%) 
van de lymfeklieren die metastasen bevatten kleiner was dan 10 mm, een kwart (26%) was 
zelfs kleiner dan 5 mm. Bovendien bleek 12% van de patiënten zonder lymfekliermetastasen 
klieren groter dan 15 mm te hebben. In slechts 13 van de 48 patiënten was de grootste 
lymfeklier ook daadwerkelijk de lokalisatie van de metastase. 
Door de “stage shift” ten gevolge van het gebruik van de PSA-test als screeningsinstrument 
wordt prostaatcarcinoom steeds eerder ontdekt (Derweesh 2004 [33]). Ook 
lymfekliermetastasen zullen daardoor in een eerder stadium worden aangetroffen. In het 
algemeen bevinden zich lymfekliermetastasen van prostaatcarcinoom niet in vergrote 
lymfeklieren. Derhalve zijn de CT-scan en de grootte criteria die worden gehanteerd 
onvoldoende sensitief om deze vroege metastasering aan te tonen. Dit is ondanks het 
feit dat nieuwe generaties CT-scanners steeds meer gedetailleerde informatie kunnen 
weergeven. [34, 36]
Magnetische resonantie beeldvorming (MRI)
Bij welke patiënten moet een magnetische resonantie imaging (MRI) worden gemaakt voor 
het stellen van de diagnose prostaatcarcinoom en voor het stageren van de aandoening?
Diagnose. Diagnosestelling met een MRI is mogelijk door de karakteristieke laesie met 
lage signaalintensiteit op T2-gewogen MRI-beelden (Cruz 2002 [41]). In een retrospectieve 
studie van 106 opeenvolgende patiënten die radicale prostatectomie ondergingen vonden 
Mullerad et al. 2005 [51] dat het gebruik van endorectale MRI bij een veldsterkte van 1,5 
tesla de lokalisatie van prostaatcarcinoom significant verbeterde vergeleken met rectaal 
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toucher en bioptresultaten. MRI was met name superieur aan de bioptresultaten in de basis 
van de prostaat terwijl de resultaten voor de apex gelijk waren. 
Directe MRI-biopten is (nog) geen gangbare methode om biopten te nemen vanwege de 
matige sensitiviteit van het onderzoek en de omslachtige procedure met endorectale coil en 
vervolgens zonder endorectale coil (Beyersdorff 2005 [39]), dan wel met een open MRI en 
gluteale weg van biopteren (Zangos 2005 [57]).
Lokale stagering. 
Een kosteneffectiviteits analyse door Jager et al. 2000 [50] gaf aan dat MRI bij een 
veldsterkte van 1,5 tesla kosteneffectief is bij patiënten met een a-priori kans van meer dan 
39% op uitgroei buiten de prostaat, dat wil zeggen de intermediaire tot hoogrisicogroep. 
De beste strategie voor het interpreteren van een MRI-scan was ‘high specificity reading’: 
het behouden van een hoge specificiteit, desnoods ten koste van de sensitiviteit, om geen 
patiënten ten onrechte een curatieve behandeling te onthouden. 
Cornud et al. 2002 [40] voerden voorafgaand aan radicale prostatectomie een MRI met 
endorectale spoel bij een veldsterkte van 1,5 tesla uit bij 336 patiënten met klinisch 
orgaanbeperkt prostaatcarcinoom. De MRI-scans werden geïnterpreteerd door twee 
radiologen in consensus aan de hand van tevoren opgestelde criteria. Op basis van de 
histopathologie werden tevens de resultaten bepaald van alleen de groep patiënten met 
uitgebreide lokale doorgroei buiten de prostaat. In de gehele patiëntengroep werden een 
sensitiviteit en specificiteit gevonden van respectievelijk 40% (45/113) en 95% (211/223). 
Voor alleen de detectie van uitgebreide lokale doorgroei waren de uitkomsten 62% (43/69) en 
95% (253/267). MRI wist dus slechts twee patiënten die wel uitgroei maar geen uitgebreide 
uitgroei hadden juist te diagnosticeren. Een beperking van de studie is het ontbreken van de 
definitie van uitgebreide lokale doorgroei. 
Nakashima et al. 2004 [52] onderzochten de waarde van MRI met een endorectale spoel 
bij een veldsterkte van 1,5 tesla voor de bepaling van het lokale stadium bij 95 patiënten 
met middels TRUS-biopt vastgesteld prostaatcarcinoom. Radicale prostatectomie was de 
referentiestandaard. Twee radiologen met 20 jaar ervaring bepaalden het stadium aan 
de hand van vooraf opgestelde criteria. Zij behaalden een gezamenlijke sensitiviteit en 
specificiteit van respectievelijk 62% en 82% en een positief en negatief voorspellende 
waarde van respectievelijk 60% en 83%. De detectie van zaadblaasjesinvasie had een lage 
sensitiviteit en positief voorspellende waarde (33% respectievelijk 67%). Kapseldoorbraak 
was eenvoudiger vast te stellen, met zowel een sensitiviteit als positief voorspellende 
waarde van 57%.
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Hricak et al. 2004 [48] beschreven het gebruik van pre-operatieve endorectale MRI bij 
een veldsterkte van 1,5 tesla bij 135 opeenvolgende patiënten die middels TRUS-biopt 
vastgesteld prostaatcarcinoom hadden met speciale aandacht voor tumoruitbreiding richting 
de neurovasculaire bundel. Op basis van de uitkomsten van de MRI werd het beleid bepaald 
voor wat betreft het doorsnijden of behouden van de neurovasculaire bundels. Bovendien 
werd het beleid bepaald zonder kennis van de MRI-uitkomsten. Uit histologisch onderzoek 
van de radicale prostatectomie preparaten bleek bij 44 van de 270 neurovasculaire bundels 
resectie noodzakelijk. De MRI-bevindingen veranderde de chirurgische planning in 106 van 
de 270 gevallen (39%). De oppervlakte onder de ROC-curve voor chirurgische planning steeg 
significant van 0,741 zonder MRI naar 0,832 met MRI-uitkomsten.
Door Fütterer et al. 2005 [43] werd aangetoond dat het gebruik van een contrastmiddel bij 
endorectale MRI bij een veldsterkte van 1,5 tesla de diagnostische waarde voor bepaling 
van het lokale stadium kan verbeteren voor relatief onervaren radiologen. Voor een ervaren 
radioloog had contrasttoediening echter geen effect op de accuratesse. De sensitiviteit van 
de onervaren radiologen nam toe van 50% met alleen anatomische plaatjes tot 74% als 
daarbij de contrastmiddel opnames werden geanalyseerd. De specificiteit bleef hierbij hoog 
(94%).
In een retrospectieve studie van 106 opeenvolgende patiënten vonden Mullerad et al. 2005 
[51] dat het gebruik van endorectale MRI bij een veldsterkte van 1,5 tesla de bepaling van de 
status van de zaadblaasjes significant verbeterde. De oppervlakte onder de ROC-curve nam 
toe van 0,64 met rectaal toucher tot 0,90 met MRI.
Fütterer et al. 2006 [44] beschreven de eerste resultaten van MRI met een endorectale spoel 
bij een veldsterkte van 3 tesla in een groep van 32 opeenvolgende patiënten met klinisch 
orgaanbeperkt prostaatcarcinoom waarbij een radicale prostatectomie werd verricht. 
Ervaren radiologen behaalden een sensitiviteit van 88% en een specificiteit van 96%. 
Ervaring bleek een belangrijke rol te spelen voor het verkrijgen van een hoge sensitiviteit 
voor het detecteren van lokaal uitgebreide tumor. Zelfs minimale kapselpenetratie (<2 mm 
radiale afstand) kon met deze techniek gedetecteerd worden.
In een grote studie met 612 geïncludeerde patiënten en middels TRUS-biopt vastgesteld 
prostaatcarcinoom toonden Wang et al. 2006 [55] de significante meerwaarde aan van MRI 
met een endorectale spoel bij een veldsterkte van 1,5 tesla voor het bepalen van het lokale 
stadium vergeleken met het gebruik van nomogrammen die het PSA-niveau, de Gleasonscore 
en het rectaal toucher hanteren. Radicale prostatectomie was de referentiestandaard. MRI 
had een toegevoegde waarde voor de laag risico, intermediair risico en hoog risico patiënten. 
Heijmink et al. 2006 [47] vergeleken de stagering met en zonder endorectale spoel bij 
een veldsterkte van 3 tesla en concludeerden dat alleen met endorectale spoel accuraat 
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kon worden gestageerd. Ervaren radiologen konden kapselpenetratie van 0.5 mm alleen 
met endorectale spoel detecteren. Dit kan van nut zijn bij het verkrijgen van negatieve 
resectiemarges bij radicale prostatectomie.
Sala et al. 2006 [53] beschreven in een groep van 354 patiënten met middels TRUS-biopt 
vastgesteld prostaatcarcinoom de diagnostische waarde van MRI met een endorectale 
spoel voor het bepalen van zaadblaasjesinvasie. Radicale prostatectomie was de 
referentiestandaard. Oppervlakten onder de ROC-curve waren 0,81 en 0,93 voor twee 
radiologen. Het meest voorspellend voor zaadblaasjesinvasie waren tumor in de basis 
van de prostaat met kapseldoorbraak en een gebied met lage signaalintensiteit in een 
zaadblaasje dat de normale architectuur verloren heeft. Endorectale MRI heeft derhalve 
een grote accuratesse in het bepalen van zaadblaasjesinvasie. Dit kan van belang zijn bij het 
selecteren van patiënten voor een radicale prostatectomie.
Lymfeklierstagering
Bij een conventionele MRI wordt, gelijk aan de CT-scan, gebruik gemaakt van vorm- en 
groottecriteria (Jager 1996 [49]). Een kosteneffectiviteitsstudie van Wolf et al. 1995 [56] bij 
174 patiënten toonde aan dat conventionele MRI kosteneffectief is bij patiënten die meer 
dan 45% a-priori kans hebben op lymfekliermetastasen bij een sensitiviteit van 25%.
De meest recente studie met conventionele MRI op 1,5 tesla werd uitgevoerd door 
Harisinghani et al. 2003 [45] bij 80 patiënten uit twee klinieken. De criteria voor een 
positieve lymfeklier waren een diameter van de korte as van >10 mm als de klier langgerekt 
was of >8 mm in geval van een ronde klier. De resultaten werden op zowel patiënt- als 
lymfeklierniveau bepaald. Als referentiestandaard werd lymfeklierdissectie of CT-geleid 
biopt gebruikt. Op patiëntniveau werd een sensitiviteit van 45,4% met een specificiteit van 
78,8% behaald. Op lymfeklierniveau waren deze respectievelijk 35,4% en 90,4%. Naarmate 
de lymfeklieren kleiner waren daalde de sensitiviteit. Bij lymfeklieren tussen 5 en 10 mm 
was deze 28,5%, terwijl bij klieren kleiner dan 5 mm de sensitiviteit 0% was. 
Een nieuwe methode voor lymfeklierdiagnostiek is het gebruik van een lymfeklierspecifiek 
contrastmiddel, de ultrasmall superparamagnetic iron-oxide containing particles (USPIO’s), 
waaronder ferumoxtran-10. In dezelfde studie van Harisinghani et al. werd een directe 
vergelijking gemaakt tussen conventionele MRI en een MRI met ferumoxtran-10 bij 
een veldsterkte van 1,5 tesla. Zowel op patiënt- als op lymfeklierniveau verbeterde de 
sensitiviteit significant: van 45,4% naar 100% op patiëntniveau en van 35,4% naar 90,5% 
op lymfeklierniveau. Bij lymfeklieren met een diameter tussen 5-10 mm verbeterde 
de sensitiviteit significant van 28,5% met de conventionele techniek naar 96,4% met 
ferumoxtran-10. Bij lymfeklieren kleiner dan 5 mm verbeterde de sensitiviteit van 0% naar 
41,4%, hoewel dit geen significante verbetering was. Met deze methode kunnen lymfeklieren 
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tot een grootte van 5 mm met grote nauwkeurigheid gediagnosticeerd worden. Gebruik van 
deze techniek bij een veldsterkte van 3 tesla kan de beeldvorming nog verder verbeteren 
(Heesakkers, 2006 [46]). Een huidige beperking voor het gebruik van ferumoxtran-10 is dat 
het op dit moment nog niet geregistreerd is. Thans is het middel beperkt beschikbaar in 
enkele centra. [40, 42, 54] 
Skeletscan
Bij welke patiënten is het zinvol om een skeletscan te verrichten voor het stellen van de 
diagnose prostaatcarcinoom en voor het stageren van de aandoening? 
Het skelet is de belangrijkste lokalisatie van afstandsmetastasen bij patiënten met 
prostaatcarcinoom. Botmetastasen bij prostaatcarcinoom hebben meestal een osteoblastisch 
karakter. Skeletscintigrafie uitgevoerd met 99m Technetium gelabeld difosfonaat is een 
sensitieve techniek om osteoblastische metastasen af te beelden. Deze techniek wordt sinds 
decennia als standaard toegepast bij het stageren van patiënten met prostaatcarcinoom. 
De incidentie van botmetastasen varieert sterk, van minder dan 1% bij screeningspopulaties, 
tussen 5-15% bij klinisch gedetecteerde populaties tot meer dan 85% bij patiënten met 
hormoon refractair prostaatcarcinoom. 
In een systematische review beschijven Abuzallouf et al. 2004 [58] de gepoolde resultaten 
van 23 klinische studies naar de voorspellende waarde van skeletscintigrafie bij patiënten 
met de primaire diagnose prostaatcarcinoom. In totaal betreft dit een populatie van 8644 
patiënten waarvan bij 1453 patiënten botmetastasen werden aangetoond. 
Verdeeld naar PSA werd bij respectievelijk 2,3%, 5,3% en 16,2% van de patiënten met PSA van 
<10, 10,1 tot 19,9 en 20 tot 49,9 ng/mL botmetastasen aangetoond. Verdeeld naar klinisch 
tumorstadium werden bij 6,4% van de mannen met gelokaliseerd prostaatcarcinoom en bij 
49,5% met lokaal gevorderd prostaatcarcinoom botmetastasen aangetoond. Verdeeld naar 
Gleasonscore werd bij respectievelijk 5,6% en 29,9% van de patiënten met Gleasonscore 
kleiner of gelijk aan 7 en 8-10 botmetastasen aangetoond.
CONCLUSIES
Echografie
Prostaatcarcinoom heeft geen typische kenmerken bij grijswaarde echografie.
Niveau 1: A2 Onur 2004 [23]; Heijmink 2006 [22]
De positief voorspellende waarde van biopten uit hypo-echogene laesies is laag.
Niveau 1: A2 Onur 2004 [23]; Heijmink 2006 [22]
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Grijswaarde echografie heeft geen toegevoegde waarde voor het detecteren van niet-
palpabele tumoren.
Niveau 1: A2 Onur 2004 [23]; Heijmink 2006 [22] 
Het gebruik van niet-contrastversterkte Doppler beeldvorming geeft slechts een geringe 
verbetering van de detectie en het positief bioptpercentage. 
Niveau 3: A2 Kravchick 2003 [28]; C : Remzi 2004 [30]
Het gebruik van contrastversterkte echografie leidt tot een significant hoger percentage 
positieve biopten vergeleken met systematische biopten en detecteert relatief meer 
agressieve prostaatcarcinoomfoci. 
Niveau 3: A2 Frauscher 2002 [25], Halpern 2005 [26], Pelzer 2005 [29]
Er is onvoldoende onderzoek gedaan naar de toegevoegde waarde van Doppler beeldvorming 
bij de lokale stagering van prostaatcarcinoom om hieruit conclusies te trekken. 
Niveau 4 
Computertomografie
Het weke delen contrast bij een CT-scan, zelfs met gebruik van contrast middel, is te laag 
voor goede differentiatie tussen carcinoomweefsel en gezond weefsel in de prostaat. 
Niveau 3: C Prando 2000 [35] 
Voor lokale stagering van prostaatcarcinoom zijn de sensitiviteit (29-50%) en de negatief 
voorspellende waarde (35-77%) van een CT-scan te laag voor standaard klinisch gebruik.
Niveau 3: C Tarcan 1996 [37]
Een CT-scan heeft onvoldoende diagnostische waarde voor detectie van lymfekliermetastasen. 
Niveau 3: C Tiguert 1999 [38] 
Magnetische resonantie beeldvorming (MRI)
De lokalisatie van prostaatcarcinoom verbetert significant door gebruik van MRI met 
endorectale spoel bij een veldsterkte van 1,5 tesla vergeleken met rectaal toucher of biopten.
Niveau 3: Mullerad 2005 [51]
De nauwkeurigheid van de chirurgische planning voor het al dan niet reseceren van de 
neurovasculaire bundel verbetert significant door het pre-operatief gebruik van endorectale 
MRI bij een veldsterkte van 1,5 tesla. 
Niveau 3: C Hricak 2004 [48] 
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Vanaf een a-priori kans op lokale doorgroei van 39% is stagering met behulp van MRI bij een 
veldsterkte van 1,5 tesla kosteneffectief. 
Niveau 3: C: Jager 2000 [50]
Voor lokale stagering bij een veldsterkte van 1,5 tesla wordt een goede specificiteit bereikt, 
met beperkte sensitiviteit. Voor onervaren radiologen kan de sensitiviteit verhoogd worden 
door het gebruik van contrast middelopnames. Bij een veldsterkte van 3 tesla verbetert de 
sensitiviteit bij een gelijkblijvende specificiteit. 
Niveau 3: C Fütterer 2006 [44], Heijmink 2006 [47] 
De MRI-interpretatie van lymfeklieren op basis van grootte-criteria heeft onvoldoende 
diagnostische waarde voor detectie van lymfekliermetastasen van prostaatcarcinoom. De 
sensitiviteit van conventionele MRI voor detectie van positieve lymfeklieren is te laag (27-
60%) voor standaard klinisch gebruik in de laag- en intermediaire risicogroepen. 
Niveau 2: A2 Harisinghani 2003 [45]
Gebruik van het lymfeklierspecifieke contrastmiddel ferumoxtran-10 voor detectie van 
lymfeklieren groter dan 8-10 mm verbetert de sensitiviteit significant (van 30 naar 90%) ten 
opzichte van conventionele MRI. 
Niveau 2: A2 Harisinghani 2003 [45]
Skeletscan
Patiënten met een initieel PSA van 20 ng/mL of hoger, lokaal gevorderde tumoren of 
Gleasonscore 8 en hoger hebben een sterk verhoogde kans op botmetastasen. 
Niveau 2: A2 Abuzallouf 2004 [58]
OVERWEGINGEN
Echografie
Aangezien de meeste patiënten zich tegenwoordig presenteren zonder dat er afwijkingen 
gevoeld worden bij het rectaal toucher, zullen de biopten transrectaal, echogeleid dienen 
te worden genomen, aangezien op deze wijze de perifere zone het best kan worden 
geïdentificeerd. Indien er een uitgebreide tumorgroei aanwezig is, kan ook een biopt 
genomen worden zonder de echografie. Echografie is echter in iedere urologische praktijk 
aanwezig en er is dan ook geen reden om ook in dit geval geen echogeleide biopten te 
nemen. Voor het nemen van biopten dienen antibiotica gegeven te worden, welke een 
goede weefselpenetratie hebben in de prostaat. De patiënt dient geïnformeerd te worden 
over de mogelijke complicaties van het nemen van prostaatbiopten, zoals bloeding via de 
anus, hematurie, hemospermie en koorts.
Doppler en contrastversterkte echografie zijn niet algemeen beschikbaar in Nederland.
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Computertomografie
Mogelijk is er een toekomstige rol weggelegd voor CT-scan bij gecombineerde PET-CT-
scans (Farsad 2005 [34], Schmid 2005 [36]). In de algemene (screenings)populatie zal deze 
techniek echter te arbeids- en kostenintensief zijn. 
Een beperking van de toepassing van CT-scan is de inherente stralingsbelasting voor de patiënt 
door het gebruik van ioniserende straling. Voor lokale stagering van prostaatcarcinoom 
zijn TRUS en MRI beschikbaar die geen gebruik maken van ioniserende straling. Voor 
lymfeklierstagering geldt dat MRI met of zonder specifiek lymfekliercontrastmiddel een 
alternatief is. Derhalve gaat de voorkeur uit naar deze modaliteit.
De CT-scan kan wel worden gebruikt voor het biopteren van een voor metastase verdachte 
lymfeklier. Lymfeklieren tot een diameter van 5 mm kunnen in handen van een ervaren 
radioloog nauwkeurig worden gebiopteerd. 
Magnetische resonantie beeldvorming (MRI)
Een functionele MRI-techniek, MR spectroscopie (Kurhanewicz 2002, Coakley 2003) 
geeft additionele informatie over het metabolisme in de prostaat en heeft toegevoegde 
waarde bij de diagnosestelling (Van Dorsten 2004, Jung 2004) en lokale stagering (Yu 1999) 
van prostaatcarcinoom. Deze techniek kan worden toegevoegd aan het reguliere MRI-
onderzoek. Echter, gezien het feit dat hiervoor speciale softwarepakketten nodig zijn en de 
techniek in slechts enkele centra in Nederland op een kwalitatief voldoende hoogstaand 
niveau kan worden uitgevoerd, is er op dit moment onvoldoende reden om aan te bevelen 
deze techniek op grote schaal toe te passen.
MRI kan worden toegepast bij de planning van radiotherapie. Door het gebruik van 
goudmarkers kunnen de CT-scan en MRI gefuseerd worden en kan hierop de radiotherapie 
worden gepland (Dehnad 2003 [42]). Hierdoor kunnen functionele MRI-technieken het 
bestralingsprotocol beïnvloeden (Van Lin 2006 [54]). Derhalve kan MRI een belangrijke 
factor zijn voor het toepassen van intensitiy-modulated radiation therapy (IMRT).
Skeletscan
Naast de skeletscintigrafie worden nieuwe beeldvormende technieken als whole-body 
MRI en positron emissie tomografie (PET-scan) bij de beoordeling van botmetastasen 
beschreven. Er ontbreken echter studies met voldoende aantallen patiënten in de literatuur 
om de plaats van deze technieken te bepalen.
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CHAPTER 11
Summary and Conclusions
186 SUMMARY AND CONCLUSIONS
In Chapter 2, a systematic review of the recent literature of the various imaging modalities 
available for detecting and localizing prostate cancer was performed. In order to optimize 
patient prostate cancer care, imaging can play an important role in prostate cancer diagnosis. 
Transrectal ultrasound (TRUS), particularly with the usage of intravenous contrast agents, 
provides an excellent way of directing the biopsy needle towards a suspicious area within 
the prostate in the general (screening) population. CT scanning should not play a role in 
local prostate cancer diagnosis. MRI using functional imaging techniques such as diffusion 
weighted MR imaging (DWI), spectroscopic imaging (1H-MRSI), and dynamic contrast-
enhanced imaging is a powerful tool with high sensitivity and specificity for detection and 
localization of prostate cancer due to its high soft-tissue contrast resolution, particularly in 
patients with prior negative TRUS-guided biopsies. Water molecule diffusion restriction as 
shown by DWI may guide biopsy procedures and differentiate between low-grade and high-
grade prostate cancer. A promising new development is the performance of biopsy within 
the MR scanner. PET scanning using FDG has a relatively low accuracy in localizing prostate 
cancer while usage of 11C-choline may increase this accuracy. Subsequently, a proposal 
for optimal use of radiologic imaging was presented. Comparison of this scheme with the 
European and American urological guidelines on prostate cancer revealed that MR imaging 
is not mentioned regarding prostate cancer localization.
In Chapter 3, a systematic review of the recent literature of the imaging modalities available 
for staging prostate cancer was performed. Bone scintigraphy remained the most sensitive 
method for detecting bone metastases. However, MR imaging is a promising technique for 
the evaluation of the axial skeleton, with the advantage of possibly detecting metastatic 
disease in other organs. In lymph node staging on CT or MRI, the standard of reference is 
still the size and shape criteria, although lymph node specific contrast agents in a preclinical 
setting have provided higher accuracies. Even though TRUS is a widely available tool used for 
the assessment of the local disease stage, MR imaging with an endorectal coil was shown to 
have superior accuracy in staging prostate cancer. CT scanning should not be used for local 
staging.
In Chapter 4, a prospective study included a total of 32 men with biopsy-proved prostate 
cancer who underwent endorectal coil (ERC) T2-weighted  high-spatial-resolution MR 
imaging at 3T and subsequent radical prostatectomy. All images were evaluated by three 
radiologists (two experienced and a third less experienced radiologist) with regard to local 
disease extent, i.e. extracapsular extension and seminal vesicle invasion. Criteria indicative 
for locally advanced cancer stage were: neurovascular bundle asymmetry, obliteration of 
the rectoprostatic angle, irregular bulging of the prostatic contour, tumor signal intensity 
within the periprostatic fat, overt extracapsular tumor, and abnormal asymmetric low 
signal intensity within the seminal vesicles. Whole-mount-section histopathologic analysis 
was the standard of reference. Accuracy, sensitivity, and specificity of local staging were 
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94%, 88%, and 96%, respectively, for both experienced radiologists, and 81%, 50%, and 
92%, respectively, for the less experienced radiologist. There was substantial agreement 
between both experienced readers (0.42–0.79) and moderate agreement between the 
less experienced reader and the experienced readers with respect to all extracapsular 
criteria. In regard to the three cases of minimal capsular invasion, two were detected by 
both experienced radiologists. Thereby, this study showed that 3T MR imaging using an 
endorectal coil to accurately stage prostate cancer was feasible.
Chapter 5 contained a prospective study of another cohort of 46 men with biopsy-proved 
prostate cancer that underwent 3T T2-weighted MR imaging with both a body-array coil 
(BAC) (voxel size: 0.43 x 􏰀 0.43 x 4.0 mm) and an ERC (voxel size: 0.26 x 0.26 x 2.5 mm) prior 
to radical prostatectomy. Four radiologists with different levels of experience independently 
evaluated all data sets separately. Ten image quality characteristics related to prostate 
cancer localization and staging (discrimination between peripheral zone and central gland, 
visibility of the peripheral zone and central gland itself, visibility of the perceived lesion, and 
visualization of the internal architecture of the central gland, delineation of the prostatic 
capsule, visualization of the neurovascular bundle, visualization of the rectoprostatic angle, 
and overall image quality) were assigned scores on a five-point scale. Furthermore, prostate 
cancer presence was recorded with a five-point probability scale in each of 14 segments 
covering the entire prostate. Lastly, local disease stage was classified as organ- confined 
or locally advanced on a five-point probability scale. Whole-mount-section histopathologic 
examination was the reference standard. Significantly more motion artifacts were present 
with ERC imaging. All other image quality characteristics improved significantly with ERC 
imaging. With ERC imaging, the AUC for localization of prostate cancer was significantly 
increased from 0.62 to 0.68. ERC imaging also significantly increased the AUCs for staging as 
well as sensitivity for detection of locally advanced disease by experienced readers from 7% 
to 73-80%, whereas a high specificity of 97-100% was maintained. Extracapsular extension 
as small as 0.5 mm at histopathologic examination could be accurately detected only with 
ERC imaging. Thus, this study showed that ERC imaging outperformed BAC imaging in image 
quality, prostate cancer localization as well as staging, suggesting that an ERC should be 
used.
Chapter 6 encompassed a study of 44 consecutive men with biopsy-proven prostate cancer 
who underwent T2-weighted MR imaging examinations in three orthogonal directions at 
3T, first with a BAC and second with an inflated ERC. Prospectively, two experienced readers 
independently evaluated all data sets in random order. The maximal anteroposterior, right-
to-left, and craniocaudal prostate diameters with BAC and ERC imaging were determined. 
Likewise, by drawing a contour around the whole prostate and the peripheral zone on 
each image slice, the total prostate, peripheral zone and central gland volumes were 
measured before and after ERC introduction. Due to the ERC, the prostate shape changed 
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significantly in all three directions, with mean changes in the anteroposterior, right-to-
left, and craniocaudal diameters of 15.7% (5.5 mm), 7.7% (3.5 mm), and 6.3% (2.2 mm), 
respectively. The mean total prostate, peripheral zone, and central gland volume decreased 
significantly after ERC introduction by 17.9% (8.3 cm3), 21.6% (4.8 cm3), and 14.2% (3.4 cm3), 
respectively. The mean anteroposterior diameter was thus reduced by nearly one-sixth of 
its original diameter, and the mean total prostate volume was decreased by approximately 
18%. This study revealed that the ERC introduced significant prostate changes that should 
be considered when using ERC-based MRI for MRI-computed tomography fusion and 
endorectal balloon radiotherapy planning.
In Chapter 7, a novel 1H-MRSI technique at 3T using only external coils was described and 
applied in both the prostate and an enlarged lymph node. A 77-year-old man, who initially 
underwent prostate radiation therapy for stage T3bN0M0 prostate cancer, underwent 
repeated MR imaging more than two years after the procedure due to rising PSA levels. 
Three-dimensional 1H-MRSI using a combination of external surface coils (TR/TE: 750/145 
ms; acquisition bandwidth: 1250 Hz; 512 spectral data points; FOV: 84 x 70 x 70; matrix 
size: 12 x 10 x 10; number of weighted averages: 6; 7 saturation slabs; voxel size: 7 x 7 x 7 
mm3) revealed high choline levels throughout the prostate indicative of recurrent disease. 
Furthermore, one single enlarged pelvic lymph node was observed. A single voxel echo time 
averaged point resolved spectroscopy sequence positioning the voxel within the node was 
performed (TR 1500 ms, TE 136 to 272, 256 averages, voxel size: 15 x 17 x 13 mm3) showing a 
choline peak in the spectrum. To validate the location of the choline within the lymph node, 
a 3-dimensional 1H-MRS imaging measurement (TR/TE: 1500/100 ms; FOV: 100 x 100 x 100 
mm3; matrix size: 10 x 10 x 10) with dual frequency selective water and lipid suppression was 
performed with the volume-of-interest covering the enlarged lymph node and adjacent lipid 
tissue showing choline only inside the lymph node. Histopathology obtained from both the 
prostate and the lymph node revealed prostate cancer presence. Thus, this study described 
the first performance of 1H-MRSI at 3T using only external surface coils, both in the prostate 
as well as an enlarged lymph node.
 
Chapter 8 presented the feasibility and accuracy of localizing prostate cancer with 3T 
3D-1H-MRSI using only external radiofrequency surface coils in a cohort of 45 men with 
biopsy-proved prostate cancer that subsequently underwent radical prostatectomy. A 3D 
water- and lipid-suppressed point-resolved spectroscopy pulse sequence was performed of 
the entire prostate (TR/TE: 750/145 ms; acquisition bandwith: 1250 Hz; 512 spectral data 
points; voxel size: 7 x 7 x 7 mm3). On the basis of the prostatectomy specimens and blinded 
to the spectra, per patient 1-4 voxels were matched and classified into healthy peripheral 
zone, central gland, periurethral zone, and cancer tissue. Cancer voxels were classified 
according to cancer size and the certainty of matching histopathologic findings with MR 
images. After visual inspection of automated fitting of classified voxels, the choline plus 
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creatine-to-citrate (Cho+ Cr/Cit) ratio was calculated for all tissues. A median of 82% of the 
classified voxels per patient was used in the analysis. Mean Cho+Cr/Cit ratios for healthy 
tissues were 0.22 for peripheral zone, 0.34 for central gland, and 0.36 for the periurethral 
area; all were significantly different from that of cancer (1.3). The AUC for discrimination of 
probable and definite cancer tissue from healthy tissue for the peripheral zone (0.84) was 
significantly higher than that for the central gland (0.69). Thereby, this study demonstrated 
that 3T 3D-1H-MRSI using only external coils is feasible and achieves high accuracies in 
differentiating cancer from healthy prostatic tissue.
Chapter 9 described a prospective study in which 18 men with biopsy-proved prostate cancer 
underwent 3T 3D 1H-MRSI of the prostate both without and with an ERC prior to radical 
prostatectomy. The voxel resolution with a BAC and an ERC were 7 x 7 x 7 mm and 6 x 6 x 6 
mm, respectively (for both the scanning parameters were TR/TE: 750/145 ms; acquisition 
bandwidth: 1250 Hz; total acquisition time: 9 minutes). Semi-automatic voxel postprocessing 
resulted in a Cho+Cr/Cit ratio for each voxel. Each prostate was divided into 14 regions of 
interest (ROIs). Four readers with varying levels of experience individually scored all imaging 
sets separately and determined the presence of cancer based on predefined ratio cut-offs 
using a five-point scale for each segment. Whole mount section histopathology was the 
standard of reference. Significantly more ROIs were non-ratable with 1H-MRSI without an 
ERC compared with 1H-MRSI with an ERC. For the more experienced readers 1H-MRSI with 
an ERC had a high specificity (82-92%), but a low sensitivity (20-57%). For the novice reader, 
ERC 1H-MRSI had a high sensitivity (80%) and a low specificity (34%). For all readers, the 
negative predictive values were high (82-89%), whereas the positive predictive values were 
low (20-45%) for both imaging with and without an ERC. Prostate cancer localization with 
the use of an ERC had a significantly higher AUC (0.68) than without the use of an ERC (0.63). 
Thus, it was shown that usage of the ERC with 3T 1H-MRSI resulted in a significantly higher 
accuracy of localizing prostate cancer.
Chapter 10 reflected a selection of the chapter of the 2007 Dutch comprehensive cancer 
centers (CBO) guideline regarding the use of imaging in prostate cancer diagnosis. The 
localization of prostate cancer with MR imaging was deemed significantly superior 
compared with digital rectal examination and biopsy. It was advised to perform an MR 
imaging scan using an endorectal coil in high-risk patients with negative TRUS biopsies prior 
to subsequent further biopsies. 3T ERC improves sensitivity of local staging compared with 
1.5T. The suboptimal availability of ERC MR imaging in the Netherlands was still a concern. 
For the identification of the exact location of the cancer within the prostate gland for 
radiation therapy purposes, MR imaging was deemed the modality of choice. 
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CONCLUSIONS
The role of MR imaging in the initial diagnosis and local staging of prostate cancer is 
increasing. By using MR imaging techniques, one is able to provide more personalized 
medicine and, subsequently, to present each prostate cancer patient with his own optimal 
treatment plan. 
An overview of the current MR imaging techniques and literature available was given. 
Thereafter, the possibilities of prostate MR imaging at 3T using an endorectal coil were 
examined. An early study demonstrated the feasibility of determining the local disease stage 
with an endorectal coil using predefined criteria for extraprostatic extension, obtaining 
both a high sensitivity and specificity for determining the exact local disease stage. A 
direct comparison between imaging without and with an endorectal coil at 3T showed a 
significantly higher accuracy with endorectal coil imaging in exactly localizing prostate 
cancer within the prostate as well as in assessing the local disease stage. Minimal capsular 
penetration could be detected only using an endorectal coil.
By obtaining imaging with and without an endorectal coil at 3T, it was shown that the 
introduction of a coil significantly changed the prostate shape, particularly the anteroposterior 
diameter, as well as the determined prostate volume. This raised important concerns for 
radiation therapy planning based on MR imaging scans using an endorectal coil.
Using histopathologic confirmation, it was demonstrated that the 1H-MRSI technique at 3T 
was feasible when solely using external coils. This was first demonstrated in a case report 
in which spectroscopic imaging was performed to detect prostate cancer in both recurrent 
disease in the prostate and metastatic disease in a pelvic lymph node. Secondly, in a large 
preprostatectomy patient cohort it was shown that the technique had a high accuracy of 
differentiating cancer from healthy prostatic tissue. Lastly, in a preprostatectomy patient 
cohort, it was demonstrated that 1H-MRSI with an ERC significantly increased the localization 
accuracy compared with using only external coils.
The abovementioned more central role of MR imaging was reflected in a number of 
recommendations in the 2007 Dutch comprehensive cancer centres (CBO) prostate cancer 
guideline.
Thus, using an endorectal coil at 3T was feasible and significantly increased prostate cancer 
localization and local staging sensitivity. The changes in prostate shape by introduction 
of the coil are an important concern for exact radiation therapy planning. While proton 
spectroscopic imaging at 3T using solely external coil is feasible, usage of the endorectal coil 
significantly increased the localization accuracy.
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SAMENVATTING EN CONCLUSIES
In Hoofdstuk 2 werd een systematische review van de recente literatuur omtrent de 
beeldvormingsmodaliteiten voor het detecteren en lokaliseren van prostaatkanker 
uitgevoerd. Om de zorg rond prostaatkanker voor wat betreft de diagnose te optimaliseren 
kan beeldvorming een belangrijke rol spelen. In de algemene (screenings)populatie kan 
transrectale echografie (TRUS), in het bijzonder met intraveneus contrastmiddel, uitstekend 
de biopsienaald richting een verdacht gebied in de prostaat leiden. CT-scans behoren geen rol 
meer te spelen bij prostaatkankerdetectie of -lokalisatie. Door zijn hoge wekedelencontrast 
heeft MRI met functionele technieken zoals diffusiegewogen imaging (DWI), proton 
spectroscopie (1H-MRSI) en dynamische contrastaankleuring analyse (DCE) een hoge 
sensitiviteit en specificiteit voor de detectie en lokalisatie van prostaatkanker. Dit is nog 
uitgesprokener bij patiënten met eerdere negatieve TRUS-geleide biopten. Watermolecule 
diffusie restrictie aangetoond middels DWI kan biopten geleiden en differentiëren tussen 
laag- en hooggradige prostaatkanker. Een veelbelovende recente ontwikkeling is het 
verrichten van prostaatbiopten in een MRI-scanner. FDG-PET-scans hebben een relatief lage 
accuratesse voor het lokaliseren van prostaatkanker. Gebruik van 11C-choline als tracer 
verhoogd deze accuratesse enigszins. Vervolgens werd een protocol voor het optimaal 
toepassen van radiologische beeldvorming gepresenteerd. Vergelijking van dit schema met 
de richtlijnen van de Europese en Amerikaanse urologieverenigingen toonde dat MRI hierin 
niet genoemd werd voor prostaatkanker lokalisatie. 
In Hoofdstuk 3 werd een systematische review van de literatuur over 
beeldvormingsmodaliteiten voor wat betreft stadiëring van prostaatkanker uitgevoerd. 
Botscintigrafie was de sensitiefste methode om botmetastasen te detecteren. MRI is echter 
een veelbelovende techniek voor de evaluatie van het axiale skelet, met als voordeel de 
mogelijke detectie van metastasen in andere organen. Voor stadiëring van lymfeklieren 
met CT-scan of MRI-scan is de grootte en vorm van een lymfeklier nog steeds de enige 
leidraad. Lymfeklierspecifieke MRI-contrastmiddelen hebben in een preklinische setting al 
hoge accuratesse vertoond. Hoewel TRUS een makkelijk beschikbare modaliteit is voor de 
bepaling van het lokale ziektestadium, bleek MRI met een endorectal spoel (ERC) een hogere 
accuratesse te hebben. CT-scans dienen niet gebruikt te worden voor de lokale stadiëring 
van prostaatkanker.
In Hoofdstuk 4, werd een prospectieve studie beschreven van 32 mannen met biopsie 
bewezen prostaatkanker die een T2-gewogen hoge-spatiële-resolutie 3T MRI met ERC 
ondergingen gevolgd door radicale prostatectomie. Alle beelden werden geëvalueerd door 
drie radiologen (twee ervaren en een derde minder ervaren radioloog) met betrekking tot de 
lokale ziekte-uitbreiding, d.w.z. extracapsulaire uitbreiding en zaadblaasjes invasie. Criteria 
welke duidden op lokaal uitgebreide kanker waren: asymmetrie van de neurovasculaire 
bundel, obliteratie van de rectoprostatische hoek, irregulaire bulging van de prostaatcontour, 
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tumor signaal intensiteit in het periprostatische vet, duidelijke extracapsulaire tumor en 
abnormaal asymmetrisch lage signaal intensiteit in de zaadblaasjes. Whole-mount-sectie 
histopathologie was de gouden standaard. De accuratesse, sensitiviteit en specificiteit van 
lokale stadiëring waren respectievelijk 94%, 88% en 96% voor beide ervaren radiologen, en 
81%, 50%, en 92% voor de minder ervaren radioloog. Er was een substantiële overeenkomst 
tussen beider ervaren readers (0,42–0,79) en matige overeenkomst tussen de minder 
ervaren reader en de ervaren readers met betrekking tot alle criteria voor extracapsulaire 
uitbreiding. Twee van de drie casus met minimale extracapsulaire uitbreiding werden 
gedetecteerd door beide ervaren radiologen. Deze studie toonde aan dat 3T MRI met een 
endorectale spoel mogelijk was om prostaatkanker accuraat te stadiëren.
Hoofdstuk 5 bevatte een prospectieve studie van een ander cohort van 46 mannen met 
biopsie bewezen prostaatkanker die een 3T T2-gewogen MRI ondergingen met zowel een 
body-array coil (BAC) (voxel grootte: 0,43 x 0,43 x 4,0 mm) en een ERC (voxelgrootte: 0,26 x 
0,26 x 2,5 mm) voorafgaand aan radicale prostatectomie. Vier radiologen met verschillende 
ervaringsniveaus evalueerden alle datasets onafhankelijk van elkaar. Tien beeldkwaliteit 
karakteristieken gerelateerd aan prostaatkankerlokalisatie en -stadiëring (onderscheid 
tussen perifere en centrale zone, zichtbaarheid van de perifere en centrale zone zelf, 
waarneembaarheid van de vermeende laesie, visualisatie van de interne architectuur van 
de centrale zone, afgrensbaarheid van het prostaatkapsel, visualisatie van de neurovasulaire 
bundel en de rectoprostatische hoek en de algehele beeldkwaliteit) werden gescoord op een 
vijfpuntsschaal. Vervolgens werd de aanwezigheid van prostaatkanker in de gehele prostaat, 
verdeeld in 14 segmenten, aangegeven op een vijfpuntswaarschijnlijkheidsschaal. Als 
laatste werd het lokale ziektestadium als orgaanbegrensd of lokaal uitgebreid aangegeven 
op een vijfpuntswaarschijnlijkheidsschaal. Whole-mount-sectie histopathologie was de 
gouden standaard. Er waren significant meer bewegingsartefacten aanwezig bij onderzoek 
met een ERC. Alle andere beeldkwaliteit karakteristieken verbeterden significant met een 
ERC. De area under the curve (AUC) voor de lokalisatie van prostaatkanker nam significant 
toe van 0,62 naar 0,68 met een ERC. Tevens verbeterden de AUCs voor lokale stadiëring 
alsook de sensitiviteit voor detectie van lokaal uitgebreide ziekte van de ervaren readers van 
7% naar 73-80%, terwijl een hoge specificiteit van 97-100% werd behouden. Extracapsulaire 
uitbreiding tot 0,5 mm gevonden bij pathologie kon slechts met ERC beeldvorming accuraat 
worden gedetecteerd. Derhalve toonde deze studie aan dat beeldvorming met een 
endorectale spoel betere resultaten opleverde dan met slechts externe spoelen wat betreft 
beeldkwaliteit, prostaatkankerlokalisatie en -stadiëring.
Hoofdstuk 6 besloeg een studie van 44 opeenvolgende mannen met biopsie bewezen 
prostaatkanker die afzonderlijke T2-gewogen MRI-onderzoeken in drie richtingen op 3T met 
een BAC en een opgeblazen ERC ondergingen. Prospectief evalueerden twee ervaren readers 
onafhankelijk beide data sets in willekeurige volgorde. De maximale voor achterwaarts, 
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rechts-links en craniocaudale prostaatdiameters werden gemeten met BAC en met ERC. 
Vervolgens werd een contour getrokken rond de gehele prostaat en de perifere zone op elke 
plak. Hieruit werd het volume van de totale prostaat, perifere zone en transitie zone bepaald 
voor en na introductie van de ERC. Ten gevolge van de ERC veranderde de prostaatvorm 
significant in alle drie richtingen, met gemiddelde veranderingen in de voor achterwaartse, 
rechts-links en craniocaudale diameters van 15,7% (5,5 mm), 7,7% (3,5 mm) en 6,3% (2,2 
mm), respectievelijk. Na introductie van de ERC nam het gemiddelde totale volume van 
de prostaat, de perifere zone en de transitie zone significant af met respectievelijk 17,9% 
(8,3 cm3), 21,6% (4,8 cm3) en 14,2% (3,4 cm3). De gemiddelde voor achterwaartse diameter 
werd gereduceerd met ongeveer één-zesde en het gemiddelde totale prostaat volume nam 
af met circa 18%. Deze studie toonde dat de ERC significante veranderingen in de prostaat 
induceert welke in acht dienen te worden genomen wanneer een MRI-scan met ERC wordt 
gebruikt voor fusie met CT voor radiotherapie planning.
In Hoofdstuk 7 werd een nieuwe 1H-MRSI techniek op 3T met gebruikmaking van alleen 
externe spoelen beschreven en toegepast in zowel de prostaat als een vergrote lymfeklier. 
Een 77-jarige man onderging oorspronkelijk externe radiotherapie voor een T3bN0M0 
prostaatkanker. Meer dan twee jaar hierna onderging hij nogmaals een MRI-scan vanwege 
een stijgend PSA-niveau. Driedimensionale 1H-MRSI middels een combinatie van externe 
oppervlaktespoelen (TR/TE: 750/145 ms; acquisitie bandbreedte: 1250 Hz; 512 spectrale 
data punten; FOV: 84 x 70 x 70; matrix grootte: 12 x 10 x 10; aantal gewogen gemiddelden: 
6; 7 saturatie banden; voxel grootte: 7 x 7 x 7 mm3) toonde hoge choline niveaus in de 
gehele prostaat, duidend op recidief ziekte. Tevens werd een enkele vergrote lymfeklier 
in het kleine bekken waargenomen. Een single voxel echo time averaged point resolved 
spectroscopie sequentie met het voxel gepositioneerd in de lymfeklier werd uitgevoerd (TR 
1500 ms, TE 136 tot 272, 256 averages, voxel grootte: 15 x 17 x 13 mm3) en toonde een 
choline piek in het spectrum. Om de lokatie van de choline in de lymfeklier te valideren werd 
een 3-dimensionale 1H-MRSI meting verricht (TR/TE: 1500/100 ms; FOV: 100 x 100 x 100 
mm3; matrix grootte: 10 x 10 x 10) met dual frequency selectieve water- en vetonderdrukking 
waarbij het volume van interesse de vergrote lymfeklier en omgevend vetweefsel was. 
Deze toonde de aanwezigheid van choline in slechts de lymfeklier. Histopathologie werd 
verkregen uit zowel de prostaat als de lymfeklier en toonde in beide de aanwezigheid van 
prostaatkanker. Hiermee beschreef deze studie als eerste 1H-MRSI met alleen externe 
spoelen bij 3T in zowel de prostaat als een vergrote intra-abdominale lymfeklier.
 
Hoofdstuk 8 toonde de mogelijkheid en de accuratesse van het lokaliseren van prostaatkanker 
met 3T 3D-1H-MRSI met alleen radiofrequentie oppervlakte spoelen in een cohort van 45 
mannen met biopsie bewezen prostaatkanker die vervolgens een radicale prostatectomie 
ondergingen. Een 3D water- en vetonderdrukte point-resolved spectroscopy pulse sequence 
werd uitgevoerd op de gehele prostaat (TR/TE: 750/145 ms; acquisitie bandbreedte: 1250 
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Hz; 512 spectrale data punten; voxel grootte: 7 x 7 x 7 mm3). Gebaseerd op de prostatectomie 
specimina en geblindeerd voor de spectra, werden per patiënt 1-4 voxels op de 3D-1H-MRSI 
gematched en geclassificeerd voor gezonde perifere zone, transitiezone, peri-urethraal 
weefsel en kankerweefsel. Kankervoxels werden geclassificeerd naar kankergrootte en 
zekerheid van matching van 3D-1H-MRSI met histopathologische bevindingen. Na visuele 
inspectie van geautomatiseerde fitting van geclassificeerde voxels werden de choline plus 
creatine-gedeeld door citraat (Cho+ Cr/Cit) ratio’s berekend voor alle weefsels. Mediaan 
kon 82% van de geclassificeerde voxels per patiënt worden gebruikt voor de analyse. De 
gemiddelde Cho+Cr/Cit ratio’s voor gezond weefsel waren 0,22 voor perifere zone, 0,34 
voor de transitiezone en 0,36 voor peri-urethraal weefsel; alle verschilden significant 
met dat van kanker (1,3). De AUC voor het onderscheid tussen waarschijnlijk en zeker 
kankerweefsel en gezond weefsel voor de perifere zone (0,84) was significant hoger dan dat 
van de transitiezone (0,69). Derhalve toonde deze studie aan dat 3T 3D-1H-MRSI met alleen 
externe spoelen mogelijk was en hoge accuratesse had om kankerweefsel te onderscheiden 
van gezond prostaatweefsel.
In Hoofdstuk 9 ondergingen 18 mannen met biopsie bewezen prostaatkanker een 3T 3D-1H-
MRSI-onderzoek van de prostaat zowel zonder als met een ERC voorafgaand aan radicale 
prostatectomie. De voxelresolutie met een BAC en een ERC waren 7 x 7 x 7 mm en 6 x 6 x 
6 mm, respectievelijk (voor beide waren de scanparameters TR/TE: 750/145 ms; acquisitie 
bandbreedte: 1250 Hz; totale scantijd: 9 minuten). Semi-automatische voxel postprocessing 
resulteerde in een Cho+Cr/Cit ratio voor elk voxel. Iedere prostaat werd verdeeld in 14 
gebieden van interesse (ROI’s). Elk van de vier readers met verschillende ervaringsniveaus 
scoorden alle beeldensets apart en bepaalden de aanwezigheid van kanker op basis van een 
vooraf vastgestelde afkapwaarden van de ratio op een vijfpuntsschaal voor elk segment. 
Whole-mount-sectie histopathologie was de gouden standaard. Significant meer ROI’s 
waren niet te beoordelen bij 1H-MRSI zonder een ERC vergeleken met 1H-MRSI met een 
ERC. Voor de ervaren readers had 1H-MRSI met een ERC een hoge specificiteit (82-92%) 
maar een lage sensitiviteit (20-57%). Voor de onervaren reader had ERC 1H-MRSI een hoge 
sensitiviteit (80%) maar een lage specificiteit (34%). Voor alle readers waren de negatief 
voorspellende waarden hoog (82-89%) en de positief voorspellende waarden laag (20-45%), 
zowel voor beeldvorming zonder en met een ERC. Prostaatkankerlokalisatie met een ERC 
had een  significant hogere AUC (0,68) dan beeldvorming zonder een ERC (0,63). Hiermee 
werd aangetoond dat gebruik van een ERC bij 3T 1H-MRSI de lokalisatie van prostaatkanker 
significant verbeterde.
Hoofdstuk 10 bevat een hoofdstuk van de landelijke CBO-richtlijn Prostaatcarcinoom 
2007 met betrekking tot het gebruik van beeldvorming bij prostaatkankerdiagnostiek. De 
lokalisatie van prostaatkanker met MRI werd als significant beter gezien vergeleken met 
rectaal toucher en biopsie. Er werd geadviseerd een MRI-scan met ERC te verrichten bij 
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patiënten met een hoog risico op prostaatkanker na negatieve TRUS-biopsie voorafgaand aan 
verdere biopten. 3T ERC verbetert de sensitiviteit van de lokale stadiëring vergeleken met 
1.5T. De suboptimale beschikbaarheid van ERC MRI in Nederland was een reden van zorg. 
Voor de identificatie van de exacte lokalisatie van kanker in de prostaat voor radiotherapie 
werd MRI aangewezen als de modaliteit van keuze.
CONCLUSIES
De rol van MRI bij de initiële diagnose en lokale stadiëring van prostaatkanker neemt steeds 
verder toe. Door het gebruik van MRI-technieken kan men betere personalized medicine 
toepassen en vervolgens elke prostaatkankerpatiënt zijn individuele behandelplan toewijzen. 
Er werd een overzicht van de huidige MRI-technieken en beschikbare literatuur gegeven. 
Vervolgens werden de mogelijkheden van prostaat MRI bij 3T met een endorectale 
spoel onderzocht. Een vroege studie toonde de mogelijkheid van het accuraat bepalen 
van het lokale ziektestadium middels een endorectal spoel bij gebruikmaking van vooraf 
gedefinieerde criteria voor extraprostatische uitbreiding. Hiermee werden zowel een 
hoge sensitiviteit als specificiteit behaald. Een directe vergelijking tussen beeldvorming 
zonder en met een endorectale spoel bij 3T toonde een significant hogere accuratesse van 
endorectale spoel beeldvorming bij het lokaliseren van prostaatkanker en het bepalen van 
het lokale ziektestadium. Minimale kapselpenetratie kon slecht worden gedetecteerd met 
beeldvorming met een endorectale spoel.
Beeldvorming zonder en met een endorectale spoel bij 3T liet zien dat het gebruik van een 
endorectale spoel de prostaatvorm significant veranderde, met name de voor-achterwaartse 
diameter, alsook het prostaatvolume. Hiermee werd aangetoond dat het gebruik van de 
endorectale spoel consequenties heeft voor de planning van radiotherapie op basis van 
deze MRI-beelden.
Met histopathologische bevestiging werd aangetoond dat 1H-MRSI bij 3T met alleen externe 
spoelen mogelijk was. In een casus reportage werd de mogelijkheid van prostaatkankerdetectie 
1H-MRSI om in zowel de prostaat als in een vergrote metastatische lymfeklier in het kleine 
bekken bewezen. Vervolgens werd in een patiëntencohort aangetoond dat deze techniek 
een hoge accuratesse had voor het onderscheiden van prostaatkanker van gezond 
prostaatweefsel. Tevens werd in een patiëntencohort gedemonstreerd dat 1H-MRSI met een 
endorectale spoel de accuratesse van de prostaatkankerlokalisatie significant verbeterde.
De hierboven vastgestelde toegenomen rol van MRI bij prostaatkankerdiagnostiek werd 
gereflecteerd in een aantal aanbevelingen in de CBO-richtlijn Prostaatcarcinoom uit 2007.
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Aldus werd in dit proefschrift aangetoond dat het gebruik van een endorectale spoel bij 
een veldsterkte van 3T mogelijk was en dat dit een significante verbetering gaf van de 
prostaatkankerlokalisatie en de lokale stadiëring. De veranderingen van de prostaatvorm 
door het gebruik van de spoel zijn van belang voor de exacte planning van radiotherapie 
op basis van deze scans. Hoewel gebruik van 1H-MRSI bij 3T met alleen externe spoelen 
mogelijk is, wordt de lokalisatie accuratesse significant verbeterd door het gebruik van de 
endorectale spoel.
CHAPTER 12
Discussion
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The use of the endorectal coil at 3T has been a widely debated subject due its many 
advantages as well as disadvantages. 
A drawback of the use of an endorectal coil is the more invasive nature of the examination 
since one introduces a foreign object into a body cavity, causing at least some discomfort to 
the patient. In a number of countries, this action in male patients is deemed inapropriate, 
increasing the resistance to using the coil. When applied, contraction of the sphincter 
musculature may cause some movement artifacts in the images. This may be counteracted 
by applying bowel motion suppression drugs. Application of the coil will also lengthen the 
examination time due to the time needed for its introduction and the necessity for checking 
its correct position prior to starting the actual exam. For hospital managers this may be their 
argument against its usage as this will descrease the number of patients that can be scanned 
within the finitesimal scanner time. For radiation oncologists the treatment planning and 
the actual treatment itself is normally performed without an endorectal balloon. As outlined 
in this thesis, the prostate shape changes markedly with the introduction of the endorectal 
coil. Thus, alignment of the endorectal MR imaging scan performed with an endorectal coil 
and the planning CT scan without an endorectal balloon may be troublesome regarding the 
delineation of both the prostate as well as the delineation of the prostate cancer focus.
However, on the opposite, this thesis has established a number of advantages of using the 
endorectal coil. The main advantage is the higher resolution that is obtainable with the coil. 
For patients that are enlisted for radical prostatectomy, it was proven to be more sensitive 
in detecting both the presence as well as the exact location at which capsular penetration 
was observed. In case of extensive extraprostatic spread, the patient may chose to change 
the treatment strategy from surgery to radiation treatment. If extracapsular extension 
is small or if assessed as possibly present, the urologist may be forewarned to obtaining 
negative surgical margins at the exact site of perceived capsular penetration by resecting 
with a wider margin or sacrificing the neurovascular bundle on one side of the prostate. 
The higher resolution may also allow for more accurate local primary or salvage possibilities 
as an optimal delineation of the cancer focus allows for smaller target volumes, which is 
particularly helpful in patients that have received prior radiation treatment.
For MR spectroscopic imaging, it was demonstrated that imaging using solely external coil 
was feasible in both an enlarged lymph node as well as within the prostate itself. Since this 
part of the MR examination consumes a relatively long part of the exam, it could be argued 
that this may be performed without an endorectal coil. However, the increased localization 
accuracy with an endorectal coil may provide more certain cancer localization, particularly 
in establishing the site of the most aggressive cancer focus. 
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Lastly, it may be argued that for the special skills for and knowledge of endorectal coil 
imaging, its use could be restricted to only a number of centers. However, in displaying 
greater detail, use of the coil may very well aid less experienced readers.
Future clinical use of MR magnets with field strengths higher than 3T may possibly render 
details which possibly could compete with the use of the endorectal coil. However, more 
work is needed before this can be used in a clinical setting.
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